Appearing monthly
ANNUAL CUMULATIVE INDEX

INDEX 1985

ISSN 0027-5107
MUREAV 142–158/INDEX, 1–37 (1985)

MUTATION RESEARCH

International journal on mutagenesis, chromosome breakage and related subjects

Board of Managing Editors

H. Sobels, Leiden (Chairman)

W. Glickman, Toronto, Ont.
C. Hanawalt, Stanford, CA (DNA Repair Reports)
H.M. Lohman, Rijswijk (DNA Repair Reports)
J. Preston, Oak Ridge, TN (Mutation Research Letters)
K. Sankaranarayanan, Leiden
F.J. de Serres, Research Triangle Park, NC
H. Takebe, Kyoto (DNA Repair Reports)
E. Vogel, Leiden
J.S. Wassom, Oak Ridge, TN

Assistant Editor M. Shelby, Research Triangle Park, NC

PERIODICAL
H
31
197

Elsevier

MUTATION RESEARCH

International journal on mutagenesis, chromosome breakage and related subjects

Publication schedule for 1985

MR is published according to a volume-numbering scheme that embraces all sections of the journal, in addition each section has its own code colour.

Reg (green), 'regular' volumes; EMS (blue), Section on Environmental Mutagenesis and Related Subjects; DRR (brown), 'DNA Repair Reports', special section of Mutation Research; Rev (purple), Reviews in Genetic Toxicology; GTT (red), Genetic Toxicology Testing; MRLett (yellow), Mutation Research Letters.

1985	Reg	EMS	DRR	Rev	GTT	MRLett
Jan.	148/1		145/1	153/1	155/1	142/1
Feb.	148/2	147/1			155/2	142/2
Mar.	149/1		145/2	153/2	155/3	142/3
Apr.	149/2	147/2			156/1	142/4
May	149/3		145/3	153/3	156/2	143/1
June	150/1	147/3			156/3	143/2
July	150/2		146/1	154/1	157/1	143/3
Aug.	151/1	147/4			157/2	143/4
Sep.	151/2		146/2	154/2	157/3	144/1
Oct.	152/1	147/5			158/1	144/2
Nov.	152/2		146/3	154/3	158/2	144/3
Dec.	152/3	147/6			158/3	144/4
	INDEX *					
Total						
17 vols.	5 vols.	1 vol.	2 vols.	2 vols.	4 vols.	3 vols.
142–158	148–152	147	145, 146	153, 154	155–158	142–144
54 issues	12 issues	6 issues	6 issues	6 issues	12 issues	12 issues
+ Index						

* Author Index and Subject Index for the year 1985 (covering all sections).

Subscription Information 1985

MUTATION RESEARCH (complete)
1985, Volumes 142–158 (17 volumes in 54 issues + Cumulative Index 1985)
Full subscription: Dfl. 3723.00 (US $ 1283.50) + Dfl. 374.00 (US $ 129.00) postage, packaging and handling. Total price Dfl. 4097.00 (US $ 1412.50).

MUTATION RESEARCH/DNA REPAIR REPORTS
1985, Volumes 145, 146 (2 volumes in 6 issues)
Part subscription: Dfl. 440.00 (US $ 151.75) + Dfl.44.00 (US $15.25) postage, packaging and handling. Total price Dfl. 484.00 (US $ 167.00).

MUTATION RESEARCH/REVIEWS IN GENETIC TOXICOLOGY
1985, Volumes 153, 154 (2 volumes in 6 issues)
Part subscription: Dfl. 440.00 (US $ 151.75) + Dfl. 44.00 (US $ 15.25) postage, packaging and handling. Total price Dfl. 484.00 (US $ 167.00).

MUTATION RESEARCH/GENETIC TOXICOLOGY TESTING
1985, Volumes 155–158 (4 volumes in 12 issues)
Part subscription: Dfl. 880.00 (US $ 303.50) + Dfl. 88.00 (US $ 30.25) postage, packaging and handling. Total price Dfl. 968.00 (US $ 333.75).

MUTATION RESEARCH LETTERS
1985, Volumes 142–144 (3 volumes in 12 issues)
Part subscription: Dfl. 660.00 (US $ 227.50) + Dfl. 66.00 (US $22.75) postage, packaging and handling. Total price Dfl. 726.00 (US $250.25)

The Dutch guilder price is definitive. The US dollar price is subject to exchange rate fluctuations and is only given as a guide.

Journals are sent by surface delivery to all countries, except the following countries where SAL air delivery (Surface Airlifted Mail) is ensured: U.S.A., Canada, Japan, Australia, New Zealand, P.R. China, India, Israel, South Africa, Malaysia, Singapore, South Korea, Taiwan, Pakistan, Hong Kong, Brazil. Air mail rates for other countries are available on request.

Subscription orders can only be entered by calender year (Jan.–Dec.) and should be sent to: Elsevier Science Publishers, Journals Department, P.O. Box 211, 1000 AE Amsterdam (The Netherlands), telex 18582 ESPA NL, or to your usual subscription agent.

Claims for missing issues should be made within three months of publication, otherwise they cannot be honoured free of charge.

The Publisher reserves the right to issue additional volumes during the course of the year. Such volumes will be invoiced before publication and delivered after receipt of payment.

In the United States and Canada: For further information concerning this or any other Elsevier Science Publishers journal, contact Elsevier Science Publishers, Journal Information Center, 52 Vanderbilt Avenue, New York, NY 10017, tel. (212) 370-5520.

Reprints 50 reprints of each article are sent to the author(s) free of charge. Additional reprints can be ordered by the author(s).

Advertising For advertising rates apply to the Publishers.

MUTATION RESEARCH

International journal on mutagenesis, chromosome breakage and related subjects

Vols. 142–158 (1985)

ANNUAL CUMULATIVE INDEX

PRINTED IN THE NETHERLANDS

Mutation Research

INTERNATIONAL JOURNAL ON MUTAGENESIS, CHROMOSOME BREAKAGE AND RELATED SUBJECTS

BOARD OF MANAGING EDITORS

F.H. Sobels, *Leiden (Chairman)*; B.W. Glickman, *Toronto, Ont.*;
P.C. Hanawalt, *Stanford, CA (DNA Repair Reports)*; P.H.M. Lohman, *Rijswijk (DNA Repair Reports)*;
R.J. Preston, *Oak Ridge, TN (Mutation Research Letters)*; K. Sankaranarayanan, *Leiden*;
F.J. de Serres, *Research Triangle Park, NC*; H. Takebe, *Kyoto (DNA Repair Reports)*; E. Vogel, *Leiden*;
J.S. Wassom, *Oak Ridge, TN*

ASSISTANT EDITOR

M. Shelby, *Research Triangle Park, NC*

EDITORIAL BOARD

J. Ashby, *Macclesfield*
C. Auerbach, *Edinburgh*
H. Bartsch, *Lyon*
D. Bootsma, *Waddinxveen*
R.C. von Borstel, *Edmonton, Alberta*
B.A. Bridges, *Brighton*
A.V. Carrano, *Livermore, CA*
E.H.Y. Chu, *Ann Arbor, MI*
J.E. Cleaver, *San Francisco, CA*
U.H. Ehling, *Neuherberg*
H.J. Evans, *Edinburgh*
M.M. Green, *Davis, CA*
R.H. Haynes, *Toronto, Ont.*
J.A. Heddle, *Toronto, Ont.*
G.R. Hoffmann, *Worcester, MA*
A. Hollaender, *Washington, DC*
T. Kada, *Misima*
B.A. Kihlman, *Uppsala*
S.A. Latt, *Boston, MA*
A. Lehmann, *Brighton*
M.F. Lyon, *Harwell*
D.G. MacPhee, *Bundoora, Vic.*
H.V. Malling, *Research Triangle Park, NC*
T. Matsushima, *Tokyo*
G.R. Mohn, *Leiden*
E. Moustacchi, *Orsay*
A.T. Natarajan, *Leiden*
W.W. Nichols, *Camden, NJ*
R.A. Nilan, *Pullman, WA*
G. Obe, *Berlin*
F. Oesch, *Mainz*
G. Olivieri, *Rome*
R.B. Painter, *San Francisco, CA*
J.M. Parry, *Swansea*
M.C. Paterson, *Chalk River, Ont.*
L.S. Ripley, *Research Triangle Park, NC*
J.J. Roberts, *Sutton*
H.S. Rosenkranz, *Cleveland, OH*
L.B. Russell, *Oak Ridge, TN*
M.S. Sasaki, *Kyoto*
J.R.K. Savage, *Harwell*
D. Scott, *Manchester*
J.W.I.M. Simons, *Leiden*
A. Sivak, *Cambridge, MA*
T. Sugimura, *Tokyo*
L.H. Thompson, *Livermore, CA*
D. von Wettstein, *Copenhagen*
G.C. Walker, *Cambridge, MA*
S. Wolff, *San Francisco, CA*
F.K. Zimmermann, *Darmstadt*

Vols. 142–158 **INDEX 1985**

ELSEVIER SCIENCE PUBLISHERS B.V.
AMSTERDAM

© 1985 ELSEVIER SCIENCE PUBLISHERS B.V. (Biomedical Division)
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the permission of the publisher, Elsevier Science Publishers B.V. (Biomedical Division), P.O. Box 1527, 1000 BM Amsterdam (The Netherlands).

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in article 17 paragraph 2 of the Dutch Copyright Act of 1912 and in the Royal Decree of June 20, 1974 (S. 351) pursuant to article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, SALEM, MA 01970 (U.S.A.). If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of U.S. $2.25, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purpose, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Mutation Research, 142–158/INDEX (1985) 1–11
Elsevier

Cumulative Author Index 1985

Volumes 142–158

Abbondandolo, A., *147*, 292; *150*, 347; *154*, 85
Abbott, P.J., *145*, 25
Abe, T., *156*, 117
Abel, G., *147*, 130
Aboul-ela, E.I., *155*, 135
Abraham, S.K., *143*, 219
Adachi, S., *147*, 270
Adámková, M., *147*, 285
Adams, P.M., *147*, 197
Adzigitov, F., *147*, 285
Agurell, E., *155*, 91
Ahmad, S.I., *151*, 43
Aida, T., *149*, 95
Akasaka, S., *149*, 321
Al-Taweel, A.A., *151*, 73
Al-Watban, F.A.H., *149*, 353
Alavantić, D., *142*, 65; *147*, 283, 318
Albert, A., *156*, 139
Albertini, R.J., *150*, 411
Albertini, S., *144*, 67; *156*, 39
Albiano, N., *143*, 237
Alderson, T., *154*, 101
Alejandre-Durán, E., *147*, 153
Alexandrov, S.E., *147*, 283
Alldrick, A.J., *142*, 1; *144*, 59
Allen, P.F., *155*, 75
Allison, D.X., *157*, 63
Altmann, H., *147*, 130
Amer, S.M., *155*, 135
Ames, B.N., *148*, 25; *150*, ix
Anders, M., *142*, 163
Andersen, J., *156*, 131
Anderson, D., *142*, 13
Andersson, H.C., *150*, 313
Andoh, H., *147*, 272
Andrae, U., *145*, 201; *152*, 225
Andrews, A.W., *157*, 23
Angelini, G., *144*, 209
Angelis, K.J., *143*, 161
Antoshchina, M.M., *147*, 284
Araki, A., *147*, 255; *150*, 151
Arany, J., *147*, 290
Arauchi, T., *144*, 51
Aravindakshan, M., *144*, 99
Arima, M., *146*, 211
Arimoto, S., *147*, 255, 260
Armas-Portela, R., *158*, 77
Arni, P., *144*, 137; *147*, 284
Arwert, F., *144*, 281; *145*, 77
Asakuno, K., *147*, 273
Ashby, J., *142*, 121; *150*, 383; *154*, 111; *156*, 1, 19, 129, 239
Assinder, S.J., *142*, 179
Astengo, M., *144*, 213; *158*, 19
Athwal, R.S., *149*, 73
Au, W.W., *143*, 69
Auerbach, Ch., *150*, viii
Auletta, A., *153*, 1; *154*, 49
Aurich, O., *142*, 23, 183; *149*, 451
Avalosse, B., *149*, 1
Averbeck, D., *148*, 47; *151*, 217, 281
Averbeck, S., *148*, 47

Baan, R.A., *150*, 23
Babilon, R.W., *146*, 79
Baev, I., *147*, 325
Baker, R.S.U., *158*, 111
Bakhitova, L.M., *147*, 311
Bakke, J., *158*, 217
Ball, J.C., *142*, 141
Ball, L.M., *155*, 95
Banduhn, N., *156*, 199
Banerjee, M.R., *147*, 165
Barale, R., *144*, 193; *157*, 235
Barański, B., *147*, 285
Barbé, J., *146*, 23
Barbin, A., *152*, 147, 157
Barkan, R.S., *147*, 326
Barnes, W.S., *156*, 83
Barrett, J.C., *148*, 107
Bârta, I., *147*, 285
Bartsch, H., *147*, 324; *150*, 177; *152*, 147, 157
Bass, D., *143*, 155
Bassan, H.M., *147*, 107
Bassi, A.M., *144*, 189
Basso, C., *144*, 213; *158*, 19
Batson, A.G., *151*, 147, 161
Bauchinger, M., *142*, 37; *147*, 318; *158*, 195
Bauer, C., *147*, 231
Beagley, K.W., *157*, 95
Beaune, Ph., *156*, 139
Bechtold, W.E., *155*, 7
Becker, Y., *149*, 283
Beechy, C.V., *147*, 357
Behnsen, H., *149*, 83
Behymer, T.D., *157*, 71
Beije, B., *150*, 383
Beland, F.A., *142*, 203; *143*, 173; *149*, 25
Bellincampi, D., *147*, 287
Ben-Itzhak, J., *147*, 107
Bender, M.A., *150*, 277; *152*, 39
Benetti, D., *156*, 77
Benigni, R., *145*, 81; *147*, 139, 287
Bennett, I.P., *142*, 187
Bennicelli, C., *158*, 19
Benova, D.K., *147*, 286, 287
Bentchen, T.I., *147*, 311
Benziger, J., *148*, 135
Berends, F., *146*, 305; *151*, 129
Bérézíat, J.-C., *152*, 147
Bergman, R., *149*, 257
Bermudez, E., *155*, 75
Bernstein, H., *158*, 45
Bertazzoni, U., *147*, 319
Berzin, V.I., *147*, 308
Besson, F., *152*, 147
Bhattacharjee, S.B., *152*, 77
Bhattacharyya, N., *152*, 77
Bianchi, V., *146*, 277; *156*, 219
Bickers, D.R., *147*, 37
Bignami, M., *145*, 81
Biondi, O., *147*, 311
Bisagni, E., *148*, 47
Bishop, J.B. *142*, 193; *144*, 93
Blazak, W.F., *158*, 217
Block, A.W., *151*, 263
Bloomfield, S.F., *151*, 201
Blount, J.L., *149*, 33
Blowers, S.D., *142*, 13
Boccardo, P., *144*, 165
Bodell, W.J., *149*, 95
Börzsönyi, M., *144*, 177
Bogajewski, J., *147*, 383
Bohnert, E., *145*, 217
Bohr, V., *146*, 219

0027-5107/85/$03.30 © 1985 Elsevier Science Publishers B.V. (Biomedical Division)

Bonatti, S., *150*, 347
Bonin, A.M., *158*, 111
Bootsma, D., *145*, 217; *146*, 71; *150*, 99
Borba, H., *147*, 306
Borghi, O., *157*, 235
Borovitskaya, E.E., *147*, 297
Bos, A., *147*, 323
Bos, R.P., *151*, 195; *156*, 195
Bose, K., *157*, 63
Bošković, B., *142*, 9
Bouck, N., *152*, 5
Bouter, S., *147*, 309; *148*, 1
Boyd, J.A., *143*, 187
Braden, P.W., *152*, 217
Bradley, W.E.C., *152*, 107
Bradt, C.I., *150*, 327
Braggaar, H., *142*, 75
Braginsky, M.L., *147*, 289
Brambilla, G., *144*, 189, 209
Braun, R., *147*, 382
Breckon, G., *144*, 19
Brehm, T.M., *151*, 185
Breimer, L.H., *150*, 85
Bridges, B., *147*, 387
Bridges, B.A., *145*, 49; *146*, 135; *150*, ix, 133
Britvič, S., *144*, 63
Brockman, H.E., *142*, 19; *150*, 193
Bronzetti, G., *144*, 165; *147*, 231, 287
Brook, J.D., *157*, 215
Brooker, P.C., *158*, 209
Brookman, K.W., *149*, 249; *150*, 423
Brooks, A.L., *155*, 7
Brooks, T.M., *149*, 159; *153*, 57
Brouwer, J., *153*, 13
Bruce, R.J., *144*, 13
Bruggeman, I.M., *142*, 209
Brunner, D.P., *151*, 185
Brunnhofer, V., *157*, 163
Brusick, D., *153*, 1
Bryan, G.T., *148*, 13
Bryant, D.W., *144*, 159
Bryant, P.E., *146*, 55, 63
Bücker, M., *156*, 163
Buenaventura, S.K., *158*, 97
Buisson, J.-P., *157*, 53
Bulanova, M., *147*, 309
Burgess, J.A., *152*, 5
Burkhart, J.G., *148*, 135
Burkhart-Schultz, K., *143*, 245; *147*, 97
Burlinson, B., *156*, 1
Burrell, A., *156*, 131
Butte, W., *145*, 71

Cabral, J.R.P., *150*, 177
Cacheiro, N.L.A., *147*, 205; *152*, 49, 217
Caderni, G., *144*, 57
Cain, K.T., *143*, 51; *147*, 205; *152*, 49, 217; *156*, 103
Cairó, J., *146*, 23
Cajelli, E., *143*, 257
Calcagnile, A., *147*, 286
Call, K.M., *151*, 95
Callander, R.D., *142*, 121, 187; *156*, 19
Calvo, A., *142*, 213
Cameron, J.W., *142*, 127
Cameron, T.P., *155*, 17
Camoirano, A., *158*, 19
Camus, A.M., *147*, 324
Cao, Sh., *150*, 307
Capizzi, R.L., *147*, 369
Carere, A., *147*, 287; *155*, 105
Carlone, S., *144*, 203
Carnes, B.A., *147*, 15
Carrano, A.V., *143*, 245; *147*, 97; *149*, 133
Carter, M.H., *143*, 5; *144*, 159
Cartmel, C.L., *144*, 247
Carvalho, M.I. de O., *158*, 181
Casati, A., *147*, 311
Casida, J E., *158*, 61
Casini, D., *144*, 193
Cassier, C., *145*, 145
Cattanach, B.M., *149*, 105
Catuogno, L.S., *151*, 25
Cawood, A.H., *144*, 19
Celotti, L., *146*, 277
Černá, M., *143*, 161, 169
Cervone, T.H., *149*, 375
Chan, V.L., *149*, 141
Chandley, A.C., *157*, 215
Chanet, R., *145*, 145
Chankong, V., *153*, 135, 167, 187
Chao, C.C.-K., *146*, 191; *149*, 443
Charles, D.J., *147*, 315; *150*, 393
Chatterjee, S.N., *156*, 69
Chauhan, P.S., *144*, 99
Chaveca, T., *147*, 306
Chebotarev, A.N., *147*, 288
Chen, Y., *146*, 301
Chevalier, G., *155*, 83
Chinenkov, V.A., *147*, 289
Choi, K., *152*, 97
Chollet, C., *147*, 290
Chopra, V.L., *143*, 191
Chou, M.W., *143*, 173
Chouroulinkov, I., *147*, 306; *150*, 177; *157*, 53
Choy, H.E., *142*, 93
Choy, W.N., *143*, 55
Christensen, R.B., *150*, 211
Chu, E.H.Y. *149*, 127
Chung, T.H., *158*, 119
Čihák, R., *144*, 81; *147*, 289
Cimander, B., *147*, 289
Ciranni, R., *144*, 193
Citti, L., *156*, 77
Clare, M.G., *156*, 109
Clarkson, J.M., *143*, 109; *146*, 129
Claxton, L.D., *157*, 123
Clayson, D.B., *154*, 205
Cleaver, J.E., *150*, 69
Clive, D., *147*, 237, 243; *151*, 147, 161
Coleman, D.T., *158*, 149
Coleman, W.E., *157*, 111
Collecchi, P., *144*, 203
Collis, Ch.M., *146*, 47
Colot, M., *147*, 23, 189
Cominato, I., *144*, 183
Conti, G., *147*, 287; *155*, 105
Conti, L., *147*, 287; *155*, 105
Contreras, R., *147*, 343
Cornelis, J.J., *142*, 75; *149*, 1; *151*, 1, 9
Cornett, C.V., *143*, 51; *152*, 49, 217
Corsi, C., *147*, 231, 287
Cortés, F., *151*, 77
Cosy, Ch., *150*, 327
Côté, M.G., *155*, 83
Coton, C., *149*, 475
Cox, J.L., *146*, 249
Craddock, V.M., *142*, 13
Crebelli, R., *147*, 287; *155*, 105
Crespi, C.L., *142*, 133; *157*, 71
Creus, A., *149*, 189; *158*, 177
Cross, M.F., *142*, 187
Crossen, P.E., *149*, 101
Csík, M., *144*, 177
Csukás, I., *144*, 41
Cundari, E., *144*, 165; *147*, 231, 287
Cupido, M., *145*, 49; *146*, 135
Curtis, J.R., *147*, 171, 179
Curvall, M., *147*, 299; *157*, 169

Dahl, A.R., *158*, 141
Daisey, J.M., *144*, 107
Dallapiccola, B., *144*, 257
Dansie, D.R., *156*, 181
Darlington, G.J., *149*, 505
D'Arpa, P., *149*, 437
Darroudi, F., *143*, 263; *149*, 239; *151*, 251
Das, B.C., *144*, 85
Daub, G.H., *142*, 141
David, R.M., *156*, 181
Day, N.E., *150*, 177
Dayan, J., *157*, 1
Dean, B.J., *153*, 57; *154*, 153; *156*, 109
Dearfield, K.L., *158*, 97
De Bellecombe, Ch., *147*, 79
De Bruin, P.A.F., *150*, 23
De Bujan, E.C., *143*, 237
Decaesstecker, M., *151*, 9
De Carli, L., *147*, 311
Defais, M., *145*, 35
De Flora, S., *144*, 213; *158*, 19
De France, B.F., *144*, 159
Degawa, M., *152*, 125

Degraeve, N., *147*, 290
Degrassi, F., *150*, 359
Deguingand, S., *157*, 1
Deinum, J., *143*, 231
De Jong, G., *156*, 109
De Jonge, A.J.R., *150*, 99
Deknudt, Gh., *147*, 290, 300
Delavignette, E., *147*, 290
Del Carratore, R., *144*, 165; *147*, 231, 287
Delehanty, J.T., *153*, 13
Della Porta, G., *156*, 177; *157*, 235
Della Valle, G., *147*, 311
Del Monte, M., *156*, 77
De Meester, C., *147*, 310; *156*, 53
Dempsey, J.L., *147*, 363
Denizeau, F., *155*, 83
Denny, W.A., *157*, 29
De Renzi, G.P., *158*, 19
De Salvia, R., *150*, 359
de Serres, F.J., *147*, 59; *150*, ix, 193
De Vogel, N., *147*, 323
Dickins, M., *143*, 149; *157*, 189
Dimitrov, B., *147*, 291
Dinsart, Ch., *151*, 9
Dobiáš, L., *147*, 291
Doerr, R.C., *157*, 129
Dogliotti, E., *145*, 81
Dohn, D.R., *158*, 61
Dolara, P., *144*, 57
Dollemeier, P., *144*, 137
Domon, O.E., *142*, 193
Domshlack, M.G., *147*, 291
Dornfeld, S.S., *147*, 15
Doudney, Ch.O., *143*, 29; *144*, 151
Dozi-Vassiliades, J., *143*, 225
Dragani, T.A., *156*, 177
Drăghicescu, T., *147*, 296
Ducore, J.M., *146*, 1
Duda, R., *155*, 121
Dulout, F.N., *143*, 237
Dunkel, V.C., *155*, 17
Dunn, P.B., *147*, 171, 179
Dusenbery, R., *150*, 235
Dusenbery, R.L., *149*, 193
Dutcher, J.S., *155*, 7
Dutkowski, R.T., *149*, 505
Dutrillaux, B., *149*, 57; *152*, 197
Džidić, S., *144*, 127

Ebine, Y., *144*, 51
Ebringer, L., *147*, 321
Eckardt, F., *150*, 51; *151*, 235
Edgar, D.H., *157*, 199; *158*, 209
Edler, L., *145*, 217
Edney, E.O., *157*, 123
Eeken, J.C.J., *144*, 73; *149*, 385, 409; *150*, 261
Ehling, U.H., *147*, 279, 293; *150*, 393
Einistö, P., *147*, 292
Eisenberg, W.C., *142*, 41
Eisenstadt, E., *157*, 227
Eker, A.P.M., *146*, 71
Elbling, L., *147*, 23, 189
Elespuru, R.K., *157*, 23
Eling, T.E., *143*, 187
Elliott, G.C., *145*, 185
Emi, Y., *142*, 153
Endo, O., *147*, 264
Endo, R., *147*, 273
Enger-Valk, B.E., *148*, 35
Engle, A., *152*, 97
Enninga, I.C., *148*, 119; *152*, 233
Enzell, C.R., *157*, 169
Erexson, G.L., *157*, 181
Escalza, P., *151*, 77
Esposito, M., *144*, 203
Esterbauer, H., *148*, 25
Evans, D.M., *145*, 119
Evans, H.J., *150*, 355
Evensen, G., *146*, 143
Everson, R.B., *147*, 369

Fabricant, J., *154*, 49
Fabry, L., *149*, 475
Faccioli, M.C., *144*, 183
Faggin, P., *144*, 189
Fahl, W.E., *152*, 5
Fahmy, M.J., *152*, 169
Fahmy, O.G., *152*, 169
Falck, K., *150*, 119
Fanini, D., *147*, 197
Farrelly, J.G., *157*, 23
Fassina, G., *144*, 203; *147*, 292
Favor, J., *147*, 293; *150*, 393
Fayeulle, J.-P., *158*, 69
Feldt, E.G., *147*, 294
Fendrock, B., *150*, 333
Fenech, M., *147*, 29; *148*, 99
Ferguson, L.R., *157*, 29; *158*, 89
Ferguson, M.J., *149*, 41
Ferraro, M., *149*, 463
Ferro, W., *149*, 385, 399, 415; *150*, 225
Feuers, R.J., *142*, 193
Fiddler, W., *157*, 129
Finollo, R., *144*, 189
Fischer, E., *145*, 217
Flint, K.B., *150*, 443
Fomina, M.M., *147*, 294
Fostel, J., *155*, 75
Fowler, R.G., *142*, 93
Fox, D.P., *151*, 73
Fox, M.S., *146*, 185
Foxall-Van Aken, S., *142*, 141
Frei, H., *147*, 326
Friederich, U., *144*, 67; *156*, 39
Friederici, D.E., *147*, 136
Friedrich, U., *152*, 113
Frierson, M., *149*, 311
Friesen, M., *150*, 177
Frosina, G., *154*, 85
Fu, J., *149*, 127
Fu, P.P., *143*, 173; *144*, 1
Fujie, K., *147*, 274
Fujikawa, K., *147*, 272
Fujioka, Y., *149*, 9
Fujita, H., *158*, 135
Fujita, Y., *142*, 145; *144*, 227
Fujiwara, Y., *145*, 55; *147*, 271
Fukui, S., *142*, 103; *149*, 9
Fukunaga, A., *151*, 243
Fukuoka, S., *147*, 273
Fukushima, S., *146*, 15
Fulco, R.A., *144*, 203
Fumero, S., *147*, 295
Funeshima, M., *147*, 273
Fung, V.A., *155*, 17
Furihata, C., *147*, 256
Furui, K., *147*, 268
Furukawa, H., *147*, 256

Galendo, D., *150*, 177
Galli, A., *144*, 165
Gallie, B.L., *152*, 31
Galperin, I., *158*, 217
Gandini, E., *144*, 257
Garren, L., *150*, 177
Gasic, M.J., *144*, 63
Gaulden, M.E., *149*, 41
Gava, C., *156*, 219
Gebauer, J., *147*, 133, 134
Gebhart, E., *147*, 129; *149*, 83
Geblarian, N.P., *147*, 295
Geeroms, D., *142*, 169
Geissler, E., *147*, 324
Generoso, W.M., *143*, 51; *147*, 205; *152*, 49, 217; *156*, 103
Georgian, L., *147*, 296, 384
Georgieva, V., *157*, 13
Germanier, M., *145*, 35
Gershenson, S.M., *147*, 279
Gervasi, P.G., *156*, 77
Gescheff, K., *143*, 83
Ghia, M., *143*, 257
Gibas, Z., *151*, 263
Gibson, D., *149*, 353
Gichner, T., *149*, 431
Gielen, J., *156*, 139
Gilbert, P.J., *149*, 303
Gilet-Delhalle, J., *147*, 290
Giner-Sorolla, A., *144*, 231
Giorelli, F., *144*, 193
Girardi, A.J., *150*, 327
Giuliani, A., *147*, 139, 286
Giuliano, L., *144*, 209

Gjerset, R.A., *142*, 199
Glaser, V.M., *147*, 296
Glatt, H.R., *147*, 124, 125, 126; *149*, 265; *156*, 163
Gocke, E., *156*, 93
Goddard, A.D., *152*, 31
Göggelmann, W., *147*, 132, 297
Gold, A., *155*, 95
Goldberg, M.T., *143*, 5, 127
Goldstein, L.S., *152*, 53
Gollapudi, B.B., *144*, 13
Golovachev, G.D., *147*, 297
Gomes, M., *147*, 306
Gomez-Arroyo, S., *156*, 233
Gonzalez, L.P., *149*, 159
González Cid, M., *143*, 237
González-Fernández, A., *149*, 275
Goodall, C.M., *157*, 95
Goodwin, P.A., *145*, 103
Gorrod, J.W., *151*, 201
Gosslee, D.G., *152*, 217
Goto, S., *147*, 264, 268
Goyder, Y., *149*, 221, 231
Graf, U., *147*, 326
Grafe, A., *147*, 132
Grau, O., *143*, 201
Graw, J., *150*, 393
Grecz, N., *145*, 113
Green, S., *154*, 49
Gregor, V., *143*, 271
Griffin, F.M., *147*, 369
Grivas, S., *142*, 5; *144*, 131; *151*, 177
Groenendijk, R.T.L., *148*, 119; *152*, 233
Gröschel-Stewart, U., *144*, 67; *149*, 333; *150*, 203
Grosovsky, A.J., *149*, 147
Grossmann, A., *152*, 67
Grover, I.S., *155*, 131
Groves, L., *158*, 159
Grziwok, K., *149*, 83
Gualandi, G., *147*, 287
Guerrero, R., *146*, 23
Guildiyeva, M.S., *147*, 289
Gullvåg, B., *156*, 147
Gutiérrez, C., *142*, 213
Guttman, S., *149*, 141

Hachiya, N., *147*, 256
Hackenberg, U., *147*, 136
Hadnagy, W., *147*, 128
Hagen, I., *157*, 149
Haimes, Y.Y., *153*, 135, 167, 187
Haipek, C.A., *143*, 109; *146*, 129
Hakura, A., *147*, 259; *157*, 87
Hall, R.M., *142*, 87; *146*, 47
Halpern, M., *147*, 306
Hamasaki, T., *143*, 121
Hann, D., *156*, 39
Hanna, M.L., *151*, 293
Hannan, M.A., *149*, 353
Hannuniemi, R., *158*, 31
Hansson, K., *151*, 251
Hansteen, I.-L., *147*, 383
Hara, Y., *150*, 127
Harada, Y., *146*, 243
Haraikawa, K., *147*, 275; *149*, 327
Harbison, R.D., *144*, 93
Harnasch, D., *156*, 93
Harris, C.C., *146*, 205
Hartley-Asp, B., *143*, 231
Hasegawa, M.M., *147*, 268
Hashiba, S., *147*, 267
Hashimoto, K., *158*, 129
Hashimoto, Y., *147*, 264; *152*, 125
Hatanaka, M., *147*, 273
Hatcher, J.F., *148*, 13
Hatzittheodoridou, P., *143*, 225
Hauf, R., *142*, 37
Haught, M.A., *152*, 15
Hautefeuille, A., *150*, 177
Hayashi, A., *146*, 211
Hayashi, K., *147*, 269
Hayashi, M., *147*, 257, 267
Hayatsu, H., *143*, 165, 207; *147*, 255, 259, 260, 261; *158*, 35
Hayatsu, T., *143*, 207
Haybron, D., *158*, 159
Hayes, S., *143*, 23
Haynes, R.H., *150*, 51; *151*, 235
Hazen, M.J., *158*, 77
He, S.-M., *146*, 301; *158*, 201
Heartlein, M.W., *148*, 91; *150*, 299
Heddle, J.A., *147*, 256; *152*, 31
Hedin, A., *157*, 169
Heflich, R.H., *142*, 203; *143*, 173; *144*, 1; *149*, 25
Heindorff, K., *142*, 23, 183
Hellman, B., *149*, 495
Hemminki, K., *154*, 135
Henderson, E.E., *146*, 79
Henderson, L., *144*, 27
Henderson, P.Th., *151*, 195; *156*, 195
Henderson, R.F., *155*, 7
Hennig, U.G.G., *150*, 217
Henry, C.J., *156*, 181
Hens, L., *147*, 325; *157*, 221
Henschler, D., *156*, 33; *157*, 145
Herbert, A., *149*, 485
Hernández, P., *149*, 275
Herrlich, P., *145*, 177
Hertoghs, J.J.L., *151*, 1
Heussner, J.C., *155*, 143
Higashikawa, T., *149*, 297
Hill, R., *150*, 327
Hiraga, K., *156*, 123
Hirai, K., *142*, 103
Hirayama, T., *142*, 103; *147*, 335; *149*, 9
Hirono, I., *143*, 75; *144*, 287
Hisamatsu, Y., *147*, 257
Hites, R.A., *157*, 71
Hodson-Walker, G., *153*, 57
Högstedt, B., *156*, 229
Hoeijmakers, J.H.J., *146*, 71; *150*, 99
Höls, I., *147*, 137
Hoffmann, D., *158*, 149
Hoffmann, G.R., *150*, 107; *151*, 25
Hofnung, M., *147*, 65, 79
Holå, N., *144*, 271, 277; *147*, 298, 322
Holder, G.M., *158*, 111
Hollaender, A., *150*, viii
Holland, I.B., *151*, 43
Holloway, M., *149*, 311
Holloway, W.D., *158*, 89
Hollstein, M.C., *148*, 25
Holmgren, K., *142*, 69
Horikawa, K., *147*, 263; *157*, 39
Horne, L., *157*, 95
Howard, B.E., *151*, 147, 161
Howard, P.C., *149*, 25
Hozier, J., *147*, 237, 243; *151*, 161
Hsieh, D.P.H., *157*, 227
Hsu, L.L., *147*, 197
Huang, C.C., *142*, 115
Huang, R.-Y., *148*, 83
Hudson, S.J., *149*, 33
Hughes, L.A., *152*, 217; *156*, 103
Hughes, T.J., *155*, 17
Hunaiti, A., *144*, 119
Hung, C.Y., *150*, 193
Hung Vo Phi, *155*, 49
Hunter, B.J., *152*, 131
Hurd, H.K., *148*, 25
Husgafvel-Pursiainen, K., *147*, 298
Husum, B., *155*, 71
Hutson, D.H., *153*, 57
Hyland, V., *150*, 261

Ibuki, E., *149*, 9
Ichihashi, M., *145*, 55
Igaki, H., *143*, 11
Ignatowicz, R., *147*, 312
Iida, Y., *147*, 273
Imamura, T., *155*, 1
Imanishi, H., *147*, 271
Ino, T., *143*, 11
Inoue, H., *152*, 161
Inoue, K., *156*, 117
Inoue, M., *157*, 205
Inoue, T., *146*, 15; *147*, 257, 276
Inoue, Y., *147*, 261
Inui, N., *147*, 268
Irvin, T.R., *152*, 85
Ise, H., *147*, 273
Ishibashi, T., *147*, 275

Ishidate Jr., M., *147*, 257, 265, 269, 273
Ishii, C., *152*, 161
Ishii, K., *147*, 275
Ishikawa, T., *157*, 135
Ishizaki, K., *150*, 91
Ishizu, Y., *147*, 261
Itkonen, A., *147*, 299
Ivanov, B., *147*, 309
Ivanov, E.L. *149*, 359
Ivanov, V.I., *147*, 299
Ivanović, V., *142*, 9
Iwamoto, Y., *158*, 169
Izumikawa, S., *147*, 273

Jacobs-Meijsing, B.L.M., *148*, 35
Jacobson-Kram, D., *149*, 437; *158*, 97, 217
Jägerstad, M., *144*, 131; *147*, 267; *151*, 177
Jan, K.Y., *148*, 83
Janakat, S., *144*, 119
Janča, L., *147*, 291
Jansson, T., *147*, 299; *157*, 169
Jantunen, M.J., *147*, 299
Jaros-Kamińska, B., *147*, 285
Jaw, R., *145*, 113
Jeggo, P.A., *145*, 171; *146*, 265
Jenar-Du Buisson, G., *147*, 290
Jenderny, J., *147*, 136
Jensen, J.C., *147*, 380
Joachim, F., *156*, 131
Johanson, K.J., *149*, 257
Johnson, N.P., *145*, 35
Johnson, R.T., *145*, 185
Jolly, L.D., *143*, 183
Jones, C., *149*, 105
Jones, E., *155*, 35
Jones, G.M., *151*, 57
Jones, I.M., *143*, 245; *147*, 97; *149*, 133
Jones, W.T., *158*, 89
Jongeneelen, F.J., *156*, 195
Jordan, S.W., *157*, 63
Josephy, P.D., *143*, 5; *144*, 159
Joshi, M.G., *147*, 45
Juhl, U., *145*, 71
Jung, E.G., *145*, 217
Juon, H., *147*, 326

Kada, T., *146*, 15; *147*, 258; *149*, 17; *150*, 127
Kado, N.Y., *157*, 227
Kaighn, M.E., *145*, 81
Kaina, B., *142*, 49; *149*, 451
Kaiser, G., *156*, 93
Kaldor, J., *152*, 147
Kale, R.P., *152*, 39
Kalina, I., *147*, 300
Kalinina, L.M., *147*, 300
Kallak, H.I., *147*, 51
Kalweit, S., *147*, 127
Kammermeyer, K.L., *144*, 77
Kanamori, H., *144*, 221; *147*, 265
Kaneko, I., *144*, 265
Kaneko, K., *150*, 127
Kaneko, M., *143*, 103
Kape, R.P., *150*, 277
Kapp, L.N., *142*, 199
Kapp, R., *154*, 49
Kappas, A., *147*, 310; *157*, 13
Karai, I., *158*, 119
Karawya, E., *146*, 295
Karczmarz, T., *147*, 289
Karlsson, A., *156*, 229
Kasai, H., *147*, 258
Kato, K., *157*, 135
Kato, T., *147*, 219, 259; *158*, 35
Katoh, M., *147*, 258
Katosova, L.D., *147*, 301
Katz, A.J., *143*, 195
Kaul, B.L., *144*, 239
Kawai, K., *143*, 121; *147*, 256
Kawamura, T., *147*, 275
Kawano, S., *147*, 269
Kawazoe, Y., *147*, 259; *156*, 153; *157*, 87
Kayashima, M., *147*, 273
Kaylor, W.H., *157*, 111
Keijzer, W., *145*, 217; *150*, 99
Kerklaan, P.R.M., *147*, 302, 309; *148*, 1
Kesavan, P.C., *143*, 61, 219
Keyse, S.M., *146*, 109
Khadzhidekova, V., *147*, 303
Kharab, P., *155*, 117
Khartonik, A.M., *147*, 307
Khrebtukova, I.A., *149*, 271
Kiessling, U., *147*, 324
Kigoshi, H., *144*, 287
Kihlman, B.A., *150*, 313
Kikuchi, Y., *147*, 272
Kikugawa, K., *147*, 259; *158*, 35
Kilanowski, F.M., *144*, 89
Kilbey, B., *143*, 35
Kim, J.P., *149*, 437
Kimmel, E.C., *158*, 61
Kimura, T., *147*, 260
King, M.-T., *156*, 93
Kinouchi, T., *147*, 260, 264, 270; *158*, 3
Kinsella, T.J., *146*, 295
Kirby, P.E., *155*, 17
Kirk, K.M., *149*, 221, 231
Kirsch-Volders, M., *147*, 325, 379; *157*, 221
Kitamura, J., *143*, 121
Kleindienst, T.E., *157*, 123
Kleinhofs, A., *149*, 431
Kligerman, A.D., *155*, 75; *157*, 181
Klopman, G., *147*, 343; *149*, 311; *150*, 1
Knaap, A.G.A., *147*, 303; *155*, 41
Kneip, T.J., *144*, 107
Knežević, J., *142*, 159
Knook, D.L., *146*, 197
Kobayashi, H., *147*, 261
Kobayashi, Y., *147*, 272
Kočišová, J., *147*, 304
Kocsis, Z., *144*, 177
Kodama, M., *143*, 103
Kodama, T., *147*, 276
Køber, L., *145*, 157; *146*, 219
König, H., *147*, 134
Koga, T., *146*, 271
Kohan, M.J., *155*, 95
Kohda, K., *157*, 87
Kohout, P., *147*, 304
Koizumi, A., *152*, 187
Koizumi, N., *147*, 261
Kojima, M., *147*, 262; *152*, 125
Koleva, M., *147*, 303
Kolman, A., *146*, 43
Kondo, S., *145*, 165; *146*, 257; *147*, 272; *151*, 243
Konishi, S., *147*, 268
Konishi, Y., *142*, 153; *144*, 197; *146*, 243
Korogodina, Yu.V., *147*, 299
Korolev, V.G., *149*, 359
Korpella, R., *152*, 97
Korte, A., *147*, 131
Kosaka, H., *142*, 99; *156*, 117
Kotecki, M., *147*, 304, 312
Kotěšovec, F., *144*, 271, 277
Kounoue, E., *146*, 271
Kourakis, A., *143*, 225
Kowal, K., *147*, 289
Koyama, K., *150*, 141
Kraemer, K.H., *145*, 89
Kramers, P.G.N., *142*, 29; *147*, 303; *155*, 41
Kratochvilova, J., *150*, 393
Krause, H., *147*, 324
Krauss, B.R., *150*, 211
Kreft, K., *147*, 137
Kremers, P., *156*, 139
Krishna, G., *158*, 81
Krøkje, Å., *156*, 147
Krokan, H., *146*, 205
Krokan, R.H., *146*, 205
Krych, M., *149*, 287
Kučerová, M., *143*, 271
Kuleshov, N.P., *147*, 305
Kuliev, A.M., *147*, 280
Kunz, B.A., *150*, 51; *151*, 235
Kurelec, B., *144*, 63
Kurischko, K., *147*, 305
Kuroda, M., *147*, 262
Kuroda, Y., *147*, 262
Kuromoto, M., *147*, 263

Kurosaki, Y., *147*, 260
Kurosawa, Y., *144*, 51
Kushi, A., *147*, 263

Laakso, K., *152*, 97
Laires, A., *147*, 306
Lalande, M.E., *148*, 71
Lambert, B., *146*, 301; *147*, 384; *158*, 201
Lambert, M.W., *145*, 227
Lambert, W.C., *145*, 227
Landa, K., *147*, 298, 322
Langer, P.J., *150*, 147
Lanir, A., *147*, 107
Lansbergen, M.J., *150*, 23
Lapis, K., *149*, 51
Larcom, L.L., *145*, 17
Larson, K., *150*, 77
Lasne, C., *147*, 306; *150*, 177; *157*, 53
Latt, S.A., *148*, 71; *150*, 333
Lavia, P., *149*, 463
LaVoie, E., *158*, 149
Lawrence, Ch.W., *150*, 211
Lazjuk, G.I., *147*, 307
Lechner, J., *146*, 205
Lee, C.-S., *147*, 264
Lee, E.G.-H., *155*, 53
Lee, T.-Ch., *148*, 83
Lefevre, P.A., *156*, 1, 19
Legator, M.S., *147*, 197; *155*, 143
Lehmann, A.R., *150*, 61
Lekevičius, R.K., *147*, 308
Lemestré-Cornet, R., *156*, 139
Lemmon, M., *158*, 217
Leon, A.A., *142*, 141
Léonard, A., *147*, 281, 290, 300
Leong, P.-M., *150*, 403
Leopardi, P., *147*, 286
Leppänen, A., *147*, 317
Lesh, R., *149*, 505
Lesko, S.A., *149*, 119
Levi, B.-Z., *147*, 107
Levin, D.E., *148*, 25
Levis, A.G., *144*, 183; *156*, 219
Leyden, M.F., *151*, 209
Li, I-Chian, *149*, 127
Liang, J.C., *155*, 61
Liber, H.L., *151*, 95; *157*, 71, 77
Liewen, M.B., *157*, 49
Liimatainen, A., *147*, 299
Lijinsky, W., *157*, 23
Lindahl, T., *150*, 85
Lindenhahn, M., *147*, 319
Linnane, J.F., *151*, 25
Little, J.B., *142*, 55; *148*, 71; *149*, 147; *157*, 77
Löfroth, G., *155*, 91
Lohman, I., *147*, 291
Lohman, P.H.M., *146*, 89, 197, 305; *147*, 218; *148*, 35; *150*, 23; *151*, 129; *153*, 13
Lohrer, H., *145*, 177
Lojo, M.M., *143*, 201
Lomova, T.Y., *147*, 320
Long Jian-bin, 144, 243
Longo, V., *156*, 77
Longstaff, E., *142*, 187
López-Sáez, J.F., *142*, 213; *149*, 275
Loprieno, N., *144*, 193; *147*, 318; *157*, 235
Loria, D., *143*, 237
Lowicki, N., *147*, 137
Lowy, R., *157*, 53
Lubet, R.A., *142*, 127
Luca, D., *155*, 121
Luca, V., *155*, 121
Luchnik, N.V., *147*, 284
Lucić, D., *144*, 63
Lucier, G.W., *143*, 131
Luebbe, L., *147*, 324
Lundgren, K., *143*, 131
Luthra, U.K., *144*, 85
Lyon, M.F., *149*, 221, 231

McBlane, F., *143*, 35
McCalla, D.R., *144*, 159
McCartney, M., *144*, 231
McCormick, J.J., *146*, 285, *152*, 67
McCoy, E.C., *142*, 163; *144*, 231; *149*, 311
Macdonald, I.A., *155*, 99
McGarrity, L.J., *142*, 193
McGarry, T.J., *145*, 113
MacGregor, J.T., *143*, 55
MacPhee, D.G., *143*, 1, 183; *151*, 35, 49, 209; *157*, 29
McKelvey, V.J., *147*, 307
McKenna, P.G., *147*, 307
McLennan, A.G., *142*, 83
Mačor, M., *147*, 321
Mader, J.A., *155*, 99
Madle, E., *147*, 135
Madle, S., *147*, 131
Maekawa, A., *147*, 267
Maher, V.M., *146*, 285; *152*, 67
Mahon, G.A.T., *147*, 5
Maier, P., *143*, 143
Maillie, H.D., *149*, 67
Mainguet, P., *142*, 169
Maizumi, H., *148*, 107
Major, J., *149*, 51
Makino, R., *147*, 335
Malaveille, C., *150*, 177
Malhi, P.K., *155*, 131
Malling, H.V., *148*, 135
Manabe, Y., *147*, 264; *158*, 3
Manandhar, M., *154*, 49
Mann, R.C., *143*, 93; *144*, 287
Mannironi, C., *147*, 231
Manoharan, K., *147*, 165
Manojlovic, N., *147*, 134
Manolache, M., *147*, 133, 134
Manson, C., *157*, 227
Manuilova, E.S., *149*, 271
Maramatsu, M., *150*, 141
Marcos, R., *149*, 189; *158*, 177
Marec, F., *157*, 163
Maree, F., *143*, 1
Marinova, Ts., *147*, 303
Marion, M., *155*, 83
Markarjan, D., *147*, 285
Marklund, S.L., *148*, 129
Marnett, L.J., *148*, 25
Maronpot, R.R., *143*, 55
Maršálek, L., *147*, 304
Martelli, A., *143*, 257; *144*, 209
Marth, E.H., *157*, 49
Marui, S., *143*, 11
Marzin, D.R., *155*, 49
Masamoto, Y., *147*, 272
Mascioli, D.A., *151*, 95
Masuda, T., *149*, 327
Mathews, L., *152*, 97
Matijašević, Z., *142*, 149
Matos, E., *143*, 237
Matsuda, Y., *142*, 59; *147*, 258; *148*, 113; *151*, 121, 275
Matsuoka, A., *147*, 273
Matsushima, T., *147*, 255, 266; *150*, 141
Matsushita, H., *147*, 257, 264, 268
Matsuzaki, S., *150*, 127
Matsuzaki, T., *150*, 127
Mattern, I.E., *148*, 35
Mattocks, A.R., *149*, 485
May, J.H., *155*, 35
Mayer, R.T., *142*, 127
Mayer, V.W., *149*, 333, 339
Mehnert, K., *147*, 127
Mehta, R.D., *150*, 217
Meier, J.R., *157*, 111
Meijers, M., *144*, 33
Meistrich, M.L., *152*, 53
Mekler, Ph., *153*, 13
Melhorn, J.M., *156*, 181
Mellano, D., *147*, 295
Merkurjeva, R.V., *147*, 308
Mermelstein, R., *142*, 163; *149*, 311
Mertes, I., *147*, 125
Messing, K., *152*, 107
Mettus, R.V., *149*, 375
Meyer, L.W., *147*, 37
Meyne, J., *157*, 63
Michaelis, A., *142*, 23, 183; *143*, 79, 83; *144*, 171
Michel, G., *152*, 147

Micheli, A., *149*, 463; *150*, 293
Mierauskienė, J.R., *147*, 308
Mifuchi, I., *158*, 169
Migliore, L., *144*, 193
Mileva, M., *147*, 303, 309
Miller, A.J., *157*, 129
Miller, D.W., *143*, 173
Miller, J.H., *145*, 95
Miltenburger, H.G., *147*, 123, 133, 135, 382; *155*, 27
Mine, Y., *146*, 155
Minoda, Y., *147*, 276
Mirzayans, R., *145*, 209
Mitchell, C.S., *150*, 1
Mitchell, D.L., *143*, 109; *146*, 129
Mitchell, I. de G., *149*, 303
Mitchell, J.B., *146*, 295
Mitchell, J.D., *150*, 355
Mitra, A.B., *144*, 85
Miyake, T., *145*, 165
Miyata, R., *147*, 265
Mizokami, K., *147*, 269
Mizusaki, S., *147*, 262, 263, 277; *156*, 61
Mizuta, M., *144*, 221; *147*, 265
Møller, M., *157*, 149
Møller, M.E., *151*, 137
Mohn, G.R., *147*, 302, 309; *148*, 1; *150*, 159
Mohr, U., *150*, 177
Mondello, C., *142*, 45; *147*, 322
Montaldi, A., *156*, 219
Mooney, C.L., *150*, 423
Moore, C.M., *157*, 95
Moore, M.M., *147*, 237, 243; *151*, 147, 161
Moran, E., *146*, 229
Moraru, I., *147*, 296
Morgan, W.F., *150*, 69
Morgenthaler, S., *150*, 403
Mori, H., *143*, 75, 121; *144*, 197, 287
Mori, S., *147*, 269
Mori, Y., *142*, 153; *144*, 197
Morimoto, K., *152*, 187
Morita, H., *147*, 265
Morita, T., *156*, 153
Moriya, M., *147*, 276; *157*, 205
Morley, A.A., *147*, 29, 363; *148*, 99
Moron, L., *148*, 47
Morooka, N., *149*, 327
Morotomi, M., *147*, 260; *149*, 171
Morpurgo, G., *147*, 287
Morris, S.M., *142*, 203
Moseley, B.E.B., *145*, 119
Motykiewicz, G., *147*, 289
Mourelatos, D., *143*, 225
Moustacchi, E., *145*, 145
Moutschen, J., *147*, 290
Moutschen-Dahmen, M., *147*, 290
Mower, H.F., *143*, 207; *158*, 159
Mruk, M., *147*, 312
Müller, D., *144*, 137; *147*, 123, 133
Müller, E.W., *147*, 133, 135
Müller, L., *147*, 137
Müller, W.E.G., *144*, 63
Mugnetian, E.G., *147*, 295
Mukherjee, U., *144*, 33
Mukhtar, H., *147*, 37
Muleris, M., *149*, 57
Mullaart, E., *146*, 197
Mullenders, L.H.F., *144*, 33; *151*, 269
Munch, J.W., *157*, 111
Murakami, A., *147*, 266
Muramatsu, M., *147*, 266
Murata, M., *147*, 264
Mutai, M., *147*, 260; *149*, 171
Muth, A., *147*, 130
Mylius, E., *156*, 147

Nagafuchi, S., *146*, 271
Nagao, M., *142*, 145; *143*, 17; *144*, 227; *147*, 264, 269, 275; *158*, 119
Nagasawa, H., *148*, 71
Nagase, H., *157*, 135
Nagata, C., *143*, 103
Nagayabu, O., *147*, 272
Nakabeppu, Y., *146*, 149, 155
Nakadate, M., *147*, 257, 265, 267
Nakagawa, R., *147*, 263; *157*, 39
Nakai, H., *147*, 275
Nakai, S., *151*, 121
Nakamura, M., *146*, 271
Nakamura, S., *147*, 267, 270
Nakamura, S.-i., *147*, 219
Nakamura, Y., *146*, 15; *149*, 17
Nakano, K., *144*, 265
Nakano, S., *146*, 271; *149*, 327
Nakata, A., *147*, 267
Nakayama, T., *147*, 260
Nanno, M., *149*, 171
Nass, G., *152*, 113
Natarajan, A.T., *143*, 61, 263; *144*, 33, 41, 281; *149*, 239; *150*, 283; *151*, 251, 269; *152*, 205
Nath, J., *149*, 365; *156*, 171; *158*, 81
Natori, S., *150*, 141
Nayak, B.N., *143*, 45
Negishi, C., *147*, 267, 335
Negishi, K., *147*, 262
Nehl, P., *150*, 13
Neis, J.M., *151*, 195
Nestmann, E.R., *155*, 53
Neudecker, T., *156*, 33; *157*, 145
Neuhäuser-Klaus, A., *147*, 293; *150*, 393
Neuteboom, I., *147*, 323
Newman, C.N., *145*, 95
Newton, M.S., *150*, 355
Ngoy, K., *147*, 310; *156*, 53
Nichols, W.W., *150*, 327
Nickols, J.W., *151*, 15
Nicoloff, H., *143*, 83; *147*, 310
Nicoloff, N., *147*, 380
Nicotera, T.M., *151*, 263
Niebuhr, E., *155*, 71
Nielsen, P.E., *145*, 157
Nieri, R., *147*, 231, 287
Niho, Y., *146*, 271
Nikolaev, D.L., *147*, 307
Nilan, R.A., *149*, 431
Nilsson, L., *155*, 91
Nims, R.W., *142*, 127
Ninomiya, R., *147*, 261
Nishi, Y., *147*, 268
Nishimura, S., *147*, 258
Nishimura, T., *147*, 257, 268
Nishioka, H., *147*, 268, 269
Nishioka, K., *145*, 55
Nishiyama, C., *144*, 265
Niwa, H., *143*, 75; *144*, 287
Niwa, O., *145*, 195
Noda, K., *147*, 265
Noda, M., *147*, 275
Nogami, H., *147*, 268
Nohara, M., *142*, 103; *149*, 9
Nohmi, T., *147*, 265, 269, 273
Norman, A., *143*, 155
Noro, T., *146*, 15
Noronha, R.F.X., *157*, 95
Norppa, H., *147*, 298
Novákova, A., *144*, 277
Nowak, C., *149*, 469
Nozu, K., *146*, 243
Nunoshiba, T., *147*, 268, 269
Nuzzo, F., *142*, 45; *147*, 311, 322
Nyhammar, T., *142*, 5; *151*, 177

Obe, G., *147*, 126; *149*, 469; *150*, 359; *152*, 25, 205; *156*, 199
Ochi, T., *143*, 137
Ochiai, M., *143*, 17; *147*, 269; *158*, 119
O'Connell, D.F., *150*, 217
Oda, Y., *142*, 99; *147*, 219, 267, 270; *149*, 297
Odagiri, Y., *147*, 270
Oesch, F., *147*, 124, 125, 126; *149*, 265; *156*, 163
Ogawa, S., *142*, 103
Ogorek, B., *146*, 55, 63
Ohara, Y., *147*, 255
Ohashi, Y., *146*, 243
Ohgaki, H., *147*, 269
Ohkawa, Y., *147*, 268
Ohnishi, T., *146*, 33, 243
Ohnishi, Y., *147*, 260, 264, 270; *158*, 3
Ohsawa, K., *150*, 141

Ohsawa, M., *143*, 137
Ohshima, T., *147*, 271
Ohta, K., *149*, 297
Ohta, T., *147*, 271, 276
Ohtsuka, K., *147*, 258
Ojika, M., *143*, 75; *144*, 287
Okada, H., *144*, 9
Okamoto, H.S., *143*, 213
Okamoto, M., *151*, 121
Oki, I., *147*, 219, 270
Okinaka, R.T., *151*, 15
Okui, T., *147*, 271
Olivero, O.A., *143*, 237
Olivieri, G., *149*, 463; *150*, 293
Olsson, K., *151*, 177
Olthoff-Smit, F.P., *148*, 35
Ondráček, J., *157*, 163
O'Neil, I.K., *150*, 177
O'Neill, J.P., *150*, 443
Ong, T., *158*, 81
Ong, T.-m., *142*, 19; *149*, 365; *156*, 171; *158*, 105
Onozuka, H., *147*, 273
Ord, M.J., *149*, 485
Orrego, C., *146*, 185
Osada, T., *147*, 267
Ose, Y., *157*, 135
Ostrovskaya, L.A., *147*, 294
Otsuka, M., *146*, 149
Otto, P.A., *158*, 181
Ou Bao-xiang, *144*, 243
Owais, W.M., *144*, 119
Ozaki, V.H., *157*, 77
Ozasa, S., *149*, 9

Pachter, R., *143*, 87
Paglialunga, S., *156*, 219
Pai, V., *151*, 201
Painter, R.B., *143*, 113; *145*, 63
Pal, A.K., *156*, 69
Palajda, M., *153*, 79
Palatti, F., *150*, 359
Pall, M.L., *152*, 131
Palmer, K.A., *155*, 17
Pantelias, G.E., *149*, 67; *151*, 65
Paolini, M., *147*, 231, 287
Papadopoulo, D., *151*, 281
Papworth, D.G., *149*, 105
Paravatou-Petsota, M., *149*, 57
Parente, L.A., *151*, 25
Parkes, D.J.G., *147*, 113
Parodi, S., *147*, 292
Parry, E.M., *150*, 369
Parry, J.M., *150*, 369
Parshad, R., *151*, 57
Partanen, P., *150*, 119
Paschin, Y.V., *147*, 311
Pastori, M.C., *143*, 237
Paul, M., *149*, 353
Pavlenko, G.I., *147*, 301
Pawlak, A.L., *147*, 304, 312, 313
Peak, M.J., *147*, 15
Peano, S., *147*, 295
Pearson, P., *153*, 13
Pečevski, J., *147*, 283, 318
Pelliccia, F., *150*, 293
Pence, B.C., *158*, 53
Penman, B.W., *142*, 133
Penman, M.G., *154*, 183; *156*, 1
Penn, A.L., *146*, 121
Pensabene, J.W., *157*, 129
Pentland, B., *150*, 355
Pero, R.W., *142*, 69
Perrard, M.-H., *152*, 147
Perry, K.L., *150*, 147
Perry, P.E., *144*, 89
Peryt, B., *147*, 324
Pet-Edwards, J., *153*, 135, 167, 187
Petersen, M., *158*, 81
Petters, R.M., *149*, 375
Pettersson, B., *157*, 169
Philipp, E., *147*, 135
Philippova, T.V., *147*, 313
Phillips, M., *143*, 149; *157*, 189
Phillips, R.A., *152*, 31
Picciotto, A., *144*, 213
Piechocki, R., *144*, 145
Pieńkowska, M., *147*, 324
Pietrzykowska, I., *149*, 287
Pino, A., *144*, 209
Pintér, A., *144*, 177
Piperakis, S.M., *142*, 83
Pirovano, R., *147*, 295
Platt, K.L., *156*, 163
Plooy, A.C.M., *151*, 129
Podger, D.M., *142*, 87; *146*, 47
Pohlova, H., *147*, 314
Polívková, Z., *143*, 271
Poll, E.H.A., *145*, 77
Pomerantseva, M.D., *147*, 314
Pons, F.W., *144*, 141
Popanda, O., *145*, 217
Popkin, D.J., *142*, 109
Popp, D.M., *143*, 93; *144*, 287
Popp, R.A., *143*, 93; *144*, 287
Porfirio, B., *144*, 257
Pouwels, P.H., *148*, 35; *153*, 13
Preston, R.J., *148*, 91; *150*, 299
Presutti, M., *156*, 177
Pretsch, W., *147*, 315; *150*, 393
Prieur, M., *149*, 57
Prival, M.J., *142*, 109
Proctor, B.L., *149*, 41
Prod'homme, M., *152*, 197
Prokěs, K., *147*, 285
Protić-Sabljić, M., *145*, 89
Przybojewska, B., *147*, 285
Pueyo, C., *147*, 153
Puri, E.C., *147*, 133
Puro, J., *149*, 179
Puska, P., *152*, 97
Putman, D.L., *156*, 181
Pyta, E.M.T., *144*, 247

Qin, S., *142*, 115
Quillardet, Ph., *147*, 65, 79

Raaymakers-Jansen Verplanke, C.A., *150*, 241
Rabello-Gay, M.N., *158*, 181
Radivojević, D., *147*, 283, 318
Radman, M., *152*, 157
Răileanu, L., *155*, 121
Rajewsky, M.F., *150*, 13
Ramaya, L.K., *147*, 314
Ramdahl, T., *147*, 299; *157*, 149
Ramel, C., *147*, 282; *150*, vii; *153*, 13
Randerath, K., *152*, 85
Rani, R., *144*, 85
Rao, A.R., *158*, 189, 193
Rapić, V., *142*, 9
Rary, J.M., *150*, 277; *152*, 39
Rasmuson, Å., *148*, 65; *157*, 157
Rasmussen, J., *149*, 95
Rasmussen, J.A., *155*, 71
Reali, D., *157*, 235
Reddy, B.S., *152*, 97
Reddy, M.V., *152*, 85
Regan, T., *144*, 27
Reist, E.J., *158*, 125
Renner, H.W., *144*, 251; *147*, 315
Resnick, M.A., *149*, 339; *150*, 203
Richardson, C.R., *142*, 187; *154*, 111; *156*, 19
Richold, M., *155*, 35
Ridolpho, P.F., *157*, 63
Rieger, R., *142*, 23, 183; *143*, 79, 83; *144*, 171
Rinaldi, Ch.N., *143*, 29; *144*, 151
Ringhand, H.P., *157*, 111
Rittner, G., *147*, 316
Robbiano, L., *144*, 209
Roberfroid, M., *142*, 169
Roe, D., *143*, 155
Röhrborn, G., *147*, 133, 134, 136
Roelofs, H.M.J., *151*, 195
Römer, K., *147*, 128
Rollman, B., *147*, 310
Romano, M., *144*, 213
Rommelaere, J., *149*, 1; *151*, 1, 9
Rose, F.L., *142*, 121
Rosenkranz, H.S., *142*, 163; *144*, 231; *147*, 343; *149*, 311; *150*, 1; *153*, 79, 135, 167, 187

Rosenstein, B.S., *146*, 1, 191; *149*, 443
Rosenstein, R.B., *149*, 443
Rosin, M.P., *150*, 43
Rossberger, S., *145*, 201
Rossi, L., *147*, 295
Roupova, I., *147*, 287
Rowland, I.R., *142*, 1; *144*, 59
Roza, L., *146*, 89, 305
Rožnícková, I., *147*, 298, 322
Rudnykh, A.A., *147*, 316
Rueff, J., *147*, 306
Ruiz-Rubio, M., *147*, 153
Rupp, W.D., *145*, 43
Russell, L.B., *154*, 69
Russell, W.L., *142*, 217
Ryan, A.J., *158*, 111
Ryan, C.G., *142*, 133
Ryo, H., *146*, 257

Saffiotti, U., *145*, 81
Sahm, J., *150*, 77
Saint-Ruf, G., *147*, 310; *156*, 53
Saito, H., *147*, 267
Saje, A., *155*, 35
Sakabe, Y., *147*, 275
Sakai, K., *150*, 333
Sakai, M., *156*, 61
Sakamoto, Y., *147*, 272
Sakano, Y., *147*, 272
Sakurai, T., *149*, 171
Sala, F., *147*, 311
Sala, M., *150*, 177
Salaj-Šmic, E., *144*, 127
Salazar, E.P., *149*, 249
Salimov, O.N., *147*, 308
Salomaa, S., *147*, 317
Salvadori, G., *144*, 57
Samadashvili, M.P., *147*, 296
Sandberg, A.A., *151*, 263
Sandford, K.K., *151*, 57
Sandhu, S.S., *149*, 73
Sangaiah, R., *155*, 95
Sankaranarayanan, K., *149*, 415; *150*, 225; *151*, 269
Sanotsky, I.V., *147*, 282
Santoni, G., *144*, 57
Sapacheva, V.A., *147*, 317
Sarachek, A., *152*, 15
Sarasin, A., *147*, 381
Sargentini, N.J., *154*, 1
Sarto, F., *144*, 183
Sasaki, M., *156*, 123
Sasaki, Y., *147*, 273, 276
Sasaki, Y.F., *157*, 205
Sasson, I.M., *158*, 149
Šatava, J., *149*, 431
Sato, S., *147*, 267, 335
Sato, T., *144*, 51; *157*, 135
Sato-Mizuno, M., *152*, 187
Satya-Prakash, K.L., *155*, 61
Savage, J.R.K., *150*, 307
Savković, N., *147*, 283, 318
Sawada, M., *147*, 273
Sawahata, T., *143*, 11
Sawyer, J., *147*, 237, 243; *151*, 161
Sazonova, L.A., *155*, 127
Sbrana, I., *147*, 318
Schaefer, E.L., *143*, 69
Schalet, A.P., *150*, 261
Schawalder, H.P., *143*, 143
Schechtman, L.M., *142*, 127
Scheel, I., *149*, 339; *150*, 203
Schenck, K.M., *157*, 111
Schiff, L.J., *142*, 41
Schlatter, Ch., *156*, 39
Schmid, E., *142*, 37; *147*, 318; *158*, 195
Schröder, J.H., *149*, 209
Schubert, I., *143*, 79; *147*, 319
Schürer, C.C., *147*, 134
Schumacher, M., *147*, 5
Schvartzman, J.B., *151*, 77
Schwanitz, G., *147*, 128, 137, 316
Schwarz, L.R., *152*, 225
Schwenn, M.R., *142*, 55
Scott, D., *143*, 251; *147*, 113; *151*, 83, 89
Scovassi, A.I., *147*, 319
Searle, A.G., *142*, 65; *147*, 357
Sedgwick, S.G., *145*, 103
Sedova, K.S., *147*, 305
Seemayer, N.H., *147*, 134
Segall, Y., *158*, 61
Seibert, G.B., *149*, 41
Seixas, G.M., *142*, 133
Sekiguchi, M., *146*, 149, 155
Selezneva, T.G., *147*, 288
Selkirk, J.K., *143*, 69
Sellman, R., *158*, 31
Serra, D., *144*, 213
Seshadri, R.S., *147*, 363
Seyama, T., *145*, 195
Shakhova, I.K., *147*, 320
Shamberger, R.J., *154*, 29
Sharma, C., *152*, 97
Sharma, R.C., *146*, 169, 177
Sharma, R.K., *158*, 217
Sharp, D.C., *150*, 369
Shawkit, M.A., *151*, 73
Shcheglova, E.G., *147*, 320
Shelby, M.D., *143*, 51, 55; *154*, 69
Shenkar, R., *150*, 77
Shepson, P.B., *157*, 123
Sheridan, W., *147*, 59
Shestakov, S.V., *147*, 296
Sheu, Ch.-j., *154*, 49
Shibata, T., *156*, 117
Shiloh, Y., *149*, 283
Shimada, H., *143*, 165; *144*, 51
Shimazu, H., *147*, 274
Shimoi, K., *146*, 15; *149*, 17
Shinagawa, H., *145*, 137; *146*, 33; *147*, 219, 267
Shiozaki, T., *147*, 268
Shipley, J., *150*, 333
Shirasu, Y., *147*, 257, 271, 276; *157*, 205
Shor, R., *147*, 107
Shudo, K., *147*, 264
Shugar, D., *149*, 287
Siekel, P., *147*, 321
Simi, L., *150*, 347
Simić. D., *142*, 159
Simons, J.W.I.M., *144*, 281; *148*, 119; *152*, 233
Singh, A., *143*, 191
Singh, C., *144*, 239
Singh, I., *155*, 117
Sinha, A., *158*, 189, 193
Sinha, A.K., *144*, 13
Sinha, R.P., *147*, 45
Sinkus, A., *147*, 321
Skopek, T.R., *155*, 75
Slozina, N.M., *147*, 297
Small, G.D., *146*, 249
Smith, J., *157*, 63
Smith, K.C., *145*, 107; *146*, 169, 177; *154*, 1
Smith, P.D., *149*, 193; *150*, 235
Sobel, N., *143*, 237
Sobels, F.H., *144*, 73, 117; *147*, 1, 211, 329, 333; *149*, 409; *150*, v, 261; *157*, 107
Sodhi, A., *156*, 187
Sofuni, T., *147*, 273
Soldatov, S.P., *147*, 296
Soprano, K.J., *146*, 79
Sorsa, M., *147*, 292, 298, 317, 381; *150*, 119; *154*, 135
Sotani, T., *147*, 269
Sousa, J., *149*, 365; *156*, 171
Souza S., V., *156*, 233
Sozzi, G., *156*, 177; *157*, 235
Speck, W.T., *147*, 37
Speit, G., *147*, 127
Spiechowicz, E., *147*, 285
Sportes, M., *152*, 197
Springer, J., *154*, 49
Šrám, R.J., *144*, 271, 277; *147*, 291, 298, 304, 314, 322
Sree Ramulu, K., *149*, 421
Stärk, G., *155*, 27
Staiano-Coico, L., *149*, 505
Stauff, J., *155*, 27
Stefanini, M., *147*, 319, 322
Sten, M., *146*, 301
Stephan, G., *147*, 128

Stephens, O.B., *157*, 95
Stevens, C.W., *152*, 5
Stewart, A., *147*, 113
Stewart, J.D., *158*, 105
Steyn, P.S., *143*, 87
Stich, H.F., *150*, 43
Stockert, J.C., *158*, 77
Stone, C.J., *156*, 181
Strauss, B., *150*, 77
Strauss, M., *147*, 324
Streicher, R.P., *157*, 111
Stretch, A., *146*, 99
Strike, P., *145*, 43
Strniste, G.F., *151*, 15
Strout, C.L., *149*, 133
Stumm-Fischer, I., *155*, 27
Stupans, I., *158*, 111
Styles, J.A., *142*, 187; *154*, 183; *156*, 19
Su, Z.Z., *149*, 1
Sugahara, T., *145*, 195
Sugie, S., *143*, 75, 121; *144*, 197, 287
Sugimura, T., *142*, 145; *143*, 17; *144*, 227; *147*, 267, 269, 275, 335; *150*, viii, 33; *158*, 119
Sugiyama, H., *147*, 275
Sugiyama, T., *147*, 274; *155*, 91
Sund, M., *149*, 209
Sundaram, K., *144*, 99
Sundell-Bergman, S., *149*, 257
Šunjevarić, I., *147*, 283, 318
Suovaniemi, O., *150*, 119
Surján, A., *144*, 177
Susanne, C., *147*, 325; *157*, 221
Suskov, I.I., *155*, 127
Suter, W., *147*, 322
Sutou, S., *147*, 274
Suzuki, H., *156*, 123
Suzuki, N., *156*, 123
Suzuki, Y., *147*, 260
Svensson, K., *148*, 135
Sybenga, J., *149*, 421
Szabad, J., *144*, 177
Szende, B., *149*, 51
Szyfter, K., *147*, 313
Szymczyk, T., *147*, 324

Tabor, E., *149*, 283
Tadashi, I., *147*, 258
Tagami, M., *147*, 274
Tahira, T., *143*, 17; *158*, 119
Takagi, Y., *147*, 264
Takahashi, F., *147*, 255
Takahashi, K., *144*, 265; *156*, 153
Takahashi, M., *147*, 275
Takaki, R., *146*, 271
Takebe, H., *145*, 195; *150*, 91
Takehisa, S., *144*, 171
Takemoto, K., *147*, 270
Takenaka, Y., *147*, 267
Takimoto, K., *146*, 9
Takizawa, Y., *147*, 256, 275
Talcott, R.E., *155*, 1
Tamaoki, M., *147*, 271
Tanaka, K., *143*, 11
Tanaka, S., *147*, 267
Tandon, P., *156*, 187
Tanga, M.J., *158*, 125
Tanii, H., *158*, 129
Tano, S., *148*, 59
Tantravahi, U., *150*, 333
Tanzarella, C., *150*, 359
Tarasov, V.A., *147*, 300
Targa, H.J., *158*, 181
Tarnavschi, R., *147*, 296
Tates, A.D., *147*, 323
Tawn, E.J., *144*, 247
Taylor, K., *142*, 41
Taylor, R.T., *151*, 293
Taylor-Mayer, R.E., *149*, 333
Teaf, Ch.M., *144*, 93
Tease, C., *151*, 109
Tecchio, G., *156*, 219
Tenenbaum, L., *152*, 157
Terada, M., *147*, 269
Terwel, L., *152*, 1
Tessera, L. *147*, 322
Tezuka, H., *157*, 205
Thacker, J., *146*, 99; *150*, 431
Thaler, H., *149*, 505
Theile, M., *147*, 324
Thész, Zs., *149*, 51
Theuws, J.L.G., *156*, 195
Thielmann, H.W., *145*, 217
Thilly, W.G., *150*, 403; *151*, 95; *157*, 71
Thomale, J., *152*, 113
Thomas, S.M., *151*, 49
Thompson, L.H., *149*, 249; *150*, 423
Thomson, E.J., *144*, 89
Thorgeirsson, S.S., *151*, 137
Tikowa, H., *157*, 39
Tiltnes, A., *156*, 147
Titenko, N.V., *147*, 288
Tjälve, H., *149*, 495
Tobari, I., *142*, 59; *148*, 113; *151*, 121, 275
Todd, N., *143*, 149; *157*, 189
Todo, T., *145*, 165
Török, G., *144*, 177
Török, O., *147*, 130
Tokiwa, H., *147*, 263
Tokuda, M., *142*, 103
Toman, Z., *152*, 157
Tomimori, H., *150*, 141
Tomita, I., *146*, 15; *147*, 275; *149*, 17
Toniolo, P., *157*, 235
Topuzian, M.A., *147*, 295
Toyoshi, K., *142*, 153; *144*, 197
Trainor, K.J., *147*, 363
Traul, K.A., *144*, 107
Trgovčević, Ž., *144*, 127
Tröbner, W., *144*, 145
Trpis, L., *149*, 119
Truzman, C., *157*, 1
Tsiouris, J., *143*, 225
Tsuchida, N., *147*, 269
Tsuda, M., *147*, 335
Tsuda, S., *156*, 117
Tsukamoto, R., *147*, 257, 271
Tsukamoto, T., *147*, 261
Tsutsui, H., *147*, 260, 270
Tsutsui, T., *148*, 107
Tsutsumi, M., *142*, 153
Tsuyoshi, T., *147*, 272
Tucker, J.D., *149*, 365
Tudek, B., *147*, 324
Turanitz, K., *147*, 130
Turner, N.T., *151*, 147, 161
Turner, T.R., *142*, 133
Turusov, V., *150*, 177
Tweats, D.J., *147*, 385
Tyrrell, R.M., *145*, 129; *146*, 109
Tziolas, V., *157*, 13
Tzoneva, M., *157*, 13

Uchida, A., *157*, 205
Uchida, K., *142*, 153
Ueda, R., *145*, 165
Uehara, Y., *145*, 55
Ueno, Y., *147*, 275; *149*, 327
Ulitzur, S., *147*, 107
Ullberg, S., *149*, 495
Umeda, M., *147*, 265
Uozumi, M., *142*, 99; *156*, 117
Upshall, A., *142*, 179
Upton, A., *147*, 387
Utesch, D., *147*, 124, 126
Utsugi, T., *151*, 121

Vachkova, R., *157*, 13
Vaglenov, A., *147*, 325
Vainio, H., *150*, 119; *154*, 135
Valin, N., *158*, 159
Vance, W.A., *143*, 213
Van de Kerkhoff, J.F.J., *143*, 39
Van der Eb, A.J., *142*, 75; *151*, 1, 9
Van der Gaag, M.A., *143*, 39
Van der Heijden, C.A., *155*, 41
Van der Hoeven, J.C.M., *142*, 209; *152*, 1
Vander Jagt, D.L., *142*, 141
Van der Lubbe, J.L.M., *142*, 75; *151*, 1, 9
Van der Putte, P., *153*, 13
Van der Schans, G.P., *146*, 89, 305
Van Dijk, M., *151*, 129
Van Drunen, C.M., *151*, 1

Van Elburg, P.A., *148*, 1
Van Gemert, P.J.L., *151*, 195
Van Rijn, J.L.S., *151*, 269
Van Sittert, N.J., *156*, 109
Van Zeeland, A.A., *144*, 41, 281; *148*, 119; *150*, 159, 241, 283; *151*, 251; *152*, 233
Van Zijl, P., *158*, 89
Vapper, M.A., *147*, 51
Vashishat, R.K., *155*, 113
Vasudeva, M., *155*, 113
Vávra, R., *144*, 271
Velázquez, A., *158*, 177
Veleminský, J., *149*, 431
Venegas, W., *147*, 306; *157*, 53
Venier, P., *156*, 219
Vericat, J.A., *146*, 23
Vermeulen, W., *146*, 71; *150*, 99
Verschaeve, L., *147*, 325; *157*, 221
Viegas-Pequignot, E., *152*, 197
Vijayalaxmi, *150*, 355; *152*, 211
Vijg, J., *146*, 197
Vikhanskaya, F.L., *149*, 271
Villani, G., *145*, 35
Vishnevetskaya, O.Yu., *147*, 296
Völkner, W., *147*, 133
Vogel, E.W., *149*, 193; *150*, 241
Vollmar, J., *147*, 132, 297
Von Borstel, R.C., *150*, 217
Vontorková, M., *144*, 81; *147*, 289
Voogd, C.E., *147*, 303; *155*, 41
Vormittag, W., *143*, 117
Vos, J.-M., *149*, 1
Vrieling, H., *144*, 281
Vuković, B., *142*, 159
Vuksanović, Lj., *147*, 283, 318

Wade, M.H., *146*, 305
Wada, T., *147*, 267
Wagner, H., *147*, 129; *149*, 83
Wahrendorf, J., *147*, 5
Wakabayashi, K., *142*, 145; *143*, 17; *144*, 227; *147*, 267, 275; *158*, 119
Wakamatsu, K., *144*, 287
Wakata, A., *147*, 271
Walk, R.-A., *147*, 136
Walker, G.C., *150*, 147
Wallace, S.S., *146*, 229
Wallin, M., *143*, 231
Wang, A., *147*, 268
Wang, T.-ch.V., *145*, 107
Wang, Y.Y., *143*, 213
Ward Jr., J.B., *155*, 143
Wargovich, M.J., *143*, 127
Washington, W.J., *147*, 205
Wassom, J.S., *150*, ix
Watabe, J., *158*, 45
Watanabe, K., *147*, 257, 276
Watanabe, M., *146*, 285; *147*, 271
Watanabe, T., *147*, 273; *149*, 171
Wataya, Y., *143*, 207
Waters, M.D., *147*, 343
Waters, R., *145*, 209
Watson, W.P., *149*, 159
Weibel, B., *143*, 143
Weibezahn, K.F., *145*, 177
Weichselbaum, R.R., *142*, 55
Weinberg, G., *142*, 199
Weisburger, J.H., *156*, 83
Weitberg, A.B., *144*, 23
Weitzman, S.A., *144*, 23
Weksler, M.E., *149*, 505
West, J.D., *149*, 221, 231
White, G.L., *142*, 203; *143*, 173; *144*, 1
Whitfield, B., *154*, 49
Whong, W.-Z., *142*, 19; *158*, 105
Whyte, D.B., *145*, 89
Wiktorowicz, K.E., *147*, 313
Wild, D., *156*, 93
Willems, M.I., *150*, 23
Williams, J.R., *149*, 437; *158*, 97
Wilmer, J.L., *155*, 75; *157*, 181
Wilpart, M., *142*, 169
Wilson, S.H., *146*, 295
Winkel, E.-U., *152*, 25
Wissinger, W.L., *149*, 375
Witte, I., *145*, 71
Wolff, S., *151*, 65
Wood, D.C., *145*, 17
Woodgate, R., *150*, 133
Woodruff, R.C., *149*, 33
Wright, A.S., *149*, 159
Wright, K., *143*, 149; *157*, 189
Wu, J., *147*, 268
Wu, R., *151*, 293
Wu, S.-Ch.H., *149*, 127
Würgler, F.E., *144*, 67; *147*, 326; *156*, 39
Wulf, H.Ch., *155*, 71
Wunder, E., *152*, 211
Wynder, E.L., *158*, 149
Wyrobek, A.J., *152*, 53

Xamena, N., *149*, 189; *158*, 177
Xu, J., *158*, 81

Yagame, O., *150*, 141
Yager, J.D., *146*, 121
Yakovleva, T.K., *147*, 326
Yamada, K., *143*, 75; *144*, 287
Yamada, T., *142*, 59; *148*, 113; *151*, 275
Yamagata, H., *147*, 276
Yamagiwa, J., *151*, 121
Yamaguchi, H., *148*, 59
Yamaguchi, T., *147*, 277
Yamaizumi, J., *147*, 267, 335
Yamaizumi, Z., *143*, 17; *147*, 258
Yamamoto, K., *145*, 137; *146*, 33; *147*, 270; *149*, 297
Yamamoto, K.S., *147*, 272
Yamamoto, Y., *145*, 55
Yamashita, T., *147*, 271
Yamazaki, H., *142*, 153; *144*, 197
Yang, S.-U., *149*, 119
Yarosh, D.B., *145*, 1
Yashima, H., *143*, 11
Yasui, A., *146*, 71
Yasunaka, K., *144*, 9
Yazaki, F., *147*, 257
Yielding, L.W., *158*, 169
Yin, M.-q., *158*, 119
Yonei, S., *149*, 321
Yoo, M.A., *146*, 257
Yoshida, D. *147*, 262, 263, 277; *156*, 61
Yoshida, Y., *146*, 211
Yoshimi, N., *144*, 197

Zahn, R.K., *144*, 63
Zampetti-Bosseler, F., *143*, 251; *151*, 83, 89
Zanacchi, P., *158*, 19
Zbinden, G., *143*, 143
Zech, L., *147*, 299
Zei, G., *142*, 45
Zeiger, E., *142*, 149; *143*, 187
Zelikoff, J.T., *144*, 107
Zentilin, L., *156*, 219
Zetterberg, G., *149*, 133
Zhu, N., *147*, 268
Zhurkov, V.S., *147*, 294
Ziegler-Skylakakis, K., *152*, 225
Zieleńska, M., *147*, 324
Zijlstra, J.A., *150*, 241
Zimmering, S., *144*, 77
Zimmermann, F.K., *144*, 67; *149*, 333, 339; *150*, 203
Zoetemelk, C.E.M., *147*, 302
Zucconi, D., *144*, 193
Zurlo, J., *146*, 121
Zwanenburg, T.S.B., *144*, 41; *150*, 283; *151*, 251
Zwetsloot, J.C.M., *146*, 71

Mutation Research, 142–158/INDEX (1985) 13–35
Elsevier

Cumulative Subject Index 1985

Volumes 142–158

AAF, *see* 2-Acetylaminofluorene
Aceanthrylene, bacterial mutagenicity, *155*, 95
Acetaldehyde, human lymphocytes exposed to, SCE-inducing damage, *158*, 201
Acetohydroxamic acid, induction of DNA repair synthesis, *145*, 201
Acetone, induction of aneuploidy in yeast, *149*, 339
Acetonitrile, induction of aneuploidy in yeast, *149*, 339
N-Acetoxy-2-acetylaminofluorene, mutagenicity to V79 Chinese hamster cells, *149*, 265
2-Acetylaminofluorene, effect of quercetin on mutagenicity in *S. typhimurium*, 142, 103
–, induced UDS in primary cultures of rat, *155*, 83
–, treated rats, organ-specific induction of DNA adducts, *150*, 23
–, UDS in rats, *150*, 383
N-Acetylbenzidine, metabolic activation to mutagen, *151*, 195
N-Acetylcysteine, desmutagenic effects, on direct and indirect mutagens, *142*, 169
Acetyl metabolites, of aromatic amines, mutagenicity, *143*, 11
Acridine compounds, photodynamic mutagenic action on yeast, *158*, 169
Acridines, substituted, patterns of response, *157*, 29
Acrinol, mutagenicity in *S. typhimurium*, *144*, 9
Acrylamide, and analogues, mutagenicity in *S. typhimurium*, *158*, 129
Active oxygen species, participation in induction of chromosomal aberrations by $CdCl_2$, *143*, 137
Adaptative repair, of a mutant of *E. coli*, *145*, 35
Adaptive response of normal human bronchial epithelial cells, after treatment with MNNG, *146*, 205
Adenine, in yeast DNA, ^3H decay, *149*, 359
Adenine–thymine base pairs, mutagenicity of nitroarenes, *149*, 311
Adenosine, effect on G_2 repair, *149*, 275
Adenovirus, 2, HeLa cells, enhanced reactivation, by chemical agents, *142*, 83
ADP, ribosylation, and DNA repair, *154*, 104
–, –, and oncogenic transformation, *154*, 105
ADP-ribosyl transferase, activity, induced by γ-radiation, *142*, 69
ADPRT, *see* ADP-ribosyl transferase
Adriamycin, infertility, long-term, and dominant lethal mutations in male mice, *152*, 53
Aerosols, inhaled, cytogenetic effect, detection, *147*, 270
Aflatoxin B_1, aberrations induced in mammals, *147*, 285
Aflatoxin B_1, (*continued*)
–, biosynthesis, relation to genotoxicity of fungal metabolites, *143*, 121
–, metabolic activation, *144*, 213
–, metabolism, in hepatic microsomes of rats, *147*, 275
–, quantum-chemical study, *143*, 87
Age, mouse, influence on induction of CA and dominant lethals, *147*, 357
Airborne particulates, industrial region, *147*, 289
Airborne particulate matter, extracts, $Balb_c/3T3$ cell transformation response, *144*, 107
Airborne particulate pollutants, mutagenicity, *147*, 134
Alcohol-induced metabolites, nitrosation of, production of mutagens, *158*, 159
Alkanols, genetic toxicology testing, *153*, 72
Alkenes, genetic toxicology testing, *153*, 70
Alkoxyphenoxazones, dealkylation, in hepatic S9s and hepatocyte homogenates, effects of dicoumarol, *142*, 127
Alkylating agents, adaptive response, of bacteria to, *146*, 155
–, –, current evidence, *154*, 85
–, effects on poly(ADP-ribose) synthesis, *150*, 69
–, induction of adaptive and SOS responses, *146*, 149
–, induction of micronuclei in V79 CH cells, effect of thymidine, *150*, 347
–, reaction kinetics and mutagenic action, in higher eukaryotic systems, *149*, 193
–, SCE induction in Chinese hamster V79 cells, *149*, 451
Alkylating mutagens, human lymphocyte cultures exposed to, *152*, 187
Alkylation-induced mutagenesis, *D. melanogaster*, *150*, 235
Alkyl halides, genetic toxicology testing, *153*, 71
Alkylnitrosourea, selectivity of mutagenic action, *147*, 294
Allium cepa, effect of pyronin Y and green light, *158*, 77
Allyl acetate, genetic toxicology testing, *153*, 61, 72
Allyl chloride, genetic toxicology testing, *153*, 60
–, mutagenicity, *157*, 145
Allyl isothiocyanate, mutagenic in *S. typhimurium*, *156*, 33
Aluminium plant, testing for mutagens, *156*, 147
Aluminium workers, exposed to coal tar pitch volatiles, genetic monitoring, *155*, 143
Ames assay, assessing mutagenicity, percentile rule, *147*, 15
–, chloromethylbenzo[*a*]pyrenes, direct-acting mutagens, *142*, 141
Ames Salmonella plate assay, effects of pH on weak and positive control mutagens, *142*, 109
Ames test, automated modification with COBAS Bact, *144*, 137

0027-5107/85/$03.30 © 1985 Elsevier Science Publishers B.V. (Biomedical Division)

Amines, aromatic, limited detectability, *147*, 126
–, heterocyclic, formed during the cooking process, *150*, 33
–, –, IQ and non-IQ type, in crude pyrolyzed materials, *147*, 335
–, primary aromatic, mutagenicity of gasifier tars and coal oils, *155*, 7
Amino acids, heating with addition of hydroquinone, *147*, 277
9-Aminoacridine, frameshift mutagenesis in *E. coli*, *151*, 149
–, mutability, influence of transition, *144*, 141
–, *S. typhimurium*, anaerobic culture, *143*, 183
2-Aminoanthracene, epidermal enzyme-mediated mutagenicity, *147*, 37
3-Aminobenzamide, effects on CH cells treated with thymidine analogues and DNA-damaging agents, *151*, 251
–, effect on chromosome aberrations in human lymphocytes, *148*, 91
–, inhibition of DNA synthesis in human cells, *143*, 113
–, modulation of the induction of chromosomal aberrations and SCE by UV, *149*, 239
–, sensitization of cultured CH cells with BrdUrd-substituted DNA, *144*, 41
Aminobiphenyls, mutagenic potency in *S. typhimurium*, *149*, 9
Amino compounds, genetic toxicology testing, *153*, 73
2-Amino-3,4-dimethylimidazo[4,5-*f*]quinoline, MeIQ, activation by hepatic S9, *144*, 59
2-Amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline, formation, *147*, 266
2-Aminodipyrido[1,2-*a* : 3′,2′-*d*]imidazole, benzo derivatives, *147*, 264
2-Aminofluorene, activation by prostaglandin H synthase, *143*, 187
–, photochemical oxidation, *151*, 15
2-Aminoimidazole, moiety in heterocyclic amines, in crude pyrolyzed materials, *147*, 335
2-Amino-3-methylimidazo[4,5-*f*]quinoline, IQ, activation by hepatic S9, *144*, 59
–, mutagenicity, *156*, 83, 93
Aminophenazone, mutagenicity, *157*, 1
2-Aminopurine, induction of chromosome aberrations and aneuploidy in SHE cells, *148*, 107
Aminopyrine-*N*-demethylase, monooxygenase activity, *147*, 231
2-Amino-3,4,8-trimethylimidazo[4,5-*f*]quinoxaline, formation, identification, *147*, 266, 267
5-Aminouracil, treatment of proliferating plants, *149*, 275
Anacystis nidulans, photoreactivation enzymes from, *146*, 71
Aneuploidy, detection, by environmental chemicals, *149*, 73
–, induction, by mitotic arrestants, in mouse bone marrow, *155*, 61
–, – testing of chemicals in female mouse, *157*, 215
Anthocyanin, mutagenicity of, *147*, 262
2-Anthramine, DNA treated with, *145*, 17
Antibacterial drugs, mutagenicity, *147*, 271
Antibodies, heterologous, lactate dehydrogenase-C, *148*, 135
Anticancer agents, in cultured CH cells, *143*, 149
–, therapeutic types, *154*, 136
Anticancer drugs, in biological samples, methods of analysis, *154*, 141
–, mutagenicity, carcinogenicity, teratogenicity, *154*, 137
Anticancer drugs, (*continued*)
–, mutagenicity in CH V79 cells, *157*, 189
–, occupational exposure, *154*, 135
Anticlastogens, action, in human lymphocyte cultures, *149*, 83
–, –, influence of S9 mix, *147*, 129
Antigenic determinants, *153*, 44
Antileukemic agents, avarone and avarol, antimutagenicity, *144*, 63
Antimutator mutations, in bacteria, *154*, 6
Antineoplastic drugs, used in Finland, *154*, 136
Antineoplastics, mutagenicity, *147*, 272
Antioxidants, affecting mutagenic activity of quercetin, *148*, 13
Antitumour agents, mutagenic action on human chromosomes, *147*, 321
Aphidicolin, effect on FA lymphocytes, *144*, 257
Aprotic polar solvents, induction of aneuploidy in yeast, *149*, 339
–, induction of chromosomal malsegregation in yeast, *149*, 333
–, induction of mitotic aneuploidy, *150*, 203
Apurinic sites, putative, mutagenesis at, in alkylated single-stranded DNA, *149*, 1
Arabidopsis, genetic background damage, induced by X-rays and fission neutrons, *149*, 421
9-β-D-Arabinofuranosyladenine-resistant mutations, of baby hamster cells, *149*, 141
1-β-D-Arabinofuranosylcytosine, inhibition of DNA-repair synthesis, *150*, 299
L-Arabinose, resistance in *S. typhimurium*, *147*, 153
AraC, inhibition of DNA-repair synthesis, *150*, 299
Aralkanes, genetic toxicology testing, *153*, 70
Arecoline, induction of shape abnormality and unscheduled DNA synthesis, in mouse germ cells, *158*, 189
–, transplacental micronucleus inducing ability, in mice, *158*, 193
Arginine reversion and lambda induction in *E. coli* with benzothiadiazine diuretics, *158*, 135
Aristolochic acid, induction of TG^r mutants in extrahepatic tissue in rats, *143*, 143
–, mutagenicity, *147*, 133
Aromatic amines, mutation induction by, *147*, 292
Aromatic hydrocarbons, cyclo-penta-fused polycyclic, bacterial mutagenicity, *155*, 95
–, di-, tri-, tetra-cyclic, monochloro derivatives, Salmonella/microsome mutagenicity, *155*, 91
–, nitrated polycyclic, orientation of nitro substituent, *143*, 173
–, polycyclic, mutagenicity, *157*, 149
–, –, mutagenicity on *S. typhimurium*, *156*, 61
Arsenic compounds, inorganic, effects, *147*, 272
Arsenic, mutagenicity study in vivo, *147*, 290
Arsenic salts, mutagenicity, *157*, 157
Arsenite, sodium, in CHO cells, *148*, 83
Asbestos fibres, chrysotile, inability to modulate induced UDS in primary cultures of rat hepatocytes, *155*, 83
Aspergillus nidulans, genotoxicity of chemical carcinogens in, *147*, 288
–, mutagenicity of TCE, *155*, 105
–, sodium dodecyl sulphate activity, *142*, 179
–, Triton X-100 activity, *142*, 179

Assays, classification, tentative scheme, *153*, 147
–, development, definition, *153*, 3
–, –, sources of information, *153*, 2
–, predictivity, *153*, 143
–, selectivity, of, *153*, 141
A · T base pairs, oxidative mutagens specific for, induction of forward mutations, *147*, 153
Ataxia telangiectasia, cytotoxic effect of PMA, *149*, 283
–, DNA polymerase β in skin fibroblast cell lines, *146*, 295
–, fibroblasts, effects of X-irradiation, *148*, 71
–, lymphoblasts, DNA synthesis inhibition, *146*, 79
–, lymphocytes, G_0 chromosomal radiosensitivity, *150*, 277
–, –, G_2 chromosomal radiosensitivity, *152*, 39
Automobile exhaust, mutagenicity, *147*, 273
Autoradiography, DNA repair synthesis, comparative evaluation, *145*, 201
Auxotroph, CHO triple, induced reversion, *151*, 293
Avarol, antimutagenicity, *144*, 63
Avarone, antimutagenicity, *144*, 63
Aza-aromatic hydrocarbons, mutagenicity, *158*, 125
5-Azacytidine, and DNA methylation, in CHO cells, *150*, 333
–, effect on induction of CA and SCE, *149*, 463
–, genotoxicity, in somatic cells of *D. melanogaster*, *143*, 195
–, treated monkey kidney cells, herpes virus, *146*, 9
L-Azetidine-2-carboxylic acid, resistance, in *E. coli*, *149*, 303
Azo dyes, mutagenicity in Salmonella/microsome assay, *156*, 131
Azoxyalkanes, carcinogenic, lack of activity, *157*, 23
Azoxyethane, activity, *157*, 23
Azoxymethane, activity, *157*, 23

Bacteria, genetic duplications, relevance for genetic toxicology, *150*, 107
–, protection against damage by solar UVA and H_2O_2, *145*, 129
–, recombination proficiency, *154*, 9
Bacterial, mutagenicity assay, automated, mutascreen, *150*, 119
–, mutation assays, genetic toxicology testing, *153*, 73
–, systems, effect of selenium on, *154*, 30
–, UV mutagenesis, two-step model, *150*, 133
Bacteriophage PM2, X-ray induced inactivation, specific DNA base damage, *146*, 229
Balb/3T3 clone cells, induction of malignant transformation, *152*, 113
BaP, *see* Benzo[*a*]pyrene
Barley, clastogenic adaptation, differential response of seeds, *143*, 83
–, embryos, germinating, induction of sensitive sites by sodium azide, *149*, 431
Base-pair substitutions, determination at the molecular level, *148*, 35
–, specificity, induced by *mutL* and *mutS* mutators in *E. coli*, *142*, 93
Base tautomerization, *154*, 3
Battery selection, CPBS method, *153*, 192
Bayesian approach, CPBS method, *153*, 135
–, decision theory, and artificial intelligence, *150*, 1
Beef, fried ground —, fecal mutagenicity from, *143*, 207
Belgium, local activity report for 1984, *147*, 379
Benomyl, genotoxicity, *147*, 310
Benzamide, differential effect, in CHO cells, *142*, 203
Benzene, genetic toxicology, recent findings, *154*, 153
–, induction of micronuclei in mice, *143*, 55
–, micronuclei induction in circulating erythrocytes of mice, *144*, 193
–, mutagenic effects, *147*, 294
Benzidine, comparative chemical mutagenesis, *157*, 107
–, mutagenesis inhibition by nucleophiles, *143*, 5
–, mutagenesis and metabolism in *S. typhimurium* strains, *144*, 159
Benzodiazepines, in mice, mutagenicity, *147*, 290
Benzopyrene 4,5-oxide, host-mediated mutagenicity experiments, *156*, 163
Benzo[*a*]pyrene, antimutagenic activity of natural compounds towards, *152*, 1
–, diol epoxide, induced lesions, excision repair in XP variant cells, *146*, 285
–, –, mutagenic efficiency in human and bacterial cells, *152*, 5
–, DNA treated with, *145*, 17
–, effect of quercetin on mutagenicity in *S. typhimurium*, *142*, 103
–, host-mediated mutagenicity experiments, *156*, 163
–, induction by DDT, *158*, 111
–, metabolism and genotoxic activity, *147*, 324
–, metabolites, formation of, *147*, 107
–, mutagenesis induction, phenolic bioantioxidants as inhibitors, *147*, 312
–, mutagenicity of smoked, dried bonito products, *158*, 35
–, SCE differential induction in mouse hepatoma cells, *143*, 69
Benzothiadiazine diuretics, arginine reversion and lambda induction in *E. coli*, *158*, 135
Benzyl chloride, DNA damage induction and repair, in excision-deficient or -proficient human cells, *145*, 209
Betul nut alkaloid, arecoline, *158*, 189, 193
BHK21 transformation assays, mutagenicity data base, *153*, 79
Bile, from rats, treatment with 1-nitropyrene, *149*, 171
Bile acids, effect on formation of quercetin, *155*, 99
–, mutagenicity, fluctuation test, *158*, 45
Bio-antimutagens, natural, detection and identification, *150*, 127
–, studies on the mode of action, *147*, 258
Biphenyls, amino- and nitro-substituted, and mutagenic potency in *S. typhimurium*, *149*, 9
Bis-(4-dimethylaminophenyl)methane, genetic toxicology testing, *153*, 60
Bis(parachlorophenyl)cyclopropyl methanol, genotoxicity, *157*, 13
Bleomycin, chromosome damage, cell cycle delay and cell killing, *151*, 83
–, response to, of normal and AT cells, *151*, 89
–, treatment of wasp, reproduction and mutagenic response after, *149*, 375
Blood lymphocytes, mouse, exposure to mutagenic carcinogens, *157*, 181
–, peripheral, cytogenetic studies, tabulation and assessment, *154*, 111

Bonito products, smoked, dried, mutagenicity, *158*, 35
Bonito, smoked dried, mutagens in, *147*, 259
Bracon hebetor, bleomycin treatment, reproduction and mutagenic response after, *149*, 375
Breast cancer, effect of Se, *154*, 40
–, γ-irradiation, in vivo mutant frequency, *152*, 107
Bromochlorodifluoromethane, activity in mutation tests, *142*, 187
Bromodeoxyuridine, density-shift method, DNA repair synthesis, comparative evaluation, *145*, 201
–, dependent SCE, increase at high oxygen tension, *142*, 213
–, incorporation, in CHO cells, influence on induction of chromosomal alterations, *150*, 283
–, substituted DNA, CH cells, effect of 3AB, *144*, 41
5-Bromodeoxyuridine, effects in human lymphoblasts, *151*, 95
–, role of, incorporated into parental DNA, *151*, 77
5-Bromouracil, -induced mutagenesis, DNA lesions and SOS functions in, *149*, 287
Bronchial epithelial cells, human, MNNG treatment, *146*, 205
Bulgaria, local activity report for 1984, *147*, 379
tert.-Butylbenzene, genetic toxicology testing, *153*, 60
p-tert.-Butylcatechol, genetic toxicology testing, *153*, 61
p-tert.-Butylphenol, genetic toxicology testing, *153*, 61
p-tert.-Butyl toluene, genetic toxicology testing, *153*, 61
tert.-Butyl *m*-xylene, genetic toxicology testing, *153*, 60

CA, *see* Chromosome aberrations
Cadmium chloride, induction of chromosomal aberrations, in cultured CH cells, *143*, 137
Cadmium salts, mutagenicity, *157*, 157
Caffeine, effect on G_2 repair, *149*, 275
–, effects on UV-induced base-pair substitution and frameshift mutagenesis in Salmonella, *143*, 1
–, effect on X-ray-induced mitotic delay in normal and AT fibroblasts, *143*, 251
–, postirradiation treatment, of murine teratocarcinoma cells, *145*, 195
–, potentiation of propane sultone mutagenesis in barley, *144*, 239
–, protection and potentiation of radiation clastogenesis, *143*, 61
–, treatment, ataxia telangiectasia, increased CA, *147*, 312
Camellia sinensis, bio-antimutagen isolated from, *150*, 127
Cancer, in humans, CPBS method, *153*, 135
Candida albicans, nalidixic acid resistance, *152*, 15
Canton-S, D. melanogaster, difference with *ebony* strain, *150*, 225
Carbadox, in mouse transplacental micronucleus test, *144*, 81
3-Carbethoxypsoralen, lethal and mutagenic effects photoinduced in *S. cerevisiae, 148*, 47
–, SCE induction in human blood lymphocytes, *152*, 211
Carbonyl compounds, as direct-acting mutagens, *148*, 25
–, natural, mutagens in Salmonella TA104, *148*, 25
Carboxylic acids, genetic toxicology testing, *153*, 73
Carcinogens, dietary, hypersensitivity of XP cells, *145*, 89
–, methylating, DNA-repair host-mediated assay, *148*, 1
–, prediction of, in mutation assays, *147*, 1
Carcinogenesis, modifiers, *147*, 282
Carcinogenicity, of chemicals, prediction, developing methodologies, *153*, 79
–, prediction, and battery selection method, *153*, 135
–, –, from a battery of tests, *153*, 151
–, –, cluster analysis, *153*, 167
–, predictivity curves, *153*, 154
β-Carotene, anticlastogenic effect in CH, *144*, 251
–, reduction of chromosomal damage caused by thiotepa in Chinese hamsters, *147*, 315
CASE programme, analysis of genotoxic activity of pesticides, *147*, 343
Catabolite repression, and mutagenesis in Salmonella, *151*, 35
Catechol, genetic toxicology, *154*, 173
Cell cultures, in vitro experiments, requirements, *147*, 123
Cell cycle length, effect on SCE frequency in Rat-1 cells, *149*, 101
Cell-cycle progression, in AT fibroblasts, effects of X-irradiation, *148*, 71
Cell killing, effects of X-irradiation in AT fibroblasts, *148*, 71
Cell-replacement repair, damage in male genital imaginal discs of *D. melanogaster, 151*, 243
Cell replication kinetics, in foetal and maternal cells after treatment with chemical teratogens, *158*, 217
Cellulose, blue, use in fractionation of mutagens, *147*, 261
Chemical carcinogens, influence of Se on, *154*, 38
Chemical industry, workers in, cytogenetic examination, *147*, 301
Chemical mutagens, somatic cells, dose–effect relationships, *147*, 281
Chemicals, carcinogenicity, application of the CPBS method, *153*, 187
–, –, CPBS method, *153*, 135
–, listing by CAS number, *153*, 114
Chenodeoxycholic acid, fluctuation test, *158*, 45
Chimpanzee, radiation-induced rearrangements, *149*, 57
Chinese cabbage, mutagen precursor in, *143*, 17
Chinese hamster cells, bone marrow, SCE distribution, *147*, 135
–, chromosome damage, induction, *149*, 257
–, cultured, anti-cancer drugs, toxicity and mutagenicity, *143*, 149
–, –, HPRT locus, mutations induced by X-rays, *144*, 281
–, –, induction of chromosomal aberrations by $CdCl_2$, *143*, 137
–, DNA synthesis, *149*, 271
–, V79, detoxication by endogenous enzymes, *147*, 124
–, –, MNNG damage, molecular and cellular repair, *146*, 271
–, –, mutagenicity of AAAF and OH-AAF, *149*, 265
–, –, mutagenicity of anticancer drugs, *157*, 189
–, –, pyrrolizidine alkaloids, SCE induction, *142*, 209
–, –, SCE induction and secondary lesions, *149*, 451
–, –, treated with cisplatin and procaine, *144*, 203
Chinese hamster chromosomes, effect of Se on, *154*, 34
Chinese hamster, lung fibroblasts, mitomycin C induction of SCE, *149*, 437
Chinese hamster ovary, *see* CHO
Chironomus tepperi, polytene chromosomes, structural changes, *147*, 128

Chlamydomonas, isolation of a photoreactivation-deficient mutant, *146*, 249
Chloracetamide-*N*-metholol, non-mutagenic to Salmonella, *156*, 19
Chloral hydrate, mutagenicity in *A. nidulans*, *155*, 105
Chloramphenicol, in preirradiation treatment of *E. coli*, *144*, 151
–, promotion of resistance increase, in *E. coli*, *143*, 29
Chloroethylene oxide, induction of specific base-pair substitutions in *E. coli trpA* mutants, *152*, 147
–, *recA*-independent mutagenicity induced in *E. coli*, *152*, 157
Chloromethylbenzo[*a*]pyrenes, mutagens, direct-acting, in the Ames assay, *142*, 141
4-Chloromethylbiphenyl, DNA damage induction and repair, in excition-deficient or -proficient human cells, *145*, 209
Chloro-olefins, mutagenicity, *157*, 145
Chlorophyll, reduction of CSC- and BaP-induced mutagenicity, *152*, 1
Chlorophyllin, reduction of CSC- and BaP-induced mutagenicity, *152*, 1
Chloroquine, mutagenicity in *D. melanogaster*, *158*, 177
5-Chlorosalicylic acid, genetic toxicology testing, *153*, 60
CHO, cells, CA and SCE, trenimon-induced, *149*, 469
–, –, DNA adducts, comparative mutagenic efficiencies, *149*, 249
–, –, double-strand break repair and G_2 block, *145*, 177
–, –, effects of 5-azacytidine, *150*, 333
–, –, incorporation of BrdUrd into nuclear DNA, *150*, 283
–, –, induction of chromosomal aberrations by REs, *150*, 359
–, –, SCE induction by methylglyoxal, *144*, 189
–, –, UV, sodium arsenite, *148*, 83
–, –, X-ray induction of TG^r mutants, *150*, 443
–, cell line, repair-deficient, cytological characterization, *149*, 239
–, –, X-ray-sensitivity mutants, *145*, 171
–, –, –, genetic analysis, *146*, 265
–, cell mutants, X-ray-sensitive, responses of, *146*, 99
–, cells, deoxynucleoside triphosphate pool imbalance, UV-induced, *145*, 95
–, mutants, UV-sensitive, genetic complementation with XP fibroblasts, *150*, 423
–, triple auxotroph, induced reversion, *151*, 293
Cholic acid, fluctuation test, *158*, 45
Chortophage viridifasciata, living neuroblasts, effects of mitomycin C, *149*, 41
Chromatid aberrations, induction, effect of 5-azaC, *149*, 463
Chromatid breaks, distribution, in human lymphocytes, *150*, 293
Chromatid damage, induced by fluorescent light, *151*, 57
Chromatin, human, monomerization, *146*, 71
Chromatography, HPL, isolation of clastogenic agents from urine, *147*, 171
Chromium chloride, genetic activity in *S. cerevisiae*, *144*, 165
Chromium compounds, insoluble, effects of NTA on induction of gene mutations and SCE, *156*, 219
Chromium salts, mutagenicity, *157*, 157
Chromosome aberrations, cytogenetic studies, tabulation and assessment, *154*, 111
Chromosome aberrations, (*continued*)
–, definition of normal (control) incidence, *154*, 126
–, effects of X-irradiation in AT fibroblasts, *148*, 71
–, in eggs of mice fertilized in vitro after irradiation, *148*, 113
–, in human lymphocytes, *148*, 91
–, induced in mature oocytes and fertilized eggs at pronuclear stage following X-irradiation, *151*, 275
–, induced in mice sperm after X-irradiation, *148*, 113
–, induction of, by paraquat in CH fibroblasts, *151*, 263
–, induction by X-rays, in mice spermatogonial stem cells, *152*, 217
–, influence of mating status and age, in irradiated female mice, *147*, 357
–, multiple, cells with, in control individuals, *144*, 247
–, in newborns, effect of environmental factors, *143*, 271
–, and SCE, comparative efficiency, *147*, 320
–, screening human populations for, *143*, 155
–, tests in vitro, book review, *156*, 129
Chromosome breaks, spontaneous, in autoimmune disease, *148*, 129
Chromosome changes, in lymphocytes after exposure to toluene, *142*, 37
Chromosome condensation, correlation with unscheduled DNA synthesis in mitoses from human lymphocytes, *142*, 45
–, technique, premature, *149*, 67
Chromosome damage, effect of caffeine and adenosine on G_2 repair, *149*, 275
–, measurement, micronucleus technique, *147*, 29
Chromosome fragments, X-ray-induced, repair, in unstimulated human lymphocytes, *151*, 65
Chromosomes, increased instability, lymphocytes of elderly humans, *149*, 505
–, missegregation, resulting in aneuploidy induction, *155*, 61
–, mouse bone-marrow, cis-platin induced aberrations, *156*, 187
–, mutagenesis studies, diagrammatic representation, *149*, 57
–, rearrangements, radiation-induced, distribution, *152*, 197
–, –, unbalanced, surviving birth, *142*, 217
–, Syrian hamster, structure changes after X-irradiation of spermatogonia, 144, 19
Chromosome 11 aberrations, in small colony L5178Y $TK^{-/-}$ mutants, *147*, 231
Chromotest, SOS, genotoxins, colourimetric bacterial assay, *147*, 65, 79
Chrysotile asbestos fibers, inability to modulate 2-acetylaminofluorene-induced UDS in primary cultures of rat hepatocytes, *155*, 83
C.I. Basic Red-29, mutagenic activity, *155*, 17
Cichlasoma nigrofasciatum, mutational changes of quantitative morphological traits, *149*, 209
Cigarette-smoke, condensate, antimutagenic activity of natural compounds towards, *152*, 1
–, –, biological effects, in vitro studies, *157*, 169
–, –, induction of SCEs, *147*, 317
–, –, SCE induction, *147*, 299
–, gas phase, petite mutation induction, *158*, 69
–, SCE increase in bone marrow of mice, *156*, 181
Cigarette smokers, clastogenic agents in urine of, *147*, 179
–, urine, kinetics of mutagen excretion, *157*, 227

Cigarette smoking, and diet, effects on mutagens in human urine, *158*, 149
Cigarette tar, genotoxicity in somatic cells of Drosophila, *147*, 257
–, smoking conditions, effect on genotoxicity, *147*, 276
Cisplatin, genotoxic effects in CHO cells, influence of temperature, *151*, 129
–, treatment of CH V79 cells, *144*, 203
Clastogenesis, radiation, protection and potentiation by caffeine, *143*, 61
Clastogenic adaptation, in barley, differential response of seeds, *143*, 83
–, peroxide pretreatment of *V. faba* root-tip meristems, *142*, 23
Clastogenic agents, isolation from urine, *147*, 171
–, in urine of coffee drinkers and cigarette smokers, *147*, 179
Clastogenic cross-adaptation in *V. faba* root-tip meristems, *144*, 171
Clofibrate, mutagenicity, *157*, 1
Cluster analysis, carcinogenicity prediction, *153*, 167
–, of short-term tests, *147*, 139
Clustering methodologies, *153*, 169
Coal mine, soft coal open-cast workers, chromosomal abnormalities, *144*, 271
Coal oils, mutagenicity, primary aromatic amines, *155*, 7
Coal-tar exposed workers, ascorbic acid prophylaxis, *147*, 291
Coal tar pitch volatiles, aluminium workers exposed to, genetic monitoring, *155*, 143
Coal tar, volatile mutagens, detection, *156*, 195
Cobalt chloride, genotoxicity in diploid yeast, *155*, 117
Cobalt compounds, mutagenicity, *147*, 266
COBAS Bact, automated modification of the Ames test, *144*, 137
Coffee, drinkers, clastogenic agents in urine of, *147*, 179
–, instant, characteristics of major mutagenicity, *142*, 145
–, mutagenicity, implication of H_2O_2, *144*, 227
–, mutagenicity studies, *156*, 39
Colcemid, induction of aneuploidy, *155*, 61
Colon cancer, effect of Se on, *154*, 40
–, excretion of bile acids, *158*, 45
–, metabolic epidemiology, *152*, 97
Colon epithelial cells, carcinogen-induced nuclear damage, inhibition by diallyl sulfide, *143*, 127
Comparative chemical mutagenesis, *157*, 107
Comparative mutagenesis, a comprehensive exercise, *147*, 1
Complementation group E, xeroderma pigmentosum, *145*, 55
Compromising cellular antioxidant systems, induction of 6-TG-resistant mutants, *149*, 119
Computer-Automated Structure Evaluation (CASE), analysis of genotoxic activity of pesticides, *147*, 343
Confluent holding, UV-irradiated XP, transient enhancement, *149*, 147
Congenital anomalies, induction in mouse oocyte and uterus, effects of X-rays, *149*, 221, 231
Convict cichlid, mutational changes of quantitative morphological traits, *149*, 209
Co-recessive inheritance, model for DNA repair, genetic disease, and carcinogenesis, *145*, 227
CPBS method, application to the Gene-Tox data base, *153*, 187
–, a Bayesian approach, *153*, 135
–, schematic diagram, *153*, 139
Creosote, volatile mutagens, detection, *156*, 195
Crepis capillaris, model system for testing mutagenicity, *147*, 51
–, SCE and CA, *147*, 291
Cresols, *Allium cepa* root tips, *154*, 171
18-Crown-6-ether, genetic toxicology testing, *153*, 62
Cyanide, sodium, activation to a toxic, non-mutagenic metabolite in *S. typhimurium, 144*, 119
4-Cyanodimethylaniline, comparative chemical mutagenesis, *157*, 107
Cyclobutane pyrimidine dimers, removal from DNA of UV-irradiated mammalian cells, *143*, 109
Cyclobutyl pyrimidine dimers, effect on synthesis of RecA and UmuC proteins, *146*, 33
Cycloheptatriene, genetic toxicology testing, *153*, 59
Cyclooctadiene, genetic toxicology testing, *153*, 59
Cyclopenta-fused hydrocarbon, bacterial mutagenicity, *155*, 95
Cyclophosphamide, clastogenic action in mouse bone marrow, effects of age, sex and diet, *158*, 181
–, cytogenetic effects, *147*, 326
–, inhalation and intraperitoneal injection, *147*, 136
–, mutagenic activity, *149*, 514
–, mutagenicity of radiation and, *147*, 287
–, UDS in rats, *150*, 383
–, in vivo exposure, in vitro assays of, *158*, 97
Cyclophosphane, cytogenetic effects, *147*, 313
Cypermethrin, induction of micronuclei in mouse bone marrow, *155*, 135
Cytidine analogues, mutagenic activity, *147*, 262
Cytochrome, content in *S. cerevisiae*, modulation, *150*, 217
Cytochrome P-450, alkoxyphenoxazones dealkylation, *142*, 127
–, mediated mutagenesis, 3-MeO-AAB as substrate for, *152*, 125
Cytogenetic analysis, in in vitro systems, *147*, 126
Cytogenetic cell reactions, visualization using vital dyes, *147*, 137
Cytogenetic studies, human surveillance, tabulation and assessment, *154*, 111
Cytosine arabinoside, CA formation, human lymphocytes, *149*, 475
–, CA induced by restriction endonuclease Alu I, *152*, 205
–, influence on cell kinetics, *147*, 300
–, potent clastogen, *151*, 65
Cytostatic drugs, nurses handling, SCE, *157*, 235
Cytostatic drug activity, in plasma, *143*, 263

dam mutator, competition between isogenic wild-type and, of *E. coli, 144*, 145
Data bases, characterization, *153*, 168
–, CPBS method, *153*, 135
–, fact, development, *147*, 267
–, prediction carcinogenicity of chemicals, *153*, 79
dCMP deaminase, activity, lack of, DNA-fork displacement rates, *142*, 199
DDT, induction of benzo[*a*]pyrene, *158*, 111
Deinococcus radiodurans,, pyrimidine dimer UV endonuclease, *145*, 119

Delphinidin, induction of micronuclei in cultured V79 CH cells, *158*, 89
Denmark, local activity report for 1984, *147*, 380
Deoxycholic acid, fluctuation test, *158*, 45
Deoxynucleoside triphosphate pool concentrations, imbalance by UV radiation, *145*, 95
Deoxynucleotide pools, imbalance, UV-induced DNA repair in V79 cells, *146*, 277
Developmental status, of bioassays in genetic toxicology, *153*, 1
Diabetes, type 2, chromosomal aberration rates and SCE frequency, *143*, 117
N,*N*′-Diacetylbenzidine, metabolic activation to mutagen, *151*, 195
Diadenosine tetraphosphate, formaldehyde-induced mutagenesis, *154*, 103
Dialkylnitrosamines, mutagenic activation by intact urothelial cells, *157*, 95
–, mutagenicity with rat and rabbit nasal, lung and liver S9, *158*, 141
Diallyl sulfide, inhibition of carcinogen-induced nuclear damage, *143*, 127
Diamino compounds, aromatic, mutagenicity, *147*, 264
Diaminodiphenyl ether, mutagenicity, *S. typhimurium*, *143*, 11
Diaminodiphenylmethane, mutagenicity, *S. typhimurium*, *143*, 11
Diaminodiphenylsulphone, mutagenicity, *S. typhimurium*, *143*, 11
4,4′′-Diaminoterphenyl, comparative chemical mutagenesis, *157*, 107
cis-Diamminedichloroplatinum(II), induced damage in human fibroblasts, *145*, 77
Diazepam, mutagenic activity, *147*, 304
–, SCE in lymphocytes of patients treated with, *155*, 71
1,2-Dibromo-3-chloropropane, dominant-lethal effects, tests, *156*, 103
–, genotoxic activity, *147*, 257
1,2-Dibromoethane, mutagenicity in human lymphoblastoid cell lines, *142*, 133
2,6-Di-*tert.*-butylphenol, genetic toxicology testing, *153*, 60
cis-Dichlorodiammine platinum(II), induction of aberrations in mouse bone-marrow chromosomes, *156*, 187
1,2-Dichloroethane, mutagenicity in human lymphoblastoid cell lines, *142*, 133
1,3-Dichloropropane, genetic toxicology testing, *153*, 61
Dichlorvos, low concentrations, cultivation of *E. coli* in, *142*, 1
Dictamni Radicis Cortex, dictamnine and γ-fagarine from, *144*, 221
–, mutagenic substances, *147*, 265
Dictamnine, mutagenic activity, *144*, 221
Dictyate oocytes, female mice, non-disjunction after, *151*, 109
Dicumarol, alkoxyphenoxazones dealkylation, cytochrome P-450 dependent, measurement, *142*, 127
Diesel exhaust, nitroacetoxypyrenes and nitrohydroxypyrenes in, *158*, 3
–, particulates, direct-acting mutagens from, *155*, 27
Diet, mutation and cancer, *154*, 205
Dietary factors, affecting the urinary mutagenicity assay system, *149*, 365; *156*, 171
Diethanolamine, genetic toxicology testing, *153*, 61
N,*N*-Diethanolnitrosamine, mutagenicity with rat and rabbit nasal, lung and liver S9, *158*, 141
Diethylstilboestrol, dipropionate, effect on SCE, *144*, 27
–, induction of metaphase arrest and inhibition of microtubule assembly, *143*, 231
–, mutagenicity, *156*, 199
Diethyl sulphate, *S. typhimurium*, anaerobic culture, *143*, 183
Differentiation, in animals, *153*, 42
–, in plants, *153*, 42
2,3-Dihalopropanal, 3-substituted, promutagens, *158*, 61
trans-7,8-Dihydro-7,8-dihydroxybenzo[*a*]pyrene, host-mediated mutagenicity experiments, *156*, 163
3-Di(hydroxymethyl)amino-6-(5-nitro-2-furylethenyl)-1,2,4-triazine, induction of SOS responses in *E. coli*, *146*, 243
4-Dimethylaminoazobenzene, comparative chemical mutagenesis, *157*, 107
3-(*N*,*N*-Dimethylamino)-1-propyl chloride, genetic toxicology testing, *153*, 60
7,12-Dimethylbenz[*a*]anthracene, SCE measurement, in whole organ in vitro, *147*, 165
1,5-Dimethylbicyclooctanol, genetic toxicology testing, *153*, 62
3,3-Dimethyl-2-butanone, genetic toxicology testing, *153*, 61
Dimethylhydrazine, rats treated with, dietary synergism, *158*, 53
1,2-Dimethylhydrazine, DNA-repair host-mediated assay, *148*, 1
Dimethylnitrosamine, DNA-repair host-mediated assay, *148*, 1
–, in hybrid dysgenic system of *D. melanogaster*, *149*, 33
N,*N*-Dimethylnitrosamine, *MR P*-type transposable elements, in *D. melanogaster*, *152*, 169
3,5-Dimethylphenol, genetic toxicology testing, *153*, 61
Dinitrobenzene derivatives, mutagenicity–structure relationships, *147*, 256
Dinitropyrenes, CHO cells in vitro, induction of 6TG resistance, CA and SCE, *158*, 209
–, generated by kerosene heaters and fuel gas and liquefied petroleum gas burners *157*, 39
1,8-Dinitropyrene, oncogen of sarcomas, *147*, 270
Dioxin, hepatotoxic doses, *157*, 63
Diphtheria toxin, resistance, genes for, UV-irradiated human fibroblasts, *152*, 67
Dipyrido[1,2-*a*:3′,2′-*d*]imidazoles, derivatives, mutagenicity in *S. typhimurium*, *156*, 53
Direct-acting mutagens, from diesel-exhaust particulates, *155*, 27
Direct black, mutagenicity, *156*, 131
Direct brown, mutagenicity, *156*, 131
Direct risk estimation, tests for dominant mutations suitable for, *154*, 76
DMNA, *see* Dimethylnitrosamine
DNA, adducts, from cooked-food-related mutagens, in CHO cells, *149*, 249
–, –, dosimeters to monitor human exposure, *147*, 59
–, –, formation, diet, mutation and cancer, *154*, 211
–, –, mammalian cells, immunochemical detection, *147*, 281
–, –, organ-specific induction, in 2-AAF-treated rats, *150*, 23
–, alkylated single-stranded, mutagenesis at putative apurinic sites, *149*, 1

DNA, (*continued*)
–, alkylation, effect of Se on, *154*, 43
–, –, by nitrosureas, *149*, 95
–, barley embryos, proteinase K-sensitive sites and *M. luteus* endonuclease-sensitive sites, *149*, 431
–, base damage, specific, X-ray-induced inactivation of bacteriophage PM2, *146*, 229
–, bases, enzymatic excision, damage, *150*, 85
–, carcinogen-treated, sensitivity to inactivation by UV, *145*, 17
–, Chinese hamster cells, incorporation of ^{3}H and ^{125}I, *149*, 257
–, cross-links, human leucocytes, treatment of, *146*, 301
–, crosslinking, by nitrosoureas, *149*, 95
–, damage, enhanced induction of SV40 replication, *151*, 1
–, –, induced by nitropyrenes in primary mouse hepatocytes, *151*, 137
–, –, induction, in human skin fibroblasts, by *N*-hydroxy-2-naphthylamine, *143*, 103
–, –, –, and repair, in excision-deficient or -proficient human cells, *145*, 209
–, –, –, –, in human fibroblasts, *146*, 89
–, –, mammalian cell, by heterocyclic food mutagens, *144*, 57
–, –, and repair, *D. melanogaster*, HMPA-induced genetic alterations, *150*, 241
–, –, repairable, in *E. coli* cells, *148*, 1
–, –, sensitive bacterial mutants, *154*, 14
–, –, spontaneous, *154*, 18
–, damaging agents, CH cells treated with, effect of 3AB, *151*, 251
–, –, cytotoxic effects, on neurofibromatosis cells, *142*, 55
–, –, response to, in UV-sensitive mutants, *147*, 322
–, damaging properties and cytotoxicity in human fibroblasts, *145*, 71
–, *D. melanogaster, ebony*, larval sensitivity, to UV and UV and X induced lesions, *149*, 399
–, effect of selenium on, *154*, 30
–, element-induced lethal mutations, in hybrid dysgenic system of *D. melanogaster, 149*, 33
–, excision repair, *E. coli*, methyl cinnamate derivatives, *146*, 15
–, fork displacement rates, cultured mammalian cells, *142*, 199
–, fragmentation, by DMN and MMS, in human hepatocyte primary cultures, *144*, 209
–, incorporation of thymidine, tissue-specific inhibition, *149*, 495
–, interactions with *uvrA* and *uvrB* proteins, *145*, 43
–, interstrand cross-links, induced by 8-MOP in *T. thermophila*, 145, 157
–, lesions, in BU-induced mutagenesis, *149*, 287
–, methylation, and 5-azacytidine, in CHO cells, *150*, 333
–, nuclear, incorporation of BrdUrd, *150*, 283
–, nucleophilic sites, ethylation, *150*, 13
–, organellar, movement, *153*, 43
–, parental, role of BrdU incorporated into, *151*, 77
–, photoadducts, induced in CH V79 cells by 5-MOP and 8-MOP, *151*, 281
–, photoproducts, polyclonal antiserum for, characterisation, *146*, 129

DNA, (*continued*)
–, plasmid, carcinogen-modified, mutational and recombinational events, *145*, 25
–, platinum lesions, in *E. coli*, repair of, *145*, 35
–, polymerase β, measurement in skin fibroblast AT cell lines, *146*, 295
–, protein cross-links, induction and repair, *147*, 320
–, purine bases, in yeast, ^{3}H decay, *149*, 359
–, recombinant techniques, in cloning DNA repair genes, *150*, 61
–, repair, by alkaline elution, split-dose exposure to MNNG, *145*, 81
–, –, assay, rat hepatocyte, in vivo, *156*, 1
–, –, caffeine effects on, *143*, 1
–, –, characterization, in frog cells, solar UV, *146*, 191
–, –, deficiencies, *D. melanogaster*, irradiated in N_2 or O_2, *149*, 409
–, –, *D. melanogaster*, X-ray-induced genetic damage, *149*, 385
–, –, effect of poly(ADP-ribose) synthesis, *150*, 69
–, –, effects on UV-induced mutagenesis and cell killing, in human skin fibroblasts, *148*, 119
–, –, enzyme, requirement of Mn ions, *145*, 119
–, –, genes, use of recombinant DNA techniques, *150*, 61
–, –, host-mediated assay, *147*, 309
–, –, –, evaluation, *148*, 1
–, –, induction of, in human fibroblasts, *147*, 286
–, –, inhibitors, combinations of, *150*, 313
–, –, mechanisms, *154*, 12
–, –, in mouse embryo fibroblasts, *145*, 185
–, –, in organ cultures of hamster tracheal epithelium, *142*, 41
–, –, processes, effect on induction of genetic duplications, *151*, 25
–, –, in secondary leukemia lymphocytes, *146*, 219
–, –, synthesis, effect of Se on, *154*, 43
–, –, –, induction in primary rat hepatocyte cultures, *145*, 201
–, –, –, influence of Cr compounds, *147*, 316
–, –, –, inhibition of AraC, *150*, 299
–, –, systems, chloramphenicol in, *143*, 29
–, –, UV-induced, V79 cells, imbalance of deoxynucleotide pools, *146*, 277
–, replication, errors, *154*, 3
–, –, methylation-induced blocks, *150*, 77
–, single-strand breaks, repair, in X-irradiated yeast, *146*, 55, 63
–, –, X-ray-induced, rejoining, in tuberous sclerosis fibroblasts, *146*, 211
–, sterigmatocystin adducts, in rat liver, ^{32}P-postlabelling analysis, *152*, 85
–, synthesis, in Chinese hamster UV-sensitive mutant cells, *149*, 271
–, –, in human cells, effect of 3AB, *143*, 113
–, –, –, inhibition and recovery after UV, *145*, 63
–, –, inhibition, in AT lymphoblasts by neocarzinostatin, *146*, 79
–, –, –, effect of MNU and MNNG, in V79 cells, *142*, 49
–, –, –, after γ-irradiation, *145*, 171
–, –, replication, inhibition of, in human fibroblasts, *147*, 286

DNA, synthesis, (*continued*)
–, –, unscheduled, correlation with chromosome condensation, in mitoses from human lymphocytes, *142*, 45
–, –, –, in germ cells, *154*, 79
–, –, –, induction by arecoline in mouse germ cells, *158*, 189
–, –, –, kinetics, in UV-irradiated chicken embryo fibroblasts, *146*, 305
–, –, –, rat liver cultures, scintillometry, *143*, 257
–, –, UV-induced unscheduled, in fibroblasts of aging inbred rats, *146*, 197
–, –, X-ray-sensitive mutants of CHO cell line, *145*, 171
–, technology, recombinant, study of gene alteration, *153*, 13
–, unwinding method, to measure strand breaks, *146*, 55
–, –, repair kinetics, *146*, 63
–, UV-irradiated mammalian cells, removal of (6–4)photoproducts, *143*, 109
Dobane 102, linear alkyl benzene, genetic toxicology testing, *153*, 59
–, sulphonate, genetic toxicology testing, *153*, 59
Dobanol 23, primary synthetic fatty alcohol, genetic toxicology testing, *153*, 59
Dobanol 25-3, primary alcohol ethoxylate, genetic toxicology testing, *153*, 60
Dobanol 25-3S/27, sodium salt of sulphated Dobanol 25-3, genetic toxicology testing, *153*, 60
Dominant lethal assay, chemicals tested in, *154*, 55
–, current status, *154*, 49
Dominant lethals, induction in mouse oocytes and uterus, effects of X-rays, *149*, 221, 231
–, influence of mating status and age, in irradiated female mice, *147*, 357
–, study, male mice, effect of ofloxacin, *144*, 51
–, test, *154*, 74
Double-strand break repair, in CHO cells, *145*, 177
Doubling-dose method, *MR*-induced sex-linked recessive lethal mutations in *D. melanogaster*, *150*, 261
Down's disease, effect of methylcholanthrene, *149*, 51
Drosophila melanogaster, differential mutagenicity of IQ, *156*, 93
–, *ebony*, biochemical characterization, *149*, 399
–, feeding rejection, role of, *144*, 13
–, genetic damage induced by 8-ethoxycaffeine, *149*, 189
–, genotoxicity of spices, *143*, 219
–, hybrid dysgenic system, DNA-element-induced lethal mutations, *149*, 33
–, induction of somatic eye-colour mutations, *148*, 65
–, male genital imaginal discs, cell-replacement repair, *151*, 243
–, male germ cells, ENU induction, influence of female genotype, *144*, 77
–, *mei-9, mei-41, mei-9 mei-41* alleles, differential hypersensitivity after larval X-irradiation, *146*, 257
–, mosaic test, *N*-nitroso compounds, genotoxic activity, *144*, 177
–, *MR*-induced sex-linked recessive lethal mutations, *150*, 261
–, *MR P*-type transposable elements, *152*, 169
–, *mus201*, cell line, hypersensitivity, *145*, 165
–, mutagen-sensitive strains, *149*, 385, 399, 409, 415
Drosophila melanogaster, (*continued*)
–, mutagen-sensitivity, *150*, 225, 235
–, repair-defective mutants, effects on alkylation-induced mutagenesis, *149*, 193
–, sex-linked recessive lethal mutations, *157*, 163
–, somatic cells, genotoxicity of 5-azaC, *143*, 195
–, translocations induced, non-recovery mechanisms, *149*, 179
–, transposons in, *153*, 31
–, trenimon-induced sex chromosome loss, *142*, 29
Drugs, antibacterial, mutagenicity, *147*, 271
–, registration, evaluation of mutagenicity testing, *147*, 131
Dyes, industrial, mutagenicity, *147*, 285

ebony, D. melanogaster, difference with *Canton-S* strain, *150*, 225
Ekatin, genotoxic effects, *155*, 131
Ellagic acid, reduction of CSC- and BaP-induced mutagenicity, *152*, 1
Endodan, genotoxicity, *157*, 13
Endonucleases, restriction, induction of chromosomal aberrations, *150*, 359
–, –, induction of SCE, *144*, 33
Endonuclease Alu I, restriction, CA induced by, *152*, 205
–, –, CA induction in CHO cells, *152*, 25
England, local activity report for 1984, *147*, 384
Environmental factors, effect on induced CA in newborns, *143*, 271
Environmental mutagens, and carcinogens, detection by *umu* test, *147*, 219
–, safe levels, *147*, 282
Environmental Mutagen Societies, International Association of, news column, *147*, 329
Environmental pollutants, chemical, effects, *147*, 308
Enzymes, analysis, restriction, determination of basepair substitutions, *148*, 35
–, drug-metabolising, activities, *147*, 125
–, endogenous, detoxication, *147*, 124
Epidermal enzyme-mediated mutagenicity, of 2-aminoanthracene, *147*, 37
Epigallo-catechin-gallate, bio-antimutagen, *150*, 127
Epoxides, genetic toxicology testing, *153*, 70
Epoxy resin, cytogenetic effects in man, *155*, 127
–, hardeners, mutagenicity of aromatic amines, *143*, 11
Error-prone repair, *E. coli A2C* locus, *149*, 303
Erythrocytes, polychromatic, induction of micronuclei, effects of age and sex, *147*, 261
Escherichia coli, adaptive response, to alkylating agents, *154*, 85
–, L-azetidine-2-carboxylic acid resistance, *149*, 303
–, base-pair substitution specificity, induced by *mutL* and *mutS* mutators, *142*, 93
–, B/r, bio-antimutagenic effects of tannic acid, *149*, 17
–, cells, repairable DNA damage, *148*, 1
–, cloned *ada* gene, regulation of expression, *146*, 155
–, competition between dam mutator and isogenic wild-type, *144*, 145
–, cultivated in low concentrations of dichlorvos, *142*, 1
–, daughter-strand gaps, repair, *146*, 177

Escherichia coli, (*continued*)
–, decrease of resistance to UV killing by pKM101 derivative, *150*, 147
–, effect of a split UV dose, *144*, 127
–, excision-deficient, two-step model for UV mutagenesis, *150*, 133
–, frameshift mutagenesis by 9AA and ICR191, *151*, 49
–, induction of *recA*-independent mutagenicity by CEO, *152*, 157
–, inhibition of *uvr*-independent crosslink repair, *145*, 49
–, interaction of a mutator with a stable genetic system, *143*, 191
–, K12, DNA of, incorporation of BU, *149*, 287
–, –, genetic control of heat resistance and thermotolerance by recA and uvrA, *145*, 113
–, –, *rec*B21 influence, on prophage lambda induction, *142*, 159
–, –, *uvrB, umuC* gene in postreplication repair, *145*, 107
–, *lacI* gene, ethylene oxide, *146*, 43
–, *lexA*$^+$ gene, interspecies regulation of SOS response, *145*, 103
–, low-concentration streptomycin resistance, *147*, 269
–, MNNG-induced DNA damage, mutation fixation, *146*, 185
–, 8-MOP DNA crosslinks, repair, *146*, 135
–, mutant of, hyper-resistant to near-UV plus MPS, *151*, 43
–, mutation induction specificity, *148*, 35
–, NADPH-dependent lipid peroxidation of rat-liver microsomes, *149*, 321
–, nitropyrenes, mutagenicity of, *142*, 163
–, *polA*, UV exposure, survival modification, *144*, 151
–, postreplication repair, minor pathway, *146*, 169
–, protein synthesis, *recA* and *umuC, 149*, 297
–, *recA*, Weigle reactivation of phage lambda, *145*, 137
–, repair of Pt–DNA lesions, *145*, 35
–, *sfiA* gene, SOS chromotest, *147*, 65, 79
–, SOS response induction by Panfuran-S, *146*, 243
–, *trpA* mutants, induction of specific base-pair substitutions, by CEO, *152*, 147
–, *umu* test, evaluation, *147*, 219
–, *uvrA6*, UV damage photoreactivation, *146*, 33
Ethacridine, mutagenicity, *144*, 9
Ethanol, induction of genotoxicity, *143*, 23
–, – of late fetal death in mice, *147*, 205
Ethers, genetic toxicology testing, *153*, 73
Ethidium bromide, petite mutation induction in yeast, *158*, 69
8-Ethoxycaffeine, genetic damage in *D. melanogaster, 149*, 189
Ethyl acetate, induction of aneuploidy in yeast, *149*, 339
Ethylating agents, mutagenesis caused by, *147*, 259
Ethylbenzene, genetic toxicology testing, *153*, 60
–, hydroperoxide, genetic toxicology testing, *153*, 60, 71
Ethylene dibromide, effects on neurotransmitter enzymes, *147*, 197
–, exposure of mice to, *158*, 81
Ethylene oxide, mutagenicity in *lacI* gene of *E. coli*, *146*, 43
– plant, workers, chromosome analysis of lymphocytes, *156*, 109
Ethylene thiuram monosulphide, genotoxicity, *157*, 13
2-Ethylhexyl glycidyl ether, genetic toxicology testing, *153*, 59
Ethyl methanesulphonate, in hybrid dysgenic system of *D. melanogaster*, *149*, 33
–, induced mutations of major genes, for quantitative phenotypes, *142*, 193
–, premutational lesions in yeast, *143*, 35
Ethyl nitrosourea, Drosophila male germ cells, influence of female genotype, *144*, 77
–, exposure to, mouse-spleen lymphocytes, *143*, 245
N-Ethyl nitrosourea, benzamide differential effect, in CHO cells, *142*, 203
N-Ethyl-*N*-nitrosourea, DNA damage in mammalian tissues, *147*, 256
–, ethylation of nucleophilic sites in DNA, *150*, 13
Eukaryotic genome, recombinant DNA methodologies, *153*, 19
European Environmental Mutagen Society, 14th annual Meeting, Abstracts, *147*, 279
Exposure, human, dosimeters to monitor, *147*, 59
Eye-colour mutations, somatic, induction, *D. melanogaster, 148*, 65
Eye-colour test system, somatic, *D. melanogaster*, metal compounds 157, 157

Fact database, development, *147*, 267
γ-Fagarine, mutagenic activity, *144*, 221
Fanconi's anaemia lymphocyte chromosomes, effect of aphidicolin, *144*, 257
Fecal mutagens, in healthy subjects, Finland, *152*, 97
Fecal mutagenicity, effect of Se on, *154*, 36
–, from ingestion of fried ground beef, *143*, 207
Feeding rejection, role of, in Drosophila mutation assays, *144*, 13
Fenitrothion, genotoxic effects, *155*, 131
Fetal blood, rat, micronucleus induction by DMNA, *147*, 295
Fibroblasts, aging inbred rats, UV-induced unscheduled DNA synthesis, *146*, 197
–, chicken embryo, UV-irradiated, kinetics of UDS, *146*, 305
–, effect of caffeine on X-ray-induced mitotic delay, *143*, 251
–, human, differential response to MMC and *cis*-Pt(II), *145*, 77
–, –, – to UV, *148*, 119
–, –, diploid, benzo[*a*]pyrene diol-epoxides, efficiency, *152*, 5
–, –, –, induction of cytogenetic changes, *150*, 327
–, –, DNA-damaging properties and cytotoxicity, *145*, 71
–, –, effects of UV in different phases of the cell cycle, *148*, 119
–, –, foetal lung, effect of Se on, *154*, 36
–, –, growth-arrested, recovery, UV-induced lethal damage, *152*, 233
–, –, normal diploid, transient enhancement by confluent holding, *149*, 147
–, –, skin, permeable arrested, excision repair, *146*, 109
–, –, –, treated with *N*-hydroxy-2-naphthylamine, induced DNA damage, *143*, 103
–, –, UV-irradiation, TG and diphtheria toxin resistance, *152*, 67
–, RB patients, radiation sensitivity, *152*, 31
–, tuberous sclerosis, DNA single-strand breaks, X-ray-induced, rejoining, *146*, 211

Finland, local activity report for 1984, *147*, 381
Fish chromosomes, effect of Se on, *154*, 37
Fisher exact test, microcomputer programs, (erratum), *143*, 101
Flavonoids, comparative activity, *147*, 306
–, plant, in biology and medicine, *149*, 157
Flavonol glycoside precursors, effect of bile acids on formation of quercetin, *155*, 99
Flow microfluorometry, in AT fibroblasts, *148*, 71
Fluorescent light, induction of chromatid damage during G_2, *151*, 57
Fluoride, effect on CA and SCE in cultured human lymphocytes, *144*, 89
Fluorodeoxyuridine, induction of sex differences in baseline sister-chromatid exchanges in mice and Chinese hamsters, *143*, 45
5-Fluorodeoxyuridine, induction of SCEs, *151*, 77
p-Fluorophenylalanine, testing, aneuploidy induction, *157*, 215
5-Fluorouracil, induction of SOS response in *E. coli*, *147*, 270
Food additives, natural, mutagenicity, *147*, 275
Food black, mutagenicity, *156*, 131
Food, cooking, formation of mutagens IQ and MeIQ, *144*, 59
Foodstuffs, nitrite treatment, direct-acting mutagenicity, *158*, 119
Formaldehyde, induced mutagenesis, *154*, 101
–, mutagenic characteristics, on bacterial systems, *156*, 153
–, workers exposed to, *147*, 288, 308
–, workers in a paper factory, cytogenetic effects in lymphocytes, *158*, 195
Forward mutation, *E. coli A2C* locus, *149*, 303
Frameshift mutagenesis, by UV and γ radiation in Salmonella, *151*, 209
France, local activity report for 1984, *147*, 381
Frequency curves, mutation, non-linearities, *150*, 51
Fried beef, mutagenic activity in human urine after, *149*, 365
Frog cells, ICR 2A, induction of SCE, *149*, 443
Fungal metabolites, genotoxicity, relation to aflatoxin B_1 biosynthesis, *143*, 121
Fungal mutants, with altered spontaneous mutagenesis, *154*, 7
–, radiation-sensitive, *154*, 16
Fungi, spontaneous recombination, *154*, 11
Furazolidone, induction of λ prophage, *156*, 69
Furfural, induction of SCE in human lymphocytes, *156*, 233
Furfuryl alcohol, induction of SCE in human lymphocytes, *156*, 233
Furocoumarins, lesions induced in DNA, *151*, 217
Furoquinoline alkaloids, mutagenicity, *147*, 265

G_2 block, in CHO cells, *145*, 177
Galiton Plus, genetic and cytogenetic effects in mice, *147*, 283
Gardner's syndrome, transient enhancement, confluent holding, *149*, 147
Gas burners, identification of mutagens, *147*, 263
Gene alterations, at molecular level, analysis, *153*, 37
Gene amplification, *153*, 41
Gene mapping, recombinant DNA methodologies, *153*, 25
Gene mutations, in mice, induction, multiple endpoint approach, *150*, 393
–, somatic, in vivo, TG^r T-lymphocytes in human blood, *150*, 411
Gene transfer, interspecies, *153*, 43
Genetics, reversed, *153*, 43
Genetic damage, alkylation-induced, in Drosophila, *149*, 193
Genetic duplications, in bacteria, relevance for genetic toxicology, *150*, 107
–, induction in bacteria, effects of DNA-repair processes, *151*, 25
Genetic monitoring, in Byelorussia, *147*, 307
Genetic radiosensitivity in mammals, *147*, 325
Genetic toxicology, bioassays, current status, *154*, 49
–, –, developmental status, *153*, 1
–, relevance of genetic duplications in bacteria, *150*, 107
Gene-Tox data base, application of the CPBS method, *153*, 187
–, chemicals, alphabetical listing, *153*, 96
–, cluster analysis, application, *153*, 174
–, estimating sensitivity and specificity, *153*, 142
–, prediction of assays and batteries, *153*, 196
–, test results, listing of, *153*, 82
Gene-Tox Program, bioassays, testing experience, *153*, 4
Gene-Tox working groups, data base, *153*, 79
Genotoxic activity, estimation in vivo, *150*, 159
Genotoxic hazard, in man, evaluation, *150*, 43
Genotoxic metabolites, effects of mineral oils on the microbial mutagenicity of, *149*, 159
Genotoxic threshold dose levels, *154*, 131
Genotoxicity assays, selectivities, *153*, 132
Genotoxins, SOS chromotest, colourimetric bacterial assay, *147*, 65, 79
Germ cells, cytogenetic analysis, *154*, 80
–, mutagenesis, rat reproductive tissue, EMS induction, *144*, 93
–, mutation, and diet, *154*, 207
–, –, in mice, dose–effect relationships, *147*, 279
Germany, F.R.G., local activity report for 1984, *147*, 381
Germany, G.D.R., local activity report for 1984, *147*, 382
Gibberellic acid, molecular mechanism of genetic effects, *147*, 295
Glass workers, mineral oils, occupational exposure, analysis of peripheral blood lymphocytes, *144*, 277
Globin genes, recombinant DNA methodologies, *153*, 21
β-Glucuronidase, mutagenicity in the Ames test, *143*, 169
Glutamic acid pyrolysates, mutagenic compounds in, *147*, 310
Glutathione depression, rat reproductive tissue, EMS induction, *144*, 93
Glutathione levels, decreased, isolation of mutants of *S. typhimurium* with, *147*, 302
Glycerol-α-allyl-ether, genetic toxicology testing, *153*, 59
Gonads, quantitative histology, *154*, 78
Gonadal exposure, in mammals, tests providing evidence of, *154*, 77
–, tests for, in mammals, *154*, 69
Grape juice, absence of mutagenic activity of human urine after consumption of, *156*, 171
Grasshopper, primary spermatocytes, killing by γ-rays, *151*, 73
Green light, excitation, effect on *A. cepa*, *158*, 77
Guanine, in yeast, DNA, ^3H decay, *149*, 359
Guanosine derivatives, adducts of, mutagen detection, *147*, 258
GUM, Gesellschaft für Umweltmutationsforschung, abstracts, 1984, *147*, 123

Haematoxicity, benzene, *154*, 158
2-Halopropenals, 3-substituted, mutagenicity, *158*, 61
Hamster cells, baby, 9-β-D-arabinofuranosyladenine-resistant mutations, *149*, 141
Hamster tracheal epithelium, organ cultures, DNA repair, *142*, 41
Heat resistance, *E. coli* K12, genetic control, *145*, 113
Heat-shock-induced enhanced reactivation of UV-irradiated Herpesvirus, *146*, 121
HeLa cells, UV-irradiated adenovirus 2, enhanced reactivation, *142*, 83
Heme proteins, inhibitory action, *147*, 255
Hemin, inhibitory action, *147*, 255
HEMLA, *see* Hexamethylmelamine
Hemoglobin disorders, in man, molecular analysis, *153*, 28
Hepatic microsomes, of rat, 2-hydroxy-EM in, *149*, 327
Hepatitis B, chronic, metabolic activation of hepatocarcinogens, *144*, 213
Hepatocarcinogens, metabolic activation in chronic hepatitis B, *144*, 213
Hepatocytes, mouse, primary, DNA damage induced by nitropyrenes, *151*, 137
–, primary culture/DNA-repair test, genotoxicity of *N*-nitrosopropylamine derivatives, *144*, 197
–, rat, cultures, primary, induced UDS, inability to modulate, *155*, 83
–, –, –, –, induction of DNA repair synthesis, *145*, 201
Hereditary diseases programmes, organization, WHO activities, *147*, 280
Heritable, genetic damage, tests for, in mammals, *154*, 69
–, translocations, ^{239}Pu-induced, in male mice, *152*, 49
–, –, study, male mice, with trimethyl phosphate, *157*, 205
–, –, test, *154*, 73
Herpes simplex, reactivation and mutagenesis, in 5-azacytidine-treated monkey kidney cells, *146*, 9
Herpes virus, UV-induced SV40 replication in hamster cells, *151*, 1
–, UV-irradiated, heat-shock-induced enhanced reactivation, *146*, 121
Heterocyclic amines, in cooked foods, *147*, 275
–, IQ and non-IQ type, in crude pyrolyzed materials, *147*, 335
Heterocyclic food mutagens, mammalian cell DNA damage, *144*, 57
Hexamethylmelamine, weak mutagenicity to Salmonella, *142*, 121
Hexamethylphosphoramide, induced genetic alterations, in *D. melanogaster*, *150*, 241
Hexaoxacyclooctadecane, genetic toxicology testing, *153*, 62
Hexaploid triticale, induced quantitative variation, *147*, 45
HGPRT assay, hepatotoxic drugs, *157*, 1
Host-mediated assay, DNA-repair, evaluation, *148*, 1
–, effect of Se on, *154*, 33
HPRT locus, cultured CH cells, mutations induced by X-rays, *144*, 281
HPRT variants, autoradiographic detection, human lymphocytes, *149*, 133
Human, cell line, mutation by particle-borne chemicals, *157*, 71
–, cell strain, mutagenicity of OPP, *156*, 123
Human, (*continued*)
–, fibroblasts, DNA damage, induction and repair, *146*, 89
–, gut bacterial preparations, effect of bile acids on formation of quercetin, *155*, 99
–, lymphocyte cultures, action of anticlastogens, *149*, 83
–, lymphocytes, methods for study of mutations, *147*, 363
–, mouse hybrid cell line, detection of aneuploidy, *149*, 73
–, populations, screening for CA, *143*, 155
–, surveillance cytogenetic studies, tabulation and assessment, *154*, 111
Humic acid, chlorination, identification of mutagenic compounds during, *157*, 111
Hybrid cell line, human × mouse, detection of aneuploidy, *149*, 73
Hybrid dysgenic system of *D. melanogaster*, interaction between mobile DNA-element-induced lethal mutations and chemical mutagens, *149*, 33
Hydrazines, *V. faba* root-tip meristems, pretreatment, *142*, 183
Hydrazine sulphate, activity, in *S. cerevisiae*, *155*, 113
Hydrocarbons, aromatic, di-, tri-, tetra-cyclic, monochloro derivatives, Salmonella/microsome mutagenicity, *155*, 91
–, –, polycyclic, mutagenicity on *S. typhimurium*, *156*, 61
Hydroquinone, genetic toxicology, *154*, 172
Hydroxamic acids, aliphatic, mutagenicity, in CH V79 cells, *152*, 225
N-Hydroxy-2-acetylaminofluorene, mutagenicity to V79 Chinese hamster cells, *149*, 265
N-Hydroxy-2-aminofluorene, benzamide differential effect, in CHO cells, *142*, 203
N-Hydroxycarbamates, mutagenicity, towards *E. coli* and *S. typhimurium*, *151*, 201
2-Hydroxyemodin, in hepatic microsomes of rat, *149*, 327
N-Hydroxylamines, mutagenicity, towards *E. coli* and *S. typhimurium*, *151*, 201
N-Hydroxylaminopurine derivatives, inactive as base analogue mutagens in *S. typhimurium*, *144*, 231
6-*N*-Hydroxylaminopurine, induction of chromosome aberrations and aneuploidy in SHE cells, *148*, 107
N^6-Hydroxymethyl adenosine, formaldehyde-induced mutagenesis, *154*, 101
N-Hydroxy-2-naphthylamine, induction of DNA damage in human skin fibroblasts, *143*, 103
2-Hydroxy-5-*tert.*-nonyl acetophenone oxime, genetic toxicology testing, *153*, 59
Hydroxyurea, mediated breakage in BrdUrd substituted G2 chromosomes, *147*, 319
–, mutagenicity, in CH V79 cells, *152*, 225
N-Hydroxyurea, induction of DNA repair synthesis, *145*, 201
N-Hydroxyurethane, induction of DNA repair synthesis, *145*, 201
Hyperoxia, induction of 6-TG-resistant mutants, *149*, 119
Hyperthyroidism, cytogenetic study, *147*, 316
Hypochlorite, use in determination of heterocyclic amines, *147*, 335

ICR-170, effect of pH in *ad-3* tests of *N. crassa*, *142*, 19
ICR191, frameshift mutagenesis in *E. coli*, *151*, 49
–, SOS response induction, *S. typhimurium hisC3076* marker, *142*, 87

Imidazoquinoline compounds, 3-ethyl analogues, synthesis and mutagenicity, *114*, 131
Imidazo[4,5-*f*]quinolines, mutagenic, analysis of *142*, 5
Imidazoquinoxaline compounds, 3-ethyl analogues, synthesis and mutagenicity, *114*, 131
Imidazoquinoxalines, mutagenic, analysis of, *142*, 5
Incinerators, urban, contaminants spread by, *147*, 287
Indole-3-acetonitrile, in Chinese cabbage, *143*, 17
Indoor pollutants, mutagenic/carcinogenic agents in, *157*, 39
Industrial chemicals, genetic toxicology testing, *153*, 57
Infertility, male mice, by adriamycin, *152*, 53
Insecticides, mutagenicity induced in mice, *147*, 318
Intelligence, artificial, and Bayesian decision theory, *150*, 1
Interleukin-2, in study of mutations in human lymphocytes, *147*, 363
Interspecies regulation, of SOS response, *E. coli lexA*$^+$ gene, *145*, 103
Intestinal microflora, mutagenic activation of biliary metabolites of 1-nitropyrene, *149*, 171
Intraperitoneal injection route, of exposure, short-term rodent genotoxicity assays, *156*, 239
IQ compounds, mutagenic, analysis of, *142*, 5
–, –, in meat, *151*, 177
γ-Irradiation, induction of 6-TG-resistant mutants, *149*, 119
X-Irradiation, *D. melanogaster*, defects in DNA-repair, *149*, 385
–, effects in AT fibroblasts, *148*, 71
–, –, on translocation frequency in male mice, *142*, 65
–, mouse eggs, in vitro fertilization rate, *142*, 59
Isomalathion, production of alkylated NBP, *155*, 1
Isoprene metabolism, epoxidic intermediates, mutagenicity, *156*, 77

Japan, Environmental Mutagen Society, abstracts of papers, *147*, 255

Keracyanin, mutagenicity of, *147*, 262
Kerosene heater, mutagenicity and nitropyrene content, *147*, 270
Ketones, genetic toxicology testing, *153*, 73
Kilacar, genotoxicity, *157*, 13

L5178Y TK$^{-/-}$, small colony, mutants, chromosome 11 aberrations, *147*, 231
L5178Y TK$^{+/-}$ 3.7.2C mouse lymphoma cell line, cytogenetic characterization, *147*, 243
Lactate dehydrogenase-C, heterologous antibodies, *148*, 135
lacZ fusion, induction of adaptive and SOS responses, with alkylating agents, *146*, 149
Lambda bacteriophage, repressor gene of, frameshift mutagenesis, *144*, 141
LDH-C, *see* Lactate dehydrogenase-C
LDH-X, *see* Lactate dehydrogenase-C
Lead nitrate, genotoxicity in diploid yeast, *155*, 117
Lead salts, mutagenicity, *157*, 157
Lethal damage, in yeast, induced by fast neutrons, repair, *149*, 353
Lethal mutations, recessive sex-linked, effect of repeated microwave irradiation, in *D. melanogaster*, *157*, 163
Lethality, reversion, UV damage in *E. coli uvrA6*, *146*, 33
Leukaemia, man, benzene exposure, *154*, 160
–, murine L1210, synergistic killing, by BCNU and theophylline, *146*, 1
–, secondary, lymphocytes, DNA repair in, *146*, 219
Leukocyte chromosomes, cultured, effect of Se on, *154*, 35
lexA$^+$ gene, *E. coli*, interspecies regulation of SOS response, *145*, 103
Lipid peroxidation, NADPH-dependent, rat-liver microsomes, mutation induction in *E. coli*, *149*, 321
Lithocholic acid, fluctuation test, *158*, 45
Liver cancer, effect of Se on, *154*, 39
Liver, rat, perfused, isolated, formation of metabolites of BaP, *147*, 107
Local Activity Reports, EEMS, for 1984, *147*, 379
Lymphoblasts, human, effects of BrdUrd, *151*, 95
–, –, methyl chloride genotoxic effects, *155*, 75
–, –, variance estimation in single-cell mutation assays, *150*, 403
Lymphoblastoid cell lines, human, mutagenicity of DCE and DBE, *142*, 133
–, –, mutation by particle-borne chemicals, *157*, 71
–, –, tritiated water, ionizing radiation from, *157*, 77
Lymphocytes, AT, G_2 chromosomal radiosensitivity, *152*, 39
–, blood, chimpanzee, chromosomal rearrangements, *149*, 57
–, chromosome analysis, workers at an ethylene oxide plant, *156*, 109
–, chromosome changes, after exposure to toluene, *142*, 37
–, cultures, micronucleus yield, effect of donor age, *148*, 99
–, –, from smokers and non-smokers, SCE frequency, α-naphthoflavone, *143*, 131
–, cytogenetic studies, potential sensitivity problems, *154*, 131
–, human, alkylating agents, *152*, 187
–, –, blood, SCE induced by 3-CPs and 8-MOP, *152*, 211
–, –, CA formation, repair of radioinduced lesions, *149*, 475
–, –, chromatid breaks, distribution, *150*, 293
–, –, chromosome aberrations, effect of 3-AB, *148*, 91
–, –, –, effect of iodized contrast media, *147*, 128
–, –, clastogenic changes, analysis of published papers, *154*, 114
–, –, cultures, action of anticlastogens, *149*, 83
–, –, –, induction of SCE by NC, *156*, 117
–, –, DNA-repair inhibitors, combinations, *150*, 313
–, –, effect of 5-azaC on induction of CA and SCE, *149*, 463
–, –, effect of NaF on SCE and CA, *144*, 89
–, –, elderly, increased chromosomal instability, *149*, 505
–, –, HPRT variants, resistant to RNA synthesis inhibition, *149*, 133
–, –, induction of SCE by pyrrole compounds, *149*, 485
–, –, liquid-holding experiments, *147*, 127
–, –, mercury-exposed cytogenetics, *157*, 221
–, –, methods for study of mutations, *147*, 363
–, –, micronuclei size, relation with induction agent, *156*, 229
–, –, mitomycin C induced aberrations, localization, *150*, 307
–, –, mitoses from, unscheduled DNA synthesis and chromosome condensation, *142*, 45
–, –, mutagenicity of MBC, DES and oestradiol, *156*, 199
–, –, neutron-induced chromosome aberrations, *148*, 91

Lymphocytes, human, (*continued*)
–, –, peripheral blood, CA in, effects of pre-treatment with sodium butyrate, *151*, 269
–, –, –, CA and SCE, trenimon-induced, *149*, 469
–, –, –, premature chromosome condensation technique, *149*, 67
–, –, SCE frequencies as function of sampling time, *147*, 113
–, –, SCE-inducing damage, by vinyl acetate and acetaldehyde, *158*, 201
–, –, SCE induction with furfural and furfuryl alcohol, *156*, 233
–, –, X-ray-induced chromosome aberrations, *148*, 91
–, measurement of micronuclei, *147*, 29
–, mouse, TG-resistant, quantification, *147*, 97
–, newborn, SCE baseline frequency, relation to aging in humans, *144*, 85
–, nurses handling cytostatic drugs, *157*, 235
–, peripheral blood, mouse, exposure to mutagenic carcinogens, *157*, 181
–, peripheral, cytogenetic analysis, checking the level of MAC, *147*, 322
–, –, exposure to cyclophosphamide, *158*, 97
–, peritoneal, in vitro assay for SCE, *147*, 268
–, SCE in, of patients treated with diazepam, *155*, 71
–, synergistic induction of SCE, *143*, 225
–, T, human blood, TG^r, *150*, 411
Lymphoma cell line, mouse, L5178Y $TK^{+/-}$ 3.7.2C, cytogenetic characterization, *147*, 243
–, –, mutagenic potency of 4 agents at the TK locus, *157*, 199

Macaca fascicularis, γ-ray-induced reciprocal translocations, *151*, 121
Malathion, commercial, mutagenic and alkylating activities of organophosphate impurities, *155*, 1
–, production of alkylated NBP, *155*, 1
Maleic hydrazide, clastogenic adaptation of *V. faba* root-tip meristems, *142*, 23, 183
–, *V. faba* root-tip meristems treatment, prior heat-shocks, 143, 79
Male recombination factor, activity, following insertion of P-elements, *144*, 73
Malignant transformation, induction, in Balb/3T3 clone cells, *152*, 113
Mammalian, cells, adaptive response to alkylating agents, *154*, 85
–, –, cultured, estimation of mutation rates, *149*, 127
–, –, cultured, molecular nature of mutations, *150*, 431
–, –, DNA damage, by heterocyclic food mutagens, *144*, 57
–, –, mitotic division aberrations, by chemical and radiation treatment, *150*, 369
–, chromosomes, effect of Se on, *154*, 33
–, spot test, standardization, *147*, 133
Man, cytogenetic effects of epoxy resin, *155*, 127
–, genotoxic hazard, evaluation, *150*, 43
Manganese ions, required in DNA-repair enzyme, *145*, 119
Manganese salts, mutagenicity, *157*, 157
Marijuana, THC induction of chromosome breakage in mice spermatogenic cells, *143*, 51
Mating status, mouse, influence on induction of CA and dominant lethals, *147*, 357
O^6-MeGua, *see* O^6-Methylguanine-DNA methyltransferase
Mercaptoethylamine, genetic toxicology testing, *153*, 59
6-Mercaptopurine, testing, aneuploidy induction, *157*, 215
Mercury, exposed human lymphocytes, cytogenetic study, *147*, 325; *157*, 221
Metabolites, genotoxic, effects of mineral oils on the microbial mutagenicity of, *149*, 159
Metal derivatives, mutagenicity study with *S. typhimurium* TA102, *155*, 49
Metal ions, affecting mutagenic activity of quercetin, *148*, 13
Metallurgic factors, mutagenic action, *147*, 305
Metaphase arrest, induction by diethylstilboestrol, *143*, 231
Methapyrilene, genotoxicity evaluation, *147*, 323
Methodologies, comparison of, prediction and battery selection method, *153*, 136
3-Methoxy-4-aminoazobenzene, substrate for cytochrome-P450-mediated mutagenesis, *152*, 125
Methoxypsoralen, genotoxic effects and DNA photoadducts, induced in CH V79 cells, *151*, 281
5-Methoxypsoralen, clastogenicity modification, *147*, 130
8-Methoxypsoralen, crosslinks, *uvr*-independent repair, in *E. coli*, *146*, 135
–, induced DNA interstrand cross-links, *T. thermophila*, *145*, 157
–, lethal and mutagenic effects photoinduced in *S. cerevisiae*, *148*, 47
–, photoinduced cross-links, in yeast, *145*, 145
–, plus near-UV, *E. coli* mutant, *151*, 43
–, SCE induction in human blood lymphocytes, *152*, 211
3-Methyladenine DNA glycosylase II, induction, *recA*$^+$-independent, *146*, 143
Methylating agents, mutagenicity, *147*, 259, 266
Methylating carcinogens, DNA-repair host-mediated assay, *148*, 1
Methylation, blocks to in vitro DNA replication, *150*, 77
Methyl 2-benzimidazolecarbamate, mutagenicity, *156*, 199
Methyl bromide, mutagenicity, *155*, 41
2-Methyl-2-butene, genetic toxicology testing, *153*, 62
1-Methyl-4-*tert.*-butyl benzene, genetic toxicology testing, *153*, 61
Methyl chloride, genotoxic effects, in human lymphoblasts, *155*, 75
Methylcholanthrene, low doses, effect on increased SCE inducibility, *149*, 51
Methyl cinnamate, derivatives, enhancement of UV-induced mutagenesis in *E. coli*, *146*, 15
Methylene bis-adenosine diphosphate, Ap4A and, *154*, 106
Methyl ethyl ketone, induction of aneuploidy in yeast, *149*, 339
Methylglyoxal, induction of SCE in CHO cells, *144*, 189
–, mutagenicity, instant coffee, *142*, 145
O^6-Methylguanine-DNA methyltransferase, role in cell survival, mutagenesis and carcinogenesis, *145*, 1
3-Methyl-5-isothiazolamine, mutagenic activity, *155*, 17
Methyl methanesulphonate, DNA fragmentation in hepatocyte cultures, *144*, 209
–, DNA-repair host-mediated assay, *148*, 1

Methyl methanesulphonate, (*continued*)
–, DNA treated with, *145*, 17
–, induction of somatic eye-colour mutations in *D. melanogaster*, *148*, 65
N-Methyl-*N'*-nitro-*N*-nitrosoguanidine, adapative response of normal human bronchial epithelial cells, *146*, 205
–, damage induced in CH V79, molecular and cellular repair, *146*, 271
–, effect in V79 cells, *142*, 49
–, interaction with UV, in V79 cells, *152*, 77
–, resistance of *E. coli* cultivated in low concentrations of dichlorvos, *142*, 1
–, split-dose exposure, evidence of DNA repair, *145*, 81
–, *S. typhimurium*, anaerobic culture, *143*, 183
4-(*N*-Methyl-*N*-nitrosamino)-1-(3-pyridyl)-1-butanone, inhibition of thymidine incorporation into DNA, *149*, 495
Methyl nitrosourea, benzamide differential effect, in CHO cells, *142*, 203
–, DNA-repair host-mediated assay, *148*, 1
–, effect in V79 cells, *142*, 49
–, induction of nuclear aberrations, in rat gut epithelium, *147*, 256
–, SCE measurement, in whole organ in vitro, *147*, 165
Methylparathion, genotoxic effects, *155*, 131
Methyl pivaloylacetate, genetic toxicology testing, *153*, 62
Micrococcus luteus, endonuclease-sensitive sites in DNA in barley, *149*, 431
–, UV-endonuclease, DNA synthesis in XP cells, *150*, 99
Microcomputer programs, Fisher exact test, (erratum), *143*, 101
Microflora, intestinal, mutagenic activation of biliary metabolites of 1-nitropyrene, *149*, 171
Micronuclei, effect of donor age, *148*, 99
–, in hepatocytes and early spermatids after exposure to mitomycin C, *147*, 323
–, induction, in circulating erythrocytes of mice, by benzene, *144*, 193
–, measurement in lymphocytes, *147*, 29
–, size, in human lymphocytes, relation with induction agent, *156*, 229
Micronucleus, technique, measurement of chromosomal damage, *147*, 29
–, test, bibliographical information, *147*, 257
–, –, sex differences in, *147*, 274
–, yield, in lymphocyte cultures, effect of donor age, *148*, 99
Microsomal assay, with mice S9 fractions, optimal temperature, *147*, 231
Microtubule assembly, inhibition by diethylstilboestrol, *143*, 231
Microwave irradiation, effect on frequency of sex-linked recessive lethal mutations in *D. melanogaster*, *157*, 163
Mineral oils, genotoxic studies with, *149*, 159
–, glass workers exposed to, analysis of peripheral blood lymphocytes, *144*, 277
Minimal medium recovery, *E. coli* repair of daughter-strand gaps, *146*, 177
Miscoding base damage, *154*, 3
Mismatch repair, mutators, antimutators and, *154*, 4
Mitomycin C, effects on cell cycle progression, in *Ch. viridifasciata*, *149*, 41
–, induced aberrations, human lymphocytes, localization, *150*, 307
–, induced damage in human fibroblasts, *145*, 77
–, induction of SCE in CHL fibroblasts, *149*, 437
–, mutagenesis, protein synthesis in *E. coli*, *149*, 297
–, in *N. crassa ad-3* forward-mutation test, *150*, 193
–, in transplacental mutagenicity test system, *147*, 137
Mitotic delay, effect of caffeine and adenosine on G_2 repair, *149*, 275
Mitotic division aberrations, mammalian cells, by chemical and radiation treatment, *150*, 369
Mitotic gene conversion assays, genetic toxicology testing, *153*, 74
Mitotic recombination, UV-induced, frequency curves, *151*, 235
MMS, *see* Methyl methanesulphonate
MNNG, *see N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine
MNU, *see* Methyl nitrosourea
Molecular dosimetry in germ cells, *154*, 79
Monochloroarenes, Salmonella/microsome mutagenicity, *155*, 91
Monoethanolamine, genetic toxicology testing, *153*, 61
Motor neurone disease, SCE, spontaneous and mutagen-induced, *150*, 355
Mouse, bone marrow, aneuploidy induction by mitotic arrestants, *155*, 61
–, –, chromosomes, cis-platin induced aberrations, *156*, 187
–, –, –, no damage by TCDD, *157*, 63
–, –, effect of Se on, *154*, 36
–, C57BL/6J, mutant alleles for altered activity of brain or liver enzymes, *142*, 193
–, differential mutagenicity of IQ, *156*, 93
–, eggs, chromosome aberrations, after fertilization in vitro, *148*, 113
–, –, fertilized in vitro after irradiation, studies on CA, *151*, 275
–, –, X-irradiation, in vitro fertilization rate, *142*, 59
–, embryo fibroblasts, DNA repair in, *145*, 185
–, exposed to ethylene dibromide, *158*, 81
–, female, aneuploidy induction, testing of chemicals, *157*, 215
–, fertilization, ethanol-induced late fetal death, *147*, 205
–, influence of mating status and age on induction of CA and dominant lethals in irradiated female mice, *147*, 357
–, lymphoma cells, analysis of TFT^r mutants, *151*, 147, 161
–, male, effects of post-irradiation interval on translocation frequency, *142*, 65
–, –, heritable translocation study, with TMP, *157*, 205
–, oocyte and uterus, effects of X-rays, on induction of dominant lethals and congenital anomalies, *149*, 221, 231
–, preimplantation embryos, SCE analysis, *147*, 23, 189
–, SCE increase, in bone marow, after whole cigarette smoke, *156*, 181
–, SCE induction kinetics, by different carcinogens, *156*, 177
–, sperm, exposed to procarbazine, *148*, 135
–, spot test, evaluation of performance, *154*, 183
–, superoxide dismutase isoenzymes, *148*, 129

Mouse, (*continued*)
–, transplacental micronucleus test, carbadox and olaquindox, *144*, 81
MR-induced sex-linked recessive lethal mutations in *D. melanogaster, 150*, 261
MR P-type transposable elements, *D. melanogaster, 152*, 169
Muc genes, of pKM101, on specificity of mutation induction in *E. coli, 148*, 35
–, products, inhibition of *uvr*-independent crosslink repair in *E. coli*, 145, 49
MucAB genes, phleomycin mutagenesis in plasmid pGW16, *146*, 47
Multiple endpoint approach, induction of gene mutations in mice, *150*, 393
Murine teratocarcinoma cells, UV radiation sensitivity, *145*, 195
Mus musculus, detection of enzyme mutants, *147*, 315
Mutagens, cooked-food-related, DNA adducts, mutagenic efficiencies, *149*, 249
–, precursor, effects of mineral oils on the microbial mutagenicity of, *149*, 159
Mutagenesis, chemical, modifiers, *147*, 282
–, comparative chemical, *157*, 107
–, comparative, a comprehensive exercise, *147*, 1
–, quantitative comparative, in bacteria, mammalian cells, and animal-mediated assays, *150*, 159
–, spontaneous, roles of DNA repair, replication and recombination, *154*, 1
Mutagenic activity, estimation using the record of SCE and CA, *147*, 284
–, and toxicity, simultaneous measurement, *143*, 201
Mutagenic potential, assessment, in vehicle engine exhaust, *155*, 35
–, of metal derivatives, *155*, 49
Mutagenicity, assessing, Ames assay, percentile rule, *147*, 15
–, risk assessment, guidelines, comments, *147*, 211
–, testing, plant tissue cultures, model system, *147*, 51
–, –, species differences, *147*, 135
Mutant frequency, rise among breast cancer patients, after γ-radiation, *152*, 107
Mutascreen, automated bacterial mutagenicity assay, *150*, 119
Mutation, assays, prediction of carcinogens, *147*, 1
–, frequencies, statistical significance, critical sample sizes, *143*, 93
–, frequency curves, non-linearities, *150*, 51
–, molecular nature, in cultured mammalian cells, *150*, 431
–, rates, estimation, in cultured mammalian cells, *149*, 127
Mutator alleles, *E. coli, mutL* and *mutS, 142*, 93
Mutator mutations, in bacteria, *154*, 6
Mutator phenotype, induction, differential effect of UV, *151*, 9

NADPH-dependent lipid peroxidation of rat-liver microsomes, mutation induction in *E. coli, 149*, 321
Na^+/K^+ ATPase system, hepatotoxic drugs, *157*, 1
Nalidixic acid, resistance to, in *C. albicans, 152*, 15
α-Naphthoflavone, SCE frequency, lymphocytes from smokers and non-smokers, *143*, 131
Naphthofurans, induction of chromosomal aberrations in V79 CH cells, *157*, 53
Naphthofurans, (*continued*)
–, SCE induction, *147*, 306
Neocarzinostatin, DNA synthesis inhibition in AT lymphoblasts, *146*, 79
Neoplasia, benzene-induced, *154*, 159
Neoplasms, in XP patients, dietary carcinogens, *145*, 89
Neurofibromatosis cells, cytotoxic effects of DNA damaging agents, *142*, 55
Neurospora crassa, ad-3 forward-mutation test, mitomycin C in, *150*, 193
–, *ad-3* tests, effect of pH, *142*, 19
–, UV-sensitive mutant with unusual photoreactivation property, *152*, 161
Neurospora endonuclease, influence on trenimon-induced CA and SCE, *149*, 469
Neurotransmitter enzymes, effects of ethylene dibromide, *147*, 197
Neutrons, fast, repair of lethal damage in yeast, *149*, 353
Newborns, chromosomal aberrations, effect of environmental factors, *143*, 271
–, lymphocytes, SCE baseline frequency, relation to aging in humans, *144*, 85
Nickel compounds, mutagenicity, *147*, 266
Nickel salts, mutagenicity, *157*, 157
Nicotinamide, effect on SCE rates induced by cytostatics, *143*, 225
Nifuroxazide, mutagenicity, *157*, 1
Nitrilotriacetic acid, effects on induction of gene mutations and SCE by insoluble Cr compounds, *156*, 219
Nitrite, treatment, direct-acting mutagenicity of foodstuffs, *158*, 119
–, use in determination of heterocyclic amines, *147*, 335
Nitroacetoxypyrenes, analysis, *147*, 264
–, in diesel-exhaust particles, *158*, 3
p-Nitroanisole *O*-demethylase, monoxygenase activity, *147*, 231
Nitroarenes, mutagenicity, adenine–thymine base pairs, *149*, 311
–, in Suimon River sediment, *157*, 135
Nitrobiphenyls, mutagenic potency in *S. typhimurium, 149*, 9
Nitrofluorenes, bifunctional, structure–activity relation, in *S. typhimurium, 143*, 213
3-(5-Nitro-2-furyl)acrylic acid, comparison of mutagenic activity, *147*, 321
Nitrogen dioxide, induction of *umuC* gene expression, in *S. typhimurium, 142*, 99
Nitrogen oxides, gaseous, mutagenicity, *147*, 263
Nitrohydroxypyrenes, analysis, *147*, 264
–, in diesel-exhaust particles, *158*, 3
–, isomer mix, mutagenicity, *157*, 149
Nitrophenols, genetic toxicology, *154*, 173
Nitropyrene, biliary metabolites, mutagenic activation, *149*, 171
–, detection in grilled chicken, *147*, 260
–, induction of DNA damage, in primary mouse hepatocytes, *151*, 137
–, metabolic activation, in *S. typhimurium* TA1538, *149*, 25
–, metabolism in germ-free and conventional rats, *147*, 261
–, mutagenicity for *E. coli, 142*, 163

Nitropyrene, (*continued*)
–, photodecomposition of, extracted from diesel-exhaust particulates, *155*, 27
4-Nitroquinoline-1-oxide, effect of quercetin on mutagenicity in *S. typhimurium*, *142*, 103
–, tannic acid suppression of mutagenesis in *E. coli* B/r, *149*, 17
Nitrosamines, cyclic, mutagenicity with rat and rabbit nasal, lung and liver S9, *158*, 141
–, tissue-specific inhibition of thymidine incorporation into DNA, *149*, 495
Nitrosation of alcohol-induced metabolites, production of mutagens, *158*, 159
N-Nitrosocimetidine, induction of SCE in cultured human lymphocytes, *156*, 117
Nitroso compounds, genotoxic activity, Drosophila mosaic test, *144*, 177
–, induction of somatic mutations in Tradescantia, *148*, 59
N-Nitrosodialkylamines, mutagenicity in Salmonella, *142*, 153
N-Nitrosodiethylamine, SCE measurement, in whole organ in vitro, *147*, 165
N-Nitrosodimethylamine, DNA fragmentation in hepatocyte cultures, *144*, 209
–, inhibition of thymidine incorporation into DNA, *149*, 495
Nitrosoguanidine, treatment of *E. coli*, mutation fixation, *146*, 185
N-Nitroso-*N*-methylaniline, in detecting target-organ specificity, *142*, 13
Nitrosomethylurea, effect on mutation spectrum in pea, *147*, 304
N-Nitrosomorpholine, near-UV irradiation, mutagenicity from, *143*, 165
N'-Nitrosonornicotine, inhibition of thymidine incorporation into DNA, *149*, 495
p-Nitrosophenol, genetic toxicology testing, *153*, 61
N-Nitrosopropylamine derivatives, genotoxicity, *144*, 197
1-Nitrosopyrene, *S. typhimurium* TA1538, *149*, 25
N-Nitrosothiazolidine, trace contaminated, mutagenicity, *157*, 129
Nitro substituent, orientation, in polycyclic aromatic hydrocarbons, *143*, 173
Nitro substitution, effect on mutagenicity of polycyclic aromatic hydrocarboms, *144*, 1
Nitrosureas, sister chromatid exchange induction, *149*, 95
–, theophylline release of replicon initiation inhibition, *146*, 1
NMA, *see* *N*-Nitroso-*N*-methylaniline
Non-disjunction, in female mice, after X-irradiation of dictyate oocytes, *151*, 109
–, tests, *154*, 75
Nonparametric approach, statistical analysis of mutagenicity data, *147*, 5
Norway, local activity report for 1984, *147*, 382
Nothobranchius rachowi, sister-chromatid staining, *143*, 39
Novobiocin, effect on frequency of CA and SCE following γ-irradiation, *144*, 265
4NQO, *see* 4-Nitroquinoline-1-oxide
Nucleases, liposome-encapsulated, chromosomal effects, *147*, 311
Nucleophiles, benzidine mutagenesis inhibition, *143*, 5
Nutrition, mutation and cancer, *154*, 209

Oesophageal cancer, in Iran, opium pyrolysates, *150*, 177
Oestradiol, mutagenicity, *156*, 199
Ofloxacin, dominant lethal study in male mice, *144*, 51
Oil dispersants, genotoxity assay, *158*, 19
Oils, mineral, *see* Mineral oils
Olaquindox, in mouse transplacental micronucleus test, *144*, 81
Olefins, mutagenicity of, *147*, 263
Oncogenes, cellular transforming, recombinant DNA methodologies, *153*, 33
Opium pyrolysates, mutagens in, *150*, 177
Organic air samples, extracts, $Balb_c/3T3$ cell transformation response, *144*, 107
Organophosphate impurities, in commercial malathion, mutagenic and alkylating activities, *155*, 1
Organophosphorous pesticides, genotoxic effects, *155*, 131
Orthophenylphenol, mutagenicity in human cell strain, *156*, 123
Oxamniquine, mutagenicity, *157*, 1
Oxidising agent, protection of bacteria against damage by, *145*, 129
Oxygen, high tension, increase of BrdUrd-dependent SCE, *142*, 213
–, radical-induced SCE, effect of vitamin C, *144*, 23
–, singlet, gas phase, exposure, DNA repair in organ cultures of hamster tracheal epithelium, *142*, 41

PAA, *see* Amines, primary aromatic
PAH, *see* Polycyclic aromatic hydrocarbons
Panfuran-S, induction of SOS responses in *E. coli*, *146*, 243
Pan troglodytes, radiation-induced rearrangements, *149*, 57
Paper mill effluents, genetic activity in *S. cerevisiae*, *155*, 53
Papovaviruses, genetic risk factors, *147*, 324
Paraquat, effects on CH cells in culture, *147*, 273
–, induction of superoxide dismutase, CA and SCE in CH fibroblasts, *151*, 263
Particle-borne chemicals, mutation of a human cell line, *157*, 71
Parvovirus H-1, propagated in human cells, treatment with ENU, *149*, 1
Peat combustion product mutagenicity, *147*, 300
Pentachlorophenol, DNA-damaging properties and cytotoxicity in human fibroblasts, *145*, 71
1,3-Pentadiene, evaluation for mutagenicity, *157*, 49
3,3',4',5,7-Pentahydroxyflavone, germinal effects, *144*, 99
Percentile rule, assessing mutagenicity in the Ames assay, *147*, 15
Perhexiline maleate, mutagenicity, *157*, 1
Permanent magnetic field, genetic structures of somatic cells, *147*, 309
Peroxide pretreatment of *V. faba* root-tip meristems, *142*, 23
Peroxyacetyl nitrate, mutagenic activity, *157*, 123
Perylenequinone, mutagenicity of, *147*, 262
Pesticides, cytogenetic effects, *155*, 135
–, mutagenous effect of bolstar, toluin and dravin, *147*, 289
–, organophosphorous, genotoxic effects, *155*, 131

Pesticides, (*continued*)
–, population exposed to, SCE and chromosomal aberrations, *143*, 237
–, structure–genotoxic activity relation, *147*, 343
Petroleum gas burners, identification of mutagens, *147*, 263
pH, effect, on ICR-170 in *ad*-3 tests of *N. crassa*, *142*, 19
–, –, on mutagenic activity of quercetin, *148*, 13
–, –, on weak and positive control mutagens, in Ames Salmonella plate assay, *142*, 109
Phage lambda, Weigle reactivation, in *recA* of *E. coli*, *145*, 137
Phenacetin, metabolic activation, *147*, 269
–, related compounds, mutagenicity tests, *147*, 273
Phenobarbital, aneuploidy induction by *S. cerevisiae*, *144*, 67
–, mutagenicity testing, *147*, 255
Phenols, divalent, mutagenesis, role of oxygen-free radicals, *147*, 272
–, genetic toxicology, recent findings, *154*, 153
–, –, testing, *153*, 72
–, workers, *147*, 308
Phenylalanine, testing, aneuploidy induction, *157*, 215
o-Phenylenediamine, cytogenetic effects, *147*, 318
Phenylhydroxylamine derivatives, mechanism of induced mutation, *147*, 265
5-Phenyl-2,4-thiazolediamine, mutagenic activity, *155*, 17
Phleomycin, *muc*-dependent mutagenesis, *146*, 47
Phorate, genotoxic effects, *155*, 131
Phorbol-12-myristate-13-acetate, cytotoxic effect in AT, *149*, 283
Phospholipids, formation of pyrolyzate mutagens from, *147*, 277
(6–4)Photoproducts, removal from DNA of UV-irradiated mammalian cells, *143*, 109
Phytohaemagglutinin, chromosomal instability in lymphocytes of elderly humans, *149*, 505
–, use in determination of 6-TG resistance of human blood mononuclear cells, *147*, 369
Picric acid, genetic toxicology, *154*, 173
Pinacolone, genetic toxicology testing, *153*, 61
Pinacolyl methylphosphonochloridate, mutagenicity in the Ames test, *142*, 9
–, in vitro covalent binding to DNA, *142*, 9
Pivalic acid, genetic toxicology testing, *153*, 59
pKM101, derivative, complementation of, *150*, 147
–, inhibition of *uvr*-independent crosslink repair in *E. coli* by *muc* gene products, *145*, 49
–, plasmid, phleomycin mutagenesis, *146*, 47
Plant flavonoids, in biology and medicine, *149*, 157
Plant mutagenesis, effect of Se on, *154*, 37
Plant tissue culture, model system for testing mutagenicity, *147*, 51
Plasma, cytostatic drug activity, *143*, 263
Plasmid DNA, carcinogen-modified, mutational and recombinational events, *145*, 25
–, dosage effects in *S. typhimurium*, *151*, 185
–, pKM101, mutagen-induced reversions, *148*, 35
Platinum–DNA lesions, in *E. coli*, repair of, *145*, 35
^{239}Plutonium-induced heritable translocations in male mice, *152*, 49
Point mutations, *E. coli A2C* locus, *149*, 303
–, systems, predictive value, *147*, 123
Poland, local activity report for 1984, *147*, 383
Polar aprotic solvents, induction of aneuploidy in yeast, *149*, 339
Poly(ADP-ribose) polymerase, variations in differential cell systems, *147*, 319
–, synthesis, correlation with C3H/10T1/2 transformation system, *147*, 130
–, –, effects of alkylating agents, *150*, 69
Polycyclic aromatic hydrocarbons, mutagenicity, *157*, 149
–, –, on *S. typhimurium*, *156*, 61
–, nitrated, orientation of nitro substituent, *143*, 173
–, nitro substitution, effect on mutagenicity, *144*, 1
–, photochemical reaction with N oxides, *147*, 257
Polygenic mutation, *153*, 41
Polymerase errors, *154*, 3
Polymerases, in excision repair in human skin fibroblasts, *146*, 109
Polynuclear aromatic hydrocarbon contents, of airborne particles, *147*, 268
Polyol E40, genetic toxicology testing, *153*, 61
Porcine brain tubulin, assembly stimulation by PB, *144*, 67
–, interference of aprotic polar solvents, *149*, 333
Postreplication repair, role of *umuC* gene, *E. coli* K12 *uvrB*, *145*, 107
Potassium bromate, acute cytogenicity, on rat bone marrow cells in vivo, *147*, 274
Potassium dichromate, genetic activity in *S. cerevisiae*, *144*, 165
–, genotoxicity in diploid yeast, *155*, 117
Potorous tridactylis, PR of ESS and SCE, *150*, 91
Precursor mutagens, effects of mineral oils on the microbial mutagenicity of, *149*, 159
Prediction of carcinogens, mutation assays, *147*, 1
Predictivity, short-term assays, *147*, 387
Procaine, treatment of CH V79 cells, *144*, 203
Procarbazine, sperm of mice exposed to, *148*, 135
Procyanidin, induction of micronuclei in cultured V79 CH cells, *158*, 89
Proliferation rate, effect on SCE, *147*, 304
Propane sultone, mutagenesis in barley, caffeine potentiation, *144*, 239
Prophage lambda, induction, *E. coli* K12, influence of *rec*B21, *142*, 159
–, –, by furazolidone, *156*, 69
β-Propiolactone, DNA treated with, *145*, 17
Propylene oxide, genetic toxicology testing, *153*, 59
Prostaglandin H synthase, dependent activation of 2-AF, *143*, 187
Protein–protein interactions, genetic change caused by interference with, *150*, 203
Protein synthesis, in *E. coli, recA* and *umuC*, *149*, 297
Pseudomonas convexa, cell extracts, antimutagenic factors, *147*, 276
Pseudomutation, effects of BrdUrd in human lymphoblasts, *151*, 95
Ptaquiloside, genotoxicity, *143*, 75
Pulp mill effluents, genetic activity in *S. cerevisiae*, *155*, 53

Purines, modified, induction of chromosome aberrations and aneuploidy in SHE cells, *148*, 107
Pyrene, mutagenicity, in Salmonella, *142*, 149
Pyrenequinone, mutagenicity of, *147*, 262
Pyridopsoralens, lethal and mutagenic effects photoinduced in *S. cerevisiae*, *148*, 47
Pyrimidine dimer UV endonuclease, from *D. radiodurans*, *145*, 119
Pyrimidine doublets, location of mutagenesis, in UV-irradiated simian virus, 40, *142*, 75
Pyrolyzed materials, crude, heterocyclic amines in, IQ and non-IQ type, *147*, 335
Pyronin Y, effect on *A. cepa*, *158*, 77
Pyrrole compounds, induction of mutations in *S. typhimurium*, *149*, 485
–, –, of SCE in human lymphocytes, *149*, 485
Pyrrolizidine alkaloids, SCE induction in V79 Chinese hamster cells, *142*, 209

Quercetin, effect, on formation, by bile acids, *155*, 99
–, –, on mutagenicity of AAF, 4NQO and BaP in *S. typhimurium*, *142*, 103
–, germinal effects, *144*, 99
–, mutagenic activity, *S. typhimurium* TA98, *148*, 13
Quinacrine, mutagenicity in *D. melanogaster*, *158*, 177
Quinones, mutagenicity on *S. typhimurium*, *156*, 61
Quinoxaline-1,4-dioxide, growth-promoting agents, cytogenetic effects, *144*, 81; *147*, 289

Radiation-induced CA, dynamics, *147*, 317
Radiations, somatic cells, dose–effect relationships, *147*, 281
γ-Radiation, induction of ADPRT activity and mammalian longevity, *142*, 69
Radionuclides, relative genetic efficiency, *147*, 314
Radioprotectors, antimutagenic and mutagenic properties, *147*, 286
Rat, bile, treatment with 1-nitropyrene, *149*, 171
–, hepatic microsomes, 2-hydroxy-EM, *149*, 327
–, hepatocyte cultures, primary, induction of DNA repair synthesis, *145*, 201
–, hepatocyte, in vivo autoradiography, for UDS, *156*, 1
–, oesophagus, salivary gland, liver, mutagenicity of NMA, *142*, 13
–, reproductive tissue, germ-cell mutagenesis and GSH depression, *144*, 93
–, Sprague–Dawley, mutagenicity of IQ, *156*, 83
Rat-1, cells, effects of temperature and cell cycle length on SCE frequency, *149*, 101
Rat-liver, chromosome assay, genetic toxicology testing, *153*, 74
–, microsomes, NADPH-dependent lipid peroxidation, mutation induction in *E. coli*, *149*, 321
X-Rays, chromosome damage, cell cycle delay and cell killing, *151*, 83
–, fractionations, unequal, specific-locus mutation response, *149*, 105
–, induced sex-linked recessive lethals, *D. melanogaster* spermatozoa, repair deficiency, *149*, 415
X-Rays, (*continued*)
–, induction of somatic eye-colour mutations in *D. melanogaster*, *148*, 65
recBC mutants, *E. coli*, SOS system induction, *146*, 23
Recessive lethals at non-specific loci, *154*, 72
Recombinant DNA techniques, *153*, 15
–, in cloning DNA repair genes, *150*, 61
Recombinant DNA technology, study of gene alteration, *153*, 13
Recombination, errors, *154*, 8
–, fast Drosophila test, *147*, 326
Red wine, absence of mutagenic activity of human urine after consumption of, *156*, 171
Repair, deficiency, *D. melanogaster* males, X-ray-induced sex-linked recessive lethals, *149*, 415
–, errors, *154*, 12
Reproduction, human, effects of anticancer drugs, *154*, 145
Reproductive performance, *154*, 77
Reproductive tissue, rat, germ-cell mutagenesis and GSH depression, *144*, 93
Resorcinol, genetic toxicology, *154*, 172
Restriction endonucleases, induction of chromosomal aberratins, *150*, 359
Restriction enzyme analysis, determination of basepair substitutions, *148*, 35
Retinoblastoma patients, bilateral, radiation sensitivity of fibroblasts, *152*, 31
Retinoids, effect, on carcinogen-induced mutagenesis in Salmonella tester strains, *142*, 115
Retrovirus gene expression, effect of selenium on, *154*, 30
Riboflavin, reduction of CSC- and BaP-induced mutagenicity, *152*, 1
Ribonucleotide reductase, DNA-fork displacement rates in cultured mammalian cells, *142*, 199
Rifampin, in preirradiation treatment of *E. coli*, *144*, 151
Risk assessment, mutagenicity, guidelines, comments, *147*, 211
–, multiple-criteria decision making and, *153*, 163
Rivanol, mutagenicity, *144*, 9
RNA synthesis inhibition, HPRT variants of human lymphocytes resistant to, *149*, 133
Rodent genotoxicity assays, short-term, intraperitoneal injection route, of exposure, *156*, 239
Rotenone, induction of micronuclei in mouse bone marrow, *155*, 135
Rubber industry workers, CA in, *147*, 283
–, cytogenicity, *147*, 297
Rumania, local activity report for 1984, *147*, 383
Rye, genetic background damage, induced by X-rays and fission neutrons, *149*, 421

Saccharomyces cerevisiae, aneuploidy induction, *149*, 339
–, –, by PB, *144*, 67
–, aprotic polar solvents, effects, *149*, 333, 339
–, chromosomal malsegregation, induction, *149*, 333
–, cytochrome content, modulation in, *150*, 217
–, DNA purine bases, ^{3}H decay, *149*, 359
–, genetic activity, of compounds, of effluents of pulp and paper mills, *155*, 53

Saccharomyces cerevisiae, (*continued*)
–, hydrazine sulphate activity, *155*, 113
–, induced mutagenesis, new mutations affecting, *150*, 211
–, 8-methoxypsoralen photoinduced cross-links, *145*, 145
–, mutagen-induced recombination, influence of chemicals, *147*, 284
–, mutagenesis, effect of Se on, *154*, 37
–, petite mutation induction by ethidium bromide, *158*, 69
–, photodynamic mutagenic action of acridine compounds on, *158*, 169
–, photoinduced lethal and mutagenic effects, *148*, 47
–, photoreactivating enzymes from, *146*, 71
–, removing EMS premutational lesions in, *143*, 35
–, repair of lethal damage by fast neutrons, *149*, 353
–, UV-induced mitotic recombination, frequency curves, *151*, 235
–, X-irradiated, repair of DNA SSB, *146*, 55, 63
Saccharomycopsis lipolytica, mapping, *147*, 305
Salmonella/mammalian microsome assay, mutagenicity of coffee, *156*, 39
Salmonella/mammalian microsome mutagenicity test, activating systems, comparison, human and rat livers, *156*, 139
Salmonella/microsome mutagenicity, of monochloroarenes, *155*, 91
Salmonella tester strains, carcinogen-induced mutagenesis, effect of retinoids, *142*, 115
Salmonella typhimurium, L-arabinose resistance, induction of forward mutations to, *147*, 153
–, AT base pairs, nitroarene mutagenicity, *149*, 311
–, benzo[*a*]pyrene diol-epoxides, efficiency, *152*, 5
–, cyclophosphamide, mutagenic activity, *149*, 514
–, effects of caffeine, on UV-induced base-pair substitution and frameshift mutagenesis, *143*, 1
–, effect of quercetin, on mutagenicity of AAF, 4NQO and BaP, *142*, 103
–, epidermal S9-mediated mutagenicity assay, *147*, 37
–, frameshift mutagenesis, *151*, 209
–, *hisC3076* marker, SOS response induction by ICR191, *142*, 87
–, induction, of mutations by pyrrole compounds, *149*, 485
–, –, of tandem duplications in, *152*, 131
–, –, of *umuC* gene expression by NO_2, *142*, 99
–, microsome test, hepatotoxic drugs, *157*, 1
–, mutagenesis, and catabolite repression, *151*, 35
–, –, by MNNG, DES, NQO, *143*, 183
–, mutagenic potency in, and chemical structure of substituted biphenyls, *149*, 9
–, mutagenicity, of allyl isothiocyanate, *156*, 33
–, –, data base, *153*, 79
–, –, of dipyridoimidazole derivatives, *156*, 53
–, –, of epoxidic intermediates of isoprene metabolism, *156*, 77
–, –, of IQ, *156*, 83, 93
–, –, of *N*-nitrosodialkylamines, *142*, 153
–, –, of peroxyacetyl nitrate, *157*, 123
–, –, pyrene, *142*, 149
–, non-mutagenicity of CAM, *156*, 19
–, plasmid-dosage effects, *151*, 185
Salmonella typhimurium, (*continued*)
–, plate-incorporation assay, NMA mutagenicity, *142*, 13
–, structure–activity relation of bifunctional nitrofluorenes, *143*, 213
–, TA97, mutagenicity of polycyclic aromatic hydrocarbons and quinones, *156*, 61
–, –, study, *147*, 132
–, TA98, quercetin mutagenic activity, *148*, 13
–, TA100, mutagenicity of HEMLA, *142*, 121
–, TA102, mutagenicity of metal derivatives, *155*, 49
–, –, results of a study, *147*, 132
–, TA104, mutagenicity of natural carbonyl compounds, *148*, 25
–, –, study, *147*, 132
–, TA1538, 1-nitrosopyrene in metabolic activation, *149*, 25
–, tester strains, effect of Se on, *154*, 32
Samples, critical sizes, mutation frequencies, statistical significance, *143*, 93
SCE, *see* Sister-chromatid exchange
Scintillometry, of UDS, in rat liver cultures, *143*, 257
SDMH, *see* 1,2-Dimethylhydrazine
Secale, genetic background damage, induced by X-rays and fission neutrons, *149*, 421
Selenium, anticarcinogenic effect, *154*, 37
–, genotoxicity, *154*, 29
Sensitivity, reliability of assays, *153*, 187
Sex-chromosome loss, *154*, 75
SHE, *see* Syrian hamster embryo
Shell metal extractant 529, genetic toxicology testing, *153*, 59
Short-term assays, cluster analysis, *153*, 167
–, estimates, for sensitivity, *153*, 190
–, –, for specificity, *153*, 191
–, for pesticides, comparison of results, *147*, 343
–, prediction of carcinogenicity of chemicals, *153*, 79
–, predictivity, *147*, 387
Short-term mutagenicity testing, *153*, 40
Short-term tests, cluster analysis of, *147*, 139
–, CPBS method, *153*, 135
Simian virus 40, *see also* SV40
–, mutagenesis predominantly at pyrimidine doublets, *142*, 75
Single-cell mutation assays, variance estimation, *150*, 403
Sister-chromatid exchange, analysis in mouse preimplantation embryos, *147*, 23
–, BrdUrd-dependent, increase at high oxygen tension, *142*, 213
–, and CA, comparative efficiency, *147*, 320
–, chemical carcinogen-induced, measurement in a whole organ in vitro, *147*, 165
–, cytogenetic studies, tabulation and assessment, *154*, 111
–, distribution in metaphase chromosomes of Chinese hamster bone marrow cells, *147*, 135
–, in foetal and maternal cells after treatment with chemical teratogens, *158*, 217
–, frequency, effect of temperature and cell cycle length in Rat-1 cells, *149*, 101
–, frequency increase, in man, aging and smoking, *144*, 183
–, inducibility, increased, by low doses of methylcholanthrene, *149*, 51

Sister-chromatid exchange, (*continued*)
–, induction, by B[*a*]P, in mouse hepatoma cells, *143*, 69
–, –, effect of 5-azaC, *149*, 463
–, –, by FdU, *151*, 77
–, –, in ICR2A frog cells, *149*, 443
–, –, kinetics, by different carcinogens in mice, *156*, 177
–, –, by nitrosoureas, *149*, 95
–, –, by paraquat in CH fibroblasts, *151*, 263
–, in vivo, analysis, improved method, *144*, 243
–, in lymphocytes of patients treated with diazepam, *155*, 71
–, in mouse spleen lymphocytes after ENU exposure, *143*, 245
–, in preimplantation embryos following superovulation in mice, *147*, 189
–, spontaneous, frequency changes, as function of sampling time of lymphocytes, *147*, 113
–, synergistic induction in lymphocytes, *143*, 225
–, test, in vitro, metabolic activation, *147*, 127
Skin cancer, effect of Se, *154*, 37
Smoked meat products, *N*-nitrosothiazolidine mutagenicity, *157*, 129
Smokers, active and passive, mutagenic activity, *147*, 292
–, lymphocytes, SCE, *147*, 298
Smoking, manner of, and mutagenicity, *147*, 268
–, SCE frequency increase in man, *144*, 183
Sodium arsenite, in CHO cells, *148*, 83
–, genotoxicity in diploid yeast, *155*, 117
Sodium azide, induction of sensitive sites in DNA of barley embryos, *149*, 431
Sodium butyrate, inhibition of recovery of growth-arrested human fibroblasts, *152*, 233
–, pre-treatment, effects, on frequencies of CA in lymphocytes, *151*, 269
Sodium cyanide, activation to a toxic, non-mutagenic metabolite in *S. typhimurium, 144*, 119
Sodium dodecyl sulphate, activity in *A. nidulans, 142*, 179
Sodium isopropylxanthate, genetic toxicology testing, *153*, 60
Sodium nitrate, induction of CA and micronuclei in rat and mouse bone marrow, *155*, 121
Soil fumigant, methyl bromide, mutagenicity, *155*, 41
Solar UVA, protection of bacteria against damage by, *145*, 129
Solvent yellow, mutagenicity, *156*, 131
Somatic mutation, fast Drosophila test, *147*, 326
SOS chromotest, genotoxins, colourimetric bacterial assay, *147*, 65, 79
SOS functions, in BU-induced mutagenesis, *149*, 287
SOS response, induction, effects of antimutagens, *147*, 271
–, –, by ICR191, *S. typhimurium hisC3076* marker, *142*, 87
–, interspecies regulation, *E. coli lexA*$^+$ gene, *145*, 103
SOS system induction, in *recBC* mutants of *E. coli, 146*, 23
Species differences, in mutagenicity testing, *147*, 135
Specific-locus mutation response to unequal X-ray fractionations, *149*, 105
Specific-locus test, with immunological markers, *154*, 72
–, with visible markers, *154*, 71
Specificity, reliability of assays, *153*, 187
Sperm abnormalities, *154*, 79
Spermatocytes, primary, grasshopper, killing by γ-rays, *151*, 73
Spermatogonia, *M. fascicularis*, γ-ray-induced reciprocal translocations, *151*, 121
Spermatogonial stem cells, mice, CA induction by *X*-rays, *152*, 217
Spices, genotoxicity, in Drosophila, *143*, 219
Spontaneous mutations, types of, *154*, 2
Spot test, mouse, evaluation of performance, *154*, 183
Sprague–Dawley rats, mutagenicity of IQ, *156*, 83
Statistical analysis, of mutagenicity data, *147*, 5
Sterigmatocystin, DNA adducts, in rat liver, ^{32}P-postlabelling analysis, *152*, 85
–, quantum-chemical study, *143*, 87
Streptomycin resistance, low concentration, new forward mutation assay, *147*, 269
Styrene, workers, *147*, 308
–, –, cytogenetic analysis, *147*, 314
Superoxide dismutase, induction of, by paraquat in CH fibroblasts, *151*, 263
–, isoenzymes, in mice, *148*, 129
Superoxide radicals, exposure of plasma to, *148*, 129
SV40, induction, differential effect of UV, *151*, 9
–, replication, enhanced induction, *151*, 1
–, transformation of human diploid cells, *150*, 327
Sweden, local activity report for 1984, *147*, 384
Syrian hamster, embryo, cells, induction of chromosome aberrations and aneuploidy, by modified purines, *148*, 107
–, spermatogonia, X-irradiation, *144*, 19

T4 endonuclease, susceptibility sites, photoreactivation in *P. tridactylis, 150*, 91
Tandem duplications, induction of, in *S. typhimurium, 152*, 131
Tannic acid, bio-antimutagenic effects, in *E. coli, 149*, 17
Tannins, condensed, induction of micronuclei in cultured V79 CH cells, *158*, 89
Tars, gasifier, mutagenicity, primary aromatic amines, *155*, 7
Tea, Japanese green, bio-antimutagen isolated from, *150*, 127
TEM, clastogenic adaptation of *V. faba* root-tip meristem, *142*, 23
Temperature, effect on SCE frequency in Rat-1 cells, *149*, 101
–, influence on genotoxic effects of cisplatin in CHO cells, *151*, 129
–, optimum, for the liver microsomal assay with mice S9 fractions, *147*, 231
Teratocarcinoma cells, murine, UV radiation sensitivity, *145*, 195
Test battery, genetic toxicology testing, industrial chemicals, *153*, 75
2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, hepatotoxic doses, *157*, 63
Tetrachlorohydroquinone, DNA-damaging properties and cytotoxicity in human fibroblasts, *145*, 71
Tetrahydrocannabinol, tests for induction of mutations and translocations in male mice, *143*, 51
Tetrahymena thermophila, repair of 8-methoxypsoralen induced DNA interstrand cross-links, *145*, 157
Thaliblastin, effects, in rat somatic cells, *147*, 303
Theophylline, effect on SCE, *147*, 304
–, release of replicon initiation inhibition, *146*, 1
–, time-dependent effect, *147*, 313
Thermotolerance, *E. coli*, K12, genetic control, *145*, 113
2-Thiazolamine, mutagenic activity, *155*, 17
Thiazole compounds, mutagenic activity, *155*, 17

Thioguanine, resistance, genes for, UV-irradiated human fibroblasts, *152*, 67
–, –, human blood mononuclear cells, *147*, 369
–, –, induction by DNPs in CHO cells in vitro, *158*, 209
–, –, in mouse spleen lymphocytes after ENU exposure, *143*, 245
Thioguanine, resistant, mouse lymphocytes, quantification, *147*, 97
–, –, mutagenicity, of UV in CHO cells, *148*, 83
–, –, mutants, induction, by aristolochic acid, *143*, 143
–, –, –, –, by hyperoxia and γ-irradiation, *149*, 119
–, –, –, X-ray induction, in CHO cells, *150*, 443
–, –, T-lymphocytes in human blood, *150*, 411
Thiophosphamide, effects, in mouse embryos, *147*, 299
Thymidine, analogues, CH cells treated with, effect of 3AB, *151*, 251
–, effect on induction of micronuclei by alkylating agents in V79 CH cells, *150*, 347
–, incorporation into DNA, tissue-specific inhibition, *149*, 495
–, kinase, locus, mouse lymphoma, mutagenic potency of 4 agents, *157*, 199
–, –, significance for DNA excision repair, *147*, 307
Ticlopidine, Salmonella/microsome test, *158*, 31
Tienilic acid, mutagenicity, *157*, 1
TMS-NMU, biological alkylating agent, mutagenicity, *157*, 87
Tobacco chewing extracts, treatment with nitrite, formation of bacterial mutagens, *158*, 105
Tobacco condensates, pipe smoking, mutagenicity in Salmonella/microsome assay, *143*, 161
α-Tocopherol, antimutagenic activity, *147*, 300
Toluene, exposure to, chromosome changes with time in lymphocytes, *142*, 37
–, –, occupational, *147*, 318
–, genetic toxicology, recent findings, *154*, 153
–, mutagenic effects, *147*, 294
Toxicity, and mutagenic activity, simultaneous measurement, *143*, 201
Tradescantia, induction of somatic mutations by nitroso compounds, *148*, 59
Transformation, assays, BHK21, mutagenicity data base, *153*, 79
–, malignant, induction, in Balb/3T3 clone cells, *152*, 113
Translocation, frequency, male mice, effects of post-irradiation interval, *142*, 65
–, heritable, ^{239}Pu-induced, in male mice, *152*, 49
–, induced in meiotic cells, non-recovery, mechanisms, *149*, 179
–, γ-ray-induced, in spermatogonia of *M. fascicularis, 151*, 121
Transposition, recombinant DNA methodologies, *153*, 29
Transposons, in Drosophila, *153*, 31
Trenimon, induction of sex chromosome loss in Drosophila, *142*, 29
Triaziquone, *see* Trenimon
Tricholoroethanol, mutagenicity in *A. nidulans, 155*, 105
Trichloroethylene, mutagenicity in *A. nidulans, 155*, 105
Triethanolamine, genetic toxicology testing, *153*, 61
Triethylenemelamine, *V. faba* root-tip meristems treatment, prior heat-shocks, *143*, 79
Trifluorothymidine, resistant mutants, analysis, in mouse lymphoma cells, *151*, 147, 161
Trimethylacetic acid, genetic toxicology testing, *153*, 59
3,4,8-Trimethyl-3*H*-imidazo[4,5-*f*]quinoxalin-2-amine, formation in model system, *151*, 177
Trimethyl phosphate, chromosome-type aberrations, *147*, 259
–, heritable translocation study in male mice, *157*, 205
Trimethyl phosphordithioate, production of alkylated NBP, *155*, 1
Trimethyl phosphorothioate, production of alkylated NBP, *155*, 1
N-Trimethylsilylmethyl-*N*-nitrosourea, biological alkylating agent, mutagenicity, *157*, 87
Tritiated water, ionizing radiation from, human lymphoblastoid cells, *157*, 77
Triticale, hexaploid, induced quantitative variation, *147*, 45
Triton X-100, activity in *A. nidulans, 142*, 179
Trypan blue, mutagenicity, *156*, 131
Tryptophan pyrolysate, gastrointestinal absorption, *147*, 260
–, metabolic activation, *144*, 213
Tubulin, porcine brain, interference of aprotic polar solvents, *149*, 333

UDS, kinetics, in UV-irradiated chicken embryo fibroblasts, *146*, 305
–, of rats, exposed to CP or 2AAF, *150*, 383
–, in vivo rat hepatocyte autoradiographic assay, *156*, 1
umu test, detection of environmental mutagen, *147*, 267
–, evaluation, detection of environmental mutagens and carcinogens, *147*, 219
umuC gene, expression, induction by NO_2, in *S. typhimurium, 142*, 99
–, role in postreplication repair, *E. coli* K12 *uvrB, 145*, 107
Unscheduled DNA synthesis, *see* UDS
Untargetted mutagenesis, *153*, 41
Urinary mutagenicity assay system, dietary factors affecting, *149*, 365; *156*, 171
Urine, clastogenic agents, in, of cigarette smokers, *147*, 179
–, –, of coffee drinkers, *147*, 179
–, human, mutagens in, effects of cigarette smoking and diet, *158*, 149
–, –, mutagenic activity, after consumption of red wine or grape juice, *156*, 171
–, –, –, after a fried beef meal, *149*, 365
–, isolation of clastogenic agents from, *147*, 171
Urothelial cells, intact, mutagenic activation of dialkylnitrosamines, *157*, 95
Ursodeoxycholic acid, fluctuation test, *158*, 45
UV, in CHO cells, sodium arsenite, *148*, 83
–, endonuclease, *M. luteus*, DNA synthesis in XP cells, *150*, 99
–, endonuclease β, from *D. radiodurans, 145*, 119
–, interaction with MNNG, in V79 cells, *152*, 77
–, irradiation, responses of nontransformed, preneoplastic and tumorigenic cells, *145*, 185
–, split dose, effect in *E. coli, 114*, 127
uvrA function, decrease, by MMC in *E. coli* protein synthesis, *149*, 297
uvrA proteins, of *E. coli*, cross-linking studies, *145*, 43

uvrB proteins, of *E. coli*, cross-linking studies, *145*, 43

V79 cells, MNNG, effect on SCE induction, cell survival, mutagenesis, aberration formation and DNA synthesis inhibition, *142*, 49
–, MNU, effect on SCE induction, cell survival, mutagenesis, aberration formation and DNA synthesis inhibition, *142*, 49
Vaccines, synthetic, development, *153*, 44
Variance estimation, single-cell mutation assays, *150*, 403
Vehicle engine exhaust, mutagenic potential assessment, *155*, 35
Versicolorin A, quantum-chemical study, *143*, 87
Vicia faba, root-tip meristem, clastogenic cross-adaptation, *144*, 171
–, –, heat-shocks prior to treatment with MH or TEM, *143*, 79
–, –, hydrazines, pretreatment with, *142*, 183
–, –, peroxide pretreatment, *142*, 23
Vinblastine, induction of aneuploidy, *155*, 61
Vinyl acetate, human lymphocytes exposed to, SCE-inducing damage, *158*, 201
–, treatment in vitro of DNA cross-links in human leucocytes, *146*, 301
Vinyl chloride metabolite, induction of specific base-pair substitutions in *E. coli trpA* mutants, *152*, 147
Vinyl compounds, mutagenicity, *147*, 303
Viruses, as environmental mutagenic factors, *147*, 279
Vitamin C, action of anticlastogens in human lymphocyte cultures, *149*, 83
–, effect on oxygen radical-induced SCE, *144*, 23
Vitamin E, action of anticlastogens in human lymphocyte cultures, *149*, 83

Wasp, bleomycin treatment, reproduction and mutagenic response after, *149*, 375
Water, samples, mutagenic activity test, *147*, 134
Weigle reactivation, phage lambda, *recA* of *E. coli*, *145*, 137

Xanthone derivatives, mutagenicity in *S. typhimurium*, *150*, 141
Xeroderma pigmentosum, cells, hypersensitivity to dietary carcinogens, *145*, 89
–, –, restoration of UDS, *150*, 99
–, complementation group E, *145*, 55
–, excision-deficient, 9th complementation group, *145*, 217
–, –, co-recessive inheritance, *145*, 227
–, fibroblasts, genetic complementation with UV-sensitive CHO mutants, *150*, 423
–, UV-irradiated, *149*, 147
–, variant cells, excision repair of UV- or benzo[*a*]pyrene diol epoxide-induced lesions, *146*, 285
Xylenes, genetic toxicology, recent findings, *154*, 153
–, Salmonella/microsome assay, *154*, 171
3,5-Xylenol, genetic toxicology testing, *153*, 61

Yeast, see also *Saccharomyces cerevisiae*
–, chromosomal malsegregation, induction by aprotic polar solvents, *149*, 333
–, 8-methoxypsoralen photoinduced cross-links, *145*, 145
–, mutagen-induced recombination, influence of chemicals, *147*, 284

Zygote, cytogenetic analysis, *154*, 75

MUTATION RESEARCH

International journal on mutagenesis, chromosome breakage and related subjects

INSTRUCTIONS TO AUTHORS

Types of paper *Mutation Research* contains 3 types of publication. (1) Papers reporting results of original fundamental research concerning mutagenesis, chromosome breakage and related subjects. (2) Review articles. (3) Short communications (published in the Section *Mutation Research Letters*).

General arrangement of papers Papers should be preferably in English, but may also be submitted in French or German. A summary (about 300 words) is mandatory for all (normal-length) articles. Papers in German or French should have a summary in English. The first paragraph of the article should summarize the research problem and the pertinent findings. The main text may be divided into sections such as Materials and methods, Experimental, Results, Discussion.

In papers mentioning chemicals, authors are requested to include *CAS registry numbers*. Registry numbers can be found by consulting Chemical Abstracts Ninth Collective Molecule Formula Index, by using Lockheed's computer access file named Chemline or by contacting the Chemical Abstracts Service, P.O. Box 3012, Columbus, Ohio 43210 (U.S.A.).

Preparation of text (a) Manuscripts should be typewritten, double-spaced with wide margins, on one side of the paper only. Legends, footnotes—everything—must also be double-spaced. (b) The full postal address(es) of the author(s), including postal code and country, should be given after their name(s). (c) Line-drawn figures (including graphs) should be submitted in black ink on white paper and must be lettered ready for direct reproduction. Sharp photoprints of lettered line drawings may also be submitted. It is important that the drawings themselves AND the lettering are in proportion and large enough to allow for reduction before printing. Figures should be prepared suitably for either one column width (76 mm) or the entire page width (160 mm). The maximum height is 206 mm. The amount of reduction that will be made can be judged from the sizes of figures in recent issues of the journal. (d) Half-tone figures should be submitted as very sharp and contrasty glossy photoprints, separate from line drawings. (e) Legends for both line-drawn and half-tone figures should be typed on separate sheets. (f) Tables (also to be typed double-spaced) should be provided with headings. (g) Typescripts should be carefully checked before submission to obviate alterations after acceptance.

References The journal uses the Harvard system, in which names and dates are given in the body of the text and an alphabetical list of references at the end of the manuscript. References in the text should give the author's surname with the year of publication, e.g.: Smith (1980); Smith and Jones (1967a, 1979b); Baker et al. (1978). In the list of references, titles of journals should be abbreviated to conform with *Chemical Abstracts Bibliographic Guide for Authors and Editors 1974*. References to books should give details of chapter title, editors, title of the book, publishers and their location.

Examples:

Ehrenberg, L., and C.A. Wachtmeister (1977) Safety precautions in work with mutagenic and carcinogenic chemicals, in: B.J. Kilbey, M.S. Legator, W. Nichols and C. Ramel (Eds.), Handbook of Mutagenicity Test Procedures, Elsevier, Amsterdam, pp. 401–410.

Kastenbaum, M.A., and K.O. Bowman (1970) Tables for determining the statistical significance of mutation frequencies, Mutation Res., 9, 527–549.

Contributions—in triplicate (one original plus two copies, also of the illustrations)—may be sent to Prof. F.H. Sobels, Managing Editor, *Mutation Research*, Department of Radiation Genetics and Chemical Mutagenesis, State University of Leiden, Sylvius Laboratories, Wassenaarseweg 72, P.O. Box 9503, 2300 RA Leiden (The Netherlands).

or to

Dr. F.J. de Serres, *Mutation Research*, NIEHS, P.O. Box 12233, Research Triangle Park, NC 27709 (U.S.A.).

Manuscripts in the field of Molecular Genetics may be submitted to Prof. B.W. Glickman, *Mutation Research*, Biology Department, York University, 4700 Keele Street, Toronto, Ont. M3J 1P3 (Canada).

Reprints 50 reprints of each article are sent to the author(s) free of charge. Additional reprints can be ordered by the author(s).

Advertising For advertising rates apply to the Publishers.

Copyright © 1985, Elsevier Science Publishers B.V. (Biomedical Division)

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the permission of the publisher, Elsevier Science Publishers B.V. (Biomedical Division), P.O. Box 1527, 1000 BM Amsterdam (The Netherlands).

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in article 17 paragraph 2 of the Dutch Copyright Act of 1912 and in the Royal Decree of June 20, 1974 (S. 351) pursuant to article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

CANCER

EXCERPTA MEDICA ABSTRACTS SECTION 16

Excerpta Medica abstracts articles from well over 3,500 biomedical, pharmaceutical and chemical journals, covering the most significant published papers in the field of biomedicine from all countries of the world.

- Abstracts are selected and indexed by practising medical specialists.
- Abstracts are arranged by major topics, giving the Abstract Journals a concise, easy-to-read form.
- Each issue includes subject and author indexes.
- Detailed specialist indexing from multiple points of view makes it easy to find the right information in the shortest possible time.

The Comprehensiveness of a Database - The Convenience of a Journal

This abstract journal contains a chapter on general aspects of the cancer problem such as different methods of diagnosis and therapy, multiple tumors, metastasis, cancer incidence, mortality, prevention and control followed by chapters on experimental cancer research and on clinical aspects of cancer (considered to be synonymous with malignant neoplasm). The chapter on experimental cancer research contains information on the different types of cancerogenesis, cytology, histopathology, transplantation and experimental therapy. The clinical subsection is divided into 42 separate categories covering individual organs and parts of the body.

Audience: Experimental and clinical cancerologists.

Editorial Board

D. F. Austin, *Berkeley*
N. N. Blochin, *Moscow*
P. Blok, *Amsterdam*
R. Lee Clark Jr., *Houston*
J. Clemmesen, *Copenhagen*
P. Denoix, *Paris*
L. Dmochowski, *Houston*
W. U. Gardner, *New Haven*
C. D. Haagensen, *New York*
J. J. van der Harten, *Amsterdam*
J. Higginson, *Lyons*
C. Huggins, *Chicago*
O. H. Iversen, *Oslo*
W. Jänisch, *Halle.*
D. J. Jussawalla, *Bombay*
G. Klein, *Stockholm*
H. E. Maisin, *Louvain*
G. Martz, *Zürich*
B. H. Morrison III, *Bethesda*
J. J. Morton, *Rochester*
M. Potter, *Bethesda*
K. B. De Ome, *Berkeley*
K. E. K. Rowson, *London*
W. Rudowski, *Warsaw*
L. Sachs, *Rehovot*
A. I. Savickij, *Moscow*
E. A. Saxén, *Helsinki*
A. Segaloff, *New Orleans*
L. Severi, *Perugia*
M. B. Shimkin, *San Diego*
C. Sirtori, *Milan*
C. J. A. Sol, *Amsterdam*
H. Sugano, *Tokyo*
J. Sugár, *Budapest*
E. K. Weisburger, *Bethesda*
D. A. Wood, *San Francisco*
R. M. Zollinger, *Columbus*

Subscription information:

Cancer Section 16
1986: Vols. 63–66
(4 volumes in 32 issues)
Price: US $ 578.00/Dfl. 1676.00
including postage and handling
ISSN 0014-4207

This Excerpta Medica Abstract Journal is also available on line via the Excerpta Medica Database: EMBASE.
EMBASE can be searched through BRS, Data-Star, Dialog, Dimdi, Jicst and Utopia.

Also of interest to Cancerologists:

PLASTIC SURGERY – Excerpta Medica Section 34
Audience: Plastic surgeons, social workers, **cancerologists**

CHEST DISEASES, THORACIC SURGERY AND TUBERCULOSIS – Excerpta Medica Section 15
Audience: Pathological anatomists and physiologists, respiratory disease specialists, **cancer specialists,** public health workers, inhalation toxicologists

For further information and/or free sample copy write to:

EXCERPTA MEDICA
ELSEVIER SCIENCE PUBLISHERS
P.O. Box 211, 1000 AE Amsterdam, The Netherlands
Distributor in the U.S.A. and Canada:
ELSEVIER SCIENCE PUBLISHING CO. INC., 52 Vanderbilt Avenue, New York, NY 10017, U.S.A.
The Dutch guilder price is definitive. US $ prices are subject to exchange rate fluctuations. Prices are excl. B.T.W. for Dutch customers.

FL37A371

CELL DIFFERENTIATION is the official journal of the International Society of Developmental Biologists (I.S.D.B.)

CELL DIFFERENTIATION

An international journal for the rapid publication of original research papers on aspects of cellular differentiation in eukaryotes

Aims and Scope
CELL DIFFERENTIATION is an international journal which serves its contributors by the rapid publication of novel research on **all** aspects of cellular differentiation in eukaryotes. Reviews and research papers deal with: molecular and structural aspects of cytodifferentiation and morphogenesis; gametogenesis and fertilisation; molecular and structural aspects of early development; cell and tissue interactions; pattern formation; genetic control of differentiation; growth factors and differentiation factors; and regeneration.

Also available
Abstracts from the X[th] International Congress of the International Society of Developmental Biologists, "New Discoveries and Technologies", Los Angeles, California, August 4-9, 1985.

By arrangement with the Japanese Society of Developmental Biologists the contents of "Development, Growth and Differentiation" are reproduced as a service to readers of CELL DIFFERENTIATION.

Editor-in-Chief
L. Saxén, *Department of Pathology, University of Helsinki, Haartmaninkatu 3, SF-00290 Helsinki 29, Finland.*

Associate Editor-in-Chief (Japan)
T. S. Okada, *National Institute for Basic Biology, Myodaiji-cho 38, Okazaki, Aichi-Ken, 444 Japan*

Editorial Board
D. Bennett, *New York, NY, USA*
Y. Ben-Shaul, *Tel Aviv, Israel*
M.R. Bernfield, *Stanford, CA, USA*
M. Buckingham, *Paris, France*
R.M. Clayton, *Edinburgh, UK*
F. Dieterlen, *Nogent-sur-Marne, France*
D. Epel, *Pacific Grove, CA, USA*
W.W. Franke, *Heidelberg, FRG*
G. Gerisch, *Martinsried, FRG*
D. Gospodarowicz, *San Francisco, CA, USA*
P.C. Guerrier, *Roscoff, France*
R. K. Hunt, *San Diego, CA, USA*
K. Illmensee, *Geneva, Switzerland*
K. Kratochwil, *Salzburg, Austria.*
J. Lash, *Philadelphia, PA, U.S.A.*
N.M. Le Douarin, *Nogent-sur-Marne, France*
F. Melchers, *Basel, Switzerland*
D. Metcalf, *Melbourne, Australia*
A. Monroy, *Naples, Italy*
G. Morata, *Madrid, Spain*
A.A. Moscona, *Chicago, IL, USA*
E. Nakano, *Nagoya, Japan*
D.J. Osborne, *Oxford, UK*
M. Spiegel, *Hanover, NH, USA*
I. Takeuchi, *Kyoto, Japan*
H. Tiedemann, *Berlin, FRG*
S.G. Vassetzky, *Moscow, USSR*
J.A. Weston, *Eugene, OR, USA*
L. Wolpert, *London, UK*

Officers of the I.S.D.B.:
T. S. Okada, *President, Okazaki, Japan*
F. S. Billett, *Secretary/Treasurer, Southampton, UK*
J. Coleman, International Secretary, Providence, RI, USA

Subscription Information:
1986 – *Volumes 18 & 19*
(2 volumes in 8 issues)
Price: US $246.00 including postage and handling
ISSN 0045-6039
I.S.D.B. members may subscribe to the journal for their personal use at a reduced rate; details are available from the I.S.D.B. treasurer.

ELSEVIER

Send your orders to:

Elsevier Scientific Publishers Ireland, Ltd., P.O. Box 85, Limerick, Ireland

Requests for free sample copies should be sent to:

In the U.S.A. and Canada
Journal Information Center
ELSEVIER SCIENCE PUBLISHERS,
52 Vanderbilt Avenue, New York, NY 10017, U.S.A.

In all other countries:
ELSEVIER SCIENTIFIC PUBLISHERS
IRELAND LTD.,
P.O. Box 85, Limerick, Ireland

The US $ price is definitive.

FL37A135

CHEMICO-BIOLOGICAL INTERACTIONS

MOLECULAR MECHANISMS
by which exogenous chemicals effect changes in biological systems

Editors-in-Chief:
P. MOLDEUS and **J. DE PIERRE,** Department of Toxicology, Karolinska Institute, S-10401, Stockholm, Sweden, **R. M. PHILPOT** and **J. R. BEND,** Laboratory of Pharmacology, NIEHS/NIH, Research Triangle Park, NC 27709, U.S.A.

Free Radicals Editor-in-Chief:
R. P. MASON, Laboratory of Molecular Biophysics, NIEHS/NIH, Research Triangle Park NC 27709, U.S.A.

Chemico-Biological Interactions publishes research reports, rapid communications, review articles and commentaries that examine:

- Molecular aspects of cytotoxicity, carcinogenesis, mutagenesis and teratogenesis.
- Molecular mechanisms by which drugs exert their therapeutic or toxic effects.

Manuscripts may deal with synthetic or naturally occurring compounds and the molecular basis of their interactions with animal systems or components thereof.

Manuscripts that are limited to description of such interactions without experimental considerations of possible mechanisms will be considered for publication only if similar interactions have not been previously delineated.

Authors of Review Articles and Commentaries are invited to consult the Editors-in-Chief.
Rapid and thorough refereeing of all submissions within the journals scope is quaranteed.
The journal aims to publish manuscripts within 4 months of acceptance. Fifty free reprints are supplied. There are no page or submission charges.

Editorial Board
P. W. Albro, *Research Triangle Park, NC*
H. Autrup, *Copenhagen*
H. Bartsch, *Lyon*
K. W. Bock, *Göttingen*
T. A. Connors, *Carshalton*
L. Den Engelse, *Amsterdam*
E. Dybing, *Oslo*
A. Eastman, *Omaha, NE*
S. Eckhardt, *Budapest*
E. Farber, *Toronto, Ont.*
I. Fridovich, *Durham, NC*
R. P. P. Fuchs, *Strasbourg*
S. Garattini, *Milan*
B. Halliwell, *London*
C. Harris, *Bethesda, MD*
E. Hodgson, *Raleigh, NC*
T. Hultin, *Stockholm*
E. F. Johnson, *La Jolla, CA*
B. Ketterer, *London*
W. Klinger, *Jena*
P. D. Lawley, *London*
B. Lindeke, *Uppsala*
W. Lijinsky, *Frederick, MD*
R. E. London, *Research Triangle Park, NC*
V. Maher, *East Lansing, MI*
D. R. McCalla, *Hamilton, Ont.*
G. J. Mulder, *Leiden*
S. Orrenius, *Stockholm*
R. B. Painter, *San Francisco, CA*
A. Pegg, *Hershey, PA*
D. H. Petering, *Milwaukee, WI*
L. R. Pohl, *Bethesda, MD*
R. A. Prough, *Dallas, TX*
K. V. Rajagopalan, *Durham, NC*
J. J. Roberts, *Chalfont St. Giles*
R. Schulte-Hermann, *Marburg*
H. Sies, *Düsseldorf*
T. J. Slaga, *Smithville, TX*
T. F. Slater, *Uxbridge*
T. Sugimura, *Tokyo*
J. A. Swenberg, *Research Triangle Park, NC*
M. Tattersall, *Sydney*
H. Tristram, *London*
G. P. Warwick, *Geneva*
M. Webb, *Carshalton*
I. B. Weinstein, *New York, NY*
A. Wendel, *Tübingen*
G. M. Williams, *Valhalla, NY*

Cited in: Biological Abstracts; Chemical Abstracts; Current Contents/Life Sciences; Science Citation Index; Excerpta Medica; Index Medicus; PASCAL M.

1986: Vols. 58-61 (4 volumes in 12 issues)
Subscription Price: US $ 512.00 including postage and handling
ISSN 0009-2797

ELSEVIER

Send your orders to:

Elsevier Scientific Publishers Ireland, Ltd., P.O. Box 85, Limerick, Ireland

Requests for free sample copies should be sent to:

In the U.S.A. and Canada
Journal Information Center
ELSEVIER SCIENCE PUBLISHERS,
52 Vanderbilt Avenue, New York, NY 10017, U.S.A.

In all other countries:
ELSEVIER SCIENTIFIC PUBLISHERS
IRELAND LTD.,
P.O. Box 85, Limerick, Ireland

The US $ price is definitive.

FL37A432

CANCER LETTERS

An international journal providing a rapid publication forum for original and pertinent contributions in cancer research.

Managing Editors

D. CLAYSON, Bureau of Chemical Safety, Health Protection Branch, Health and Welfare Canada, Ottawa, Ont. K1A OL2, Canada

P. SHUBIK, Green College, Oxford University, Oxford, OX2 6HG, U.K.

Associate Editor

T. SUGIMURA, National Cancer Center Research Institute, Tsukiji 5-chome, Chuo-ku, Tokyo 104, Japan



Editorial Board

P. Alexander, *Sutton, U.K.*
H. Bartsch, *Lyon, France*
D. J. Brusick, *Kensington, MD*
H. Busch, *Houston, TX*
J.-C. Chermann, *Paris, France*
T. A. Connors, *Carshalton, U.K.*
I. Ernberg, *Stockholm, Sweden*
N. Haran-Ghera, *Rehovot, Israel*
G. F. Kolar, *Heidelberg, F.R.G.*
R. Kroes, *Bilthoven, The Netherlands*
T. A. Lawson, *Omaha, NE*
M. Lipkin, *New York, NY*
M. L. Mendelsohn, *Livermore, CA*
U. Mohr, *Hannover-Kleefeld, F.R.G.*
N. P. Napalkov, *Leningrad, U.S.S.R.*
S. Nesnow, *Research Triangle Park, NC*
L. Philipson, *Heidelberg, F.R.G.*
H. C. Pitot, *Madison, WI*
M. R. Price, *Nottingham, U.K.*
M. F. Rajewsky, *Essen, F.R.G.*
A. Sivak, *Cambridge, MA*
B. W. Stewart, *Kensington, Australia*
B. Terracini, *Torino, Italy*
L. Tomatis, *Lyon, France*
B. K. Vonderhaar, *Bethesda, MD*
N. Wald, *London, U.K.*
I. B. Weinstein, *New York, NY*
F. Wong-Staal, *Bethesda, MD*

Aims and scope

CANCER LETTERS provides a means of rapid publication for important scientific contributions in all areas of cancer research, including:

(a) Chemical carcinogenesis including environmental and occupational cancer
(b) Viral oncology
(c) Radiation carcinogenesis
(d) Endocrinology related to cancer
(e) Geographical pathology and cancer epidemiology
(f) Cancer control
(g) Cancer chemotherapy
(h) Radiotherapy in neoplastic disease
(i) Clinical and surgical oncology
(j) Cancer biology
(k) Metastasis
(l) Molecular biology of cancer

Criteria for Clinical Papers

Papers reporting research in the following areas will be considered for publication:

(a) Basic research using human malignant tissue, blood, etc. for studies of biological markers for etiology of malignant disease.
(b) Clinical investigations based on basic laboratory research findings for developing new concepts in the treatment of malignant disease.
(c) Clinical pharmacology studies on agents of clinical utility for understanding of the mechanism of action and rational use of these drugs in the treatment of malignant diseases.

Subscription Information

1986 Volumes 30–33 (4 volumes in 12 issues)
Institutional Rate: US $ 424.00 including postage and handling
ISSN 0304-3835

ELSEVIER

Send your orders to:

Elsevier Scientific Publishers Ireland, Ltd., P.O. Box 85, Limerick, Ireland

Requests for free sample copies should be sent to:

In the U.S.A. and Canada
Journal Information Center
ELSEVIER SCIENCE PUBLISHERS,
52 Vanderbilt Avenue, New York, NY 10017, U.S.A.

In all other countries:
ELSEVIER SCIENTIFIC PUBLISHERS
IRELAND LTD.,
P.O. Box 85, Limerick, Ireland

The US $ price is definitive.

FL37A370

HANDBOOK OF MUTAGENICITY TEST PROCEDURES

Second Edition

edited by **B. J. KILBEY, M. LEGATOR, W. NICHOLS** *and* **C. RAMEL**

The aim of the first edition of this book was to record experiences in particular techniques of mutagen testing and to set these out in a form which could provide anyone attempting a specific test with all the necessary background information on materials, experimental design, pitfalls and difficulties needed to perform the test in an acceptable way with a minimal need for additional expert help. The combination of this material in one volume provides an 'on the bench' methodological text for most of the common assays for genetic damage apparently in use.

The motivation for preparing the second edition of the Handbook of Mutagenicity Test Procedures has not changed. In response to suggestions from researchers in the field, however, the authors have tried to include not only methods which are known to be reliable from their repeated usage but also some methods which are not widely used at present, but which might eventually prove to be most useful in screening for mutagenic effects. The authors have presented a broad spectrum of approaches, in sufficient detail, to allow the would be experimenter to avoid the more obvious pitfalls when he or she decides to use an unfamiliar technique.

CONTENTS

Preface to the First Edition. Preface to the Second Edition. List of Contributors.

Chapter: 1. Newer methods for determining genotoxicity using DNA repair-deficient and repair-proficient *Escherichia coli*, *H.S. Rosenkranz*. **2.** *Bacillus subtilis* repair test, *T. Kada, Y. Sadaie and Y. Sakamoto*. **3.** Methods for studying excision repair of eukaryotic DNA damaged by physical and chemical mutagens, *J. E. Cleaver*. **4.** Methods for detecting carcinogens and mutagens with the alkaline elution/rat hepatocyte assay, *M. O. Bradley and J. F. Sina*. **5.** Induced reversion using human adenovirus, *R. S. Day, III and C. H. J. Ziolkowski*. **6.** Revised methods for the Salmonella mutagenicity test, *D. M. Maron and B. N. Ames*. **7.** The fluctuation test in bacteria, *S. A. Hubbard, M. H. L. Green, D. Gatehouse and J. W. Bridges*. **8.** Mutagen testing using Trp^+ reversion in *Escherichia coli*, *M. H. L. Green*. **9.** Methodologies for the direct and animal-mediated determination of various genetic effects in derivatives of strain 343/113 of *Escherichia coli* K12, *G. Mohn, P. Kerklaan and J. Ellenberger*. **10.** Basic principles and methods of genotoxicity in the yeast *Saccharomyces cerevisiae*, *F. K. Zimmermann*. **11.** Procedures for the $L5178Y/TK^{+/-} \rightarrow TK^{-/-}$ mouse lymphoma cell mutagenicity assay, *N. T. Turner, A. G. Batson and D. Clive*. **12.** A quantitative test for mutagenicity in V79 Chinese hamster cells, *D. Jensen*. **13.** Genetic markers for quantitative mutagenesis studies in Chinese hamster ovary cells: applications to mutagen screening studies, *R. S. Gupta*. **14.** Chemical mutagenesis with diploid human fibroblasts, *L. Jacobs and R. DeMars*. **15.** 6-Thioguanine-resistant lymphocytes in human blood, *R. J. Albertini and D. L. Sylwester*. **16.** The specific locus test in the mouse, *A. G. Searle*. **17.** Procedures and evaluation of results of the mouse spot test, *L. B. Russell*. **18.** Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests, *H. J. Evans*. **19.** In vitro anaphase and metaphase preparations in mutation testing, *W. W. Nichols, R. C. Miller and C. I. Bradt*. **20.** The bone marrow micronucleus test, *J. A. Heddle, E. Stuart and M. F. Salamone*. **21.** Cytogenetic analysis of structural chromosome aberrations and aneuploidies in oocytes, zygocytes and preimplantation embryos of mammals, *G. Röhrborn and A. Basler*. **22.** The dominant lethal assay in the male mouse, *A. J. Bateman*. **23.** Test for heritable translocations in male mammals, *A. Léonard and I. D. Adler*. **24.** The methodology of sister chromatid exchanges, *P. E. Perry and E. J. Thomson*. **25.** Root tips of *Vicia faba* for the study of the induction of chromosomal aberrations and sister chromatid exchanges, *B. A. Kihlman and H. C. Andersson*. **26.** Drosophila as an assay system for detecting genetic changes, *F. E. Würgler, F. H. Sobels and E. Vogel*. **27.** Eye pigmentation changes in *Drosophila melanogaster* as a sensitive test for mutagenicity, *B. Rasmuson, A. Rasmuson and J. Nygren*. **28.** Metabolic activation systems in short-term in vitro tests, *C. Malaveille and H. Bartsch*. **29.** The intraperitoneal host-mediated assay, *T. H. Connor and M. S. Legator*. **30.** The isolated perfused liver as a metabolizing system in mutagenicity testing, *B. Beije*. **31.** The detection of induced chromosome aneuploidy using strains of the yeast *Saccharomyces cerevisiae*, *J. M. Parry and E. M. Parry*. **32.** Methods for detecting the induction of mitotic chromosomal misdistribution in *Aspergillus nidulans*, *G. Gualandi and G. Morpurgo*. **33.** Systems for detecting meiotic aneuploidy in *Sordaria* and *Neurospora*. *D. J. Bond*. **34.** Sperm morphology testing in mice, *A. J. Wyrobek, G. Watchmaker and L. Gordon*. **35.** Safety precautions in work with mutagenic and carcinogenic chemicals, *L. Ehrenberg and C. A. Wachtmeister*. **36.** Handling of mutagenic chemicals: Experimental safety, *L. Ehrenberg and C. A. Wachtmeister*. **37.** Aspects of statistical inference in testing for genetic toxicity, *L. Ehrenberg*. **38.** Prevention, detection and control of mycoplasmal infection of cell cultures, *G. J. McGarrity, T. Steiner and L. Gamon*. **39.** Mutation epidemiology and its prospects for detecting human germinal mutagens, *J. J. Mulvihill and J. R. Miller*.

1984 xvi + 860 pages
Price: US $ 150.00/Dfl. 390.00
ISBN 0-444-80519-2

ELSEVIER
ELSEVIER SCIENCE PUBLISHERS
P.O. Box 211, 1000 AE Amsterdam, The Netherlands

Distributor in the U.S.A. and Canada:
ELSEVIER SCIENCE PUBLISHING CO. INC., P.O. Box 1663, Grand Central Station, New York, NY 10163, U.S.A.

The Dutch guilder price is definitive. US $ prices are subject to exchange rate fluctuations. Prices are excl. B.T.W. for Dutch customers.

FL37A278

EVALUATION OF SHORT-TERM TESTS FOR CARCINOGENS

Report of the International Program on Chemical Safety
Collaborative Study on In Vitro Assays

Published on behalf of the International Programme on Chemical Safety (a collaborative programme of the World Health Organization, the International Labour Organisation and the United Nations Environment Program).

edited by **J. Ashby, F.J. de Serres, M. Draper, M. Ishidate Jr., B.H. Margolin, B.E. Matter** *and* **M.D. Shelby**

PROGRESS IN MUTATION RESEARCH VOLUME 5

There is concern that inadvertent exposure of humans to chemical carcinogens contributes to cancer incidence and that this can be reduced through identification and control of human carcinogens.

This book shows how the carcinogenicity of chemicals is assessed using data from rodent studies. Short-term tests have been developed to detect rodent carcinogens and short-term test performances are assessed primarily using rodent carcinogenicity results. No single short-term test is capable of detecting all carcinogens as positive.

The objective of this volume, which reports on the current IPCS Collaborative Study, is to generate a database that provides a basis for selecting one or more in vitro eukaryotic short-term tests to complement the Salmonella test developed by Professor Bruce Ames.

"The present study was, however, specifically designed to define complementary assay that can be successfully employed to screen carcinogens. If one bears this in mind one can only admire the careful thoughts that have gone into both the design and the detailed evaluation of the collected data base. As such it is unique and undoubtedly presents an important step forward in the detection of carcinogens in the human environment."

F.H. Sobels,
Leiden, The Netherlands

CONTENTS: Preface. Part I. Background and summaries (10 papers, 15 contributors). Part II. Investigators' reports (61 papers, 128 contributors). Part III. Appendices (4 appendices, 7 contributors). Author Index. Subject Index.

1985 x + 762 pages
Price: US $139.00/Dfl. 375.00
ISBN 0-444-80615-6

ELSEVIER
ELSEVIER SCIENCE PUBLISHERS
P.O. Box 211, 1000 AE Amsterdam, The Netherlands

Distributor in the U.S.A. and Canada:
ELSEVIER SCIENCE PUBLISHING CO. INC., P.O. Box 1663, Grand Central Station, New York, NY 10163, U.S.A.

The Dutch guilder price is definitive. US $ prices are subject to exchange rate fluctuations. Prices are excl. B.T.W. for Dutch customers.

FL37A121

MUTATION RESEARCH

International journal on mutagenesis, chromosome breakage and related subjects

Publication schedule for 1986

MR is published according to a volume-numbering scheme that embraces all sections of the journal, in addition each section has its own code colour.

Reg (green), 'regular' volumes; EMS (blue), Section on Environmental Mutagenesis and Related Subjects; DRR (brown), 'DNA Repair Reports', special section of Mutation Research; Rev (purple), Reviews in Genetic Toxicology; GTT (red), Genetic Toxicology Testing; MRLett (yellow), Mutation Research Letters.

1986	Reg	EMS	DRR	Rev	GTT	MRLett
Jan.	159/1		165/1	167/1	169/1	173/1
Feb.	159/2	164/1			169/2	173/2
Mar.	160/1		165/2	167/2	169/3	173/3
Apr.	160/2	164/2			170/1	173/4
May	160/3		165/3	167/3	170/2	174/1
June	161/1	164/3			170/3	174/2
July	161/2		166/1	168/1	171/1	174/3
Aug.	162/1	164/4			171/2	174/4
Sep.	162/2		166/2	168/2	171/3	175/1
Oct.	163/1	164/5			172/1	175/2
Nov.	163/2		166/3	168/3	172/2	175/3
Dec.	163/3	164/6			172/3	175/4
	INDEX *					
17 Vols.	5 Vols.	1 Vol.	2 Vols.	2 Vols.	4 Vols.	3 Vols.
159–175	159–163	164	165, 166	167, 168	169–172	173–175
54 issues	12 issues	6 issues	6 issues	6 issues	12 issues	12 issues
+ INDEX						

* Author Index and Subject Index for the year 1986 (covering all sections).

Subscription Information 1986

MUTATION RESEARCH (complete)
1986, Volumes 159–175 (17 volumes in 54 issues + Cumulative Index 1986)
Full subscription: Dfl. 3910.00 (US $ 1348.00) + Dfl. 408.00 (US $ 140.75) postage, packaging and handling. Total price Dfl. 4318.00 (US $ 1488.75)

MUTATION RESEARCH/DNA REPAIR REPORTS
1986, Volumes 165, 166 (2 volumes in 6 issues)
Part subscription: Dfl. 460.00 (US $ 158.75) + Dfl. 48.00 (US $ 16.50) postage, packaging and handling. Total price Dfl. 508.00 (US $ 175.25)

MUTATION RESEARCH/REVIEWS IN GENETIC TOXICOLOGY
1986, Volumes 167, 168 (2 volumes in 6 issues)
Part subscription: Dfl. 460.00 (US $ 158.75) + Dfl. 48.00 (US $ 16.50) postage, packaging and handling. Total price Dfl. 508.00 (US $175.25)

MUTATION RESEARCH/GENETIC TOXICOLOGY TESTING
1986, Volumes 169–172 (4 volumes in 12 issues)
Part subscription: Dfl. 920.00 (US $ 317.25) + Dfl. 96.00 (US $ 33.00) postage, packaging and handling. Total price Dfl. 1016.00 (US $ 350.25)

MUTATION RESEARCH LETTERS
1986, Volumes 173–175 (3 volumes in 12 issues)
Part subscription: Dfl. 690.00 (US $ 238.00) + Dfl. 72.00 (US $ 24.75) postage, packaging and handling. Total price Dfl. 762.00 (US $ 262.75)

The Dutch guilder price is definitive. The US dollar price is subject to exchange rate fluctuations and is only given as a guide.

Journals are sent by surface delivery to all countries, except the following countries where SAL air delivery (Surface Airlifted Mail) is ensured: U.S.A., Canada, Japan, Australia, New Zealand, P.R. China, India, Israel, South Africa, Malaysia, Singapore, South Korea, Taiwan, Pakistan, Hong Kong, Brazil. Air mail rates for other countries are available on request.

Subscription orders can only be entered by calender year (Jan.–Dec.) and should be sent to: Elsevier Science Publishers, Journals Department, P.O. Box 211, 1000 AE Amsterdam (The Netherlands), telex 18582 ESPA NL, or to your usual subscription agent.

Claims for missing issues should be made within three months of publication, otherwise they cannot be honoured free of charge.

The Publisher reserves the right to issue additional volumes during the course of the year. Such volumes will be invoiced before publication and delivered after receipt of payment.

In the United States and Canada: For further information concerning this or any other Elsevier Science Publishers journal, contact Elsevier Science Publishers, Journal Information Center, 52 Vanderbilt Avenue, New York, NY 10017, tel. (212) 370-5520.

Reprints 50 reprints of each article are sent to the author(s) free of charge. Additional reprints can be ordered by the author(s).

Advertising For advertising rates apply to the Publishers.

CONTENTS

Cumulative Author Index 1985 (Volumes 142–158) 1–11

Cumulative Subject Index 1985 (Volumes 142–158) 13–35

Instructions to Authors 37

Cited in Biological Abstracts; Chemical Abstracts; Current Contents/Life Sciences; Excerpta Medica; Index Medicus; Informedicus

PRINTED IN THE NETHERLANDS

Contributions–in triplicate (one original plus two copies, also of the illustrations)–may be sent to Prof. F.H. Sobels, Managing Editor, *Mutation Research*, Department of Radiation Genetics and Chemical Mutagenesis, State University of Leiden, Sylvius Laboratories, Wassenaarseweg 72, P.O. 9503, 2300 RA Leiden (The Netherlands).

or to

Dr. F.J. de Serres, *Mutation Research*, NIEHS, P.O. Box 12233, Research Triangle Park, NC 27709 (U.S.A.).

Manuscripts in the field of Molecular Genetics may be submitted to

Prof. B.W. Glickman, *Mutation Research*, Biology Department, York University, 4700 Keele Street, Toronto, Ont. M3J 1P3 (Canada).

Manuscripts for publication in *DNA Repair Reports* may be submitted to Professor Philip C. Hanawalt, Herrin Biology Laboratories, Stanford University, Stanford University, Stanford, CA 94305 (U.S.A.)

or to

Dr. P.H.M. Lohman, Medical Biological Laboratory TNO, Lange Kleiweg 139, P.O. Box 45, 2280 AA Rijswijk (The Netherlands)

or to

Professor H.Takebe, Department of Experimental Radiology, Faculty of Medicine, Kyoto University, Kyoto 606 (Japan)

Manuscripts for publication in *Mutation Research Letters* may be submitted to Dr. R.J. Preston, Oak Ridge National Laboratory, Biology Division, P.O. Box Y. Oak Ridge, TN 37830 (U.S.A.)

Copyright © 1985, Elsevier Science Publishers B.V. (Biomedical Division) All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without permission of the publisher, Elsevier Science Publishers B.V. (Biomedical Division), P.O. Box 1527, 1000 BM Amsterdam (The Netherlands).

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in article 17 paragraph 2 of the Dutch Copyright Act of 1912 and in the Royal Decree of June 20, 1974 (S. 351) pursuant to article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center. Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee states in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, SALEM, MA 01970 (U.S.A.). If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of U.S. $2.25, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purpose, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.